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been monitored and evaluated. While there are differences in the ways governments fund research 
around the world, and a diversity of approaches to evaluation, there are a number of common themes that 
can be observed in national experiences. As the importance of evaluation increases, the gap between 
current practice and best practice becomes more significant, and the need for comparative study and 
methods development grows. Current international ‘better-practice’ approaches to research evaluation 
and performance indicators reflect two important considerations. First, they make a clear distinction 
between input, output and outcome indicators and assessments of impact. Only limited refinements have 
occurred in recent years in input and output performance indicators. However, quite considerable 
developments have occurred in relation to the development of indicators and approaches for assessing 
the outcomes and impact of research.1 Second, evaluation and reporting mechanisms vary considerably 
according to the intended audience for the reporting. In particular, as nations move toward strategically 
targeting limited government research resources reporting demands at the programme level, and for 
specific stakeholder groups becomes all the more pressing. 
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Executive Summary 
 
The New Zealand Ministry of Research, Science and Technology (MoRST) is committed 
to the evaluation of the effectiveness and efficiency of its contributions to the New Zealand 
research system. As part of this commitment MoRST has commissioned an evaluation of 
the Health Research Output Class, which is invested by the Health Research Council of 
New Zealand (HRC). The evaluation, reported here, relates to the appropriateness of the 
New Zealand Government’s strategic investment in and management of health research 
generally (in all its aspects). The Australian Expert Group in Industry Studies (AEGIS) at 
the University of Western Sydney was commissioned to carry out a study covering six of 
the nine terms of reference for the evaluation (see Box 1.1 on page 14). Appendix 6 
provides examples from the HRC’s evaluations and ongoing work in the area of research 
uptake, and ensuring accessibility, as well as identifying current research capabilities and 
the existence of areas of international strength within the New Zealand health research 
system 
 
The body of this report presents the findings of the AEGIS study. The objective of the 
evaluation was to contribute to a better understanding of the management of Health 
Research Output Class investments, and health research investment more broadly, in order 
to better inform future policy interventions. Analysis of the New Zealand system and 
international comparisons are used to identify areas in the current system where 
improvement can be usefully pursued. A benchmark of ‘appropriateness’ (both for level of 
investment and management models) is taken as ‘comparable OECD countries’. The main 
countries selected for international benchmarks are Australia, Canada, Ireland, the 
Netherlands, Sweden and the United States.  
 
The report is organised in three parts:  
 
• Current status of and environment for health research investment in New Zealand: 
Chapters 1 and 2 provide an overview of the international environment for health 
research and the New Zealand health research policy and investment framework; 
• International benchmarks: Chapters 3 and 4 review the health research systems in 
six other OECD countries and analyse international levels of health research 
investment, while Chapter 6 discusses New Zealand’s specific commitment to 
developing Māori health research capability by comparison with health research 
programmes for aboriginal populations elsewhere; and 
• The future vision for health research investment: Chapters 5, 7 and 8 discuss a 
number of issues that flow from the local and international experience in planning 
and managing health research investments and present recommendations for 
consideration and action. The report concludes with an estimate of the cost 
implications arising from the recommendations and a possible implementation 
timeline. 
 
Overview of findings 
 
In terms of strategy and delivery of programs the New Zealand health research system 
stands up well against international experiences. The HRC has a world-class research 
assessment process and the management of the Health Research Output Class is widely 
accepted across the system as operating at a high standard.  
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However, the evaluation identified growing tensions within the system associated with a 
contradiction between the ability to develop, assess and carry out high quality health 
research and the ability to deliver adequate funding to support such research.  
Three main observations are made on the level of health research funding in New Zealand 
by comparison with the benchmark countries.  
 
• New Zealand’s current level of public investment in health research appears 
substantially lower than almost all the benchmark countries. Of these countries, 
only Ireland spends less, proportionally, on health research and development. 
 
• Most of the benchmark countries are increasing their investment in health 
research – some by as much as 20 per cent per annum. By contrast, there is no 
evidence of sustained increase in health research investment in real terms in New 
Zealand in recent years. Indeed, national data on health research in the universities 
provide clear evidence of a decline in New Zealand’s expenditure on health 
research, as a proportion of GDP. 
 
• The cost structures of many of the comparator health research funding agencies 
are lower than those of the HRC, because HRC is expected to provide a high level 
of overhead costs on research grants. Given that the overall envelope of health 
research funding available to the HRC in New Zealand is already comparatively 
smaller than in most of these countries, the HRC’s capacity to purchase high 
quality health research is all the more limited. 
 
The report points to an urgent need to increase the present level of investment in health 
research. The level of funding available for health research in New Zealand has decreased 
over the past decade, is now well below international standards, and in serious danger of 
falling below a level necessary to sustain a functioning health research system. While the 
current level of funding has absorbed the implications of full cost funding for research 
grants, the overall support for health research has declined. This has placed further 
pressure on the system and, in particular, reduced the capacity of the system to support 
career structures through scholarships and fellowships. 
 
We recognise the finite nature of funding resources. But New Zealand appears to marking 
time in terms of health research funding while other countries are developing bold plans 
for expanding investments. We also recognise that New Zealand has taken bold steps in 
terms of redesigning the funding framework. This includes implementing a clear and 
transparent mechanism for underwriting the full cost of health research, shifting from a 
disciplinary based funding system to a program and strategic objective system, and 
identifying and sustaining long term strategies for building a Māori research capacity. 
 
In order to consolidate and take advantage from these developments we believe it is 
important to take immediate steps to introduce some additional funding to sustain the top 
band of high quality health research capability in the country, and to provide more 
coherent support for collaborative health research centres and partnerships. 
 
Our recommendations suggest that an increase in the budget available to HRC of $20.1 
million in 2005-06, rising to $34.3 million in 2007-08, is necessary to absorb the total 
impact of full cost funding and allow for the appropriate level of growth required to 
achieve these strategic objectives for health research. 
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These financial tensions appear to be exacerbated by structural features associated with 
organisational arrangements, coordination, and shared responsibilities for some elements 
of the health research investment system. New Zealand’s arrangements seem more strongly 
compartmental than in the benchmark countries, in that there are not the strong cross 
cutting mechanisms evident in other systems. The comparatively small size of the New 
Zealand system presents an even stronger need for maximising coordination.  
 
We do not consider that a substantially increased concentration of research funding 
through HRC would automatically produce benefits in terms of the coherence and 
coordination of health research. Rather the challenge is to make the various funding agents 
and policy departments (MoRST, Ministry of Health) work more effectively together 
within a plural system, as is the case in many of the benchmark countries. The evaluation 
draws attention to the need to enhance coordination between agencies, in terms of 
developing a published national health research strategy, implementation and evaluation.  
 
Our main recommendation here is for an interagency coordinating committee for health 
research in which HRC would play a leading role.  
 
The HRC approach to monitoring and evaluation is impressive by international standards 
and should provide the basis for systematic national health research evaluation and 
reporting. In particular, we propose a health research ‘scorecard’, of benefit to HRC, 
MoRST and the Ministry of Health, to provide an appropriate baseline against which New 
Zealand’s health research investments and returns can be regularly assessed. 
 
We believe that New Zealand is at the stage where an increased funding commitment, 
together with increased capacity for coordination, monitoring and evaluation will enhance 
return on investment in health research. Our recommendations for improvement to the 
health research investment system follow.  
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Recommendations 
 
An appropriate policy and investment framework 
 
1. We consider that the establishment of a single research agency, responsible for 
funding all health research, broadly defined, would not be in the best interests of 
the New Zealand research system overall. We recommend the maintenance of 
diversity in the funding base provided through different agencies. However, we 
also propose an enhanced role for HRC in steering research policy, coordination, 
and evaluation toward strategic national goals. 
 
2. We recommend that MoRST establish an interdepartmental health research 
coordinating committee including the Ministries of Health and Education. The 
HRC should have a lead role in the committee. 
 
The future vision for health research 
 
3. We recommend that HRC should instigate a consultative priority setting exercise 
for future Partnership/Joint Venture investments that involves a wide range of 
stakeholders including researchers, policy agencies, other potential funders and the 
health industry. The exercise should consider both the feasibility of research and 
the potential outputs and outcomes of the investment in the research.  
 
4. We recommend that HRC should develop proposals for a National Health 
Research Centre grant scheme, complementary to those funded by CoRE and 
FRST, for consideration by MoRST. The adoption of this recommendation should 
be on the basis of HRC receiving additional funding and should not draw on 
existing funds. 
 
5. We recommend that the government should accept the principle that the HRC 
should receive full budget supplementation for any increase in costs arising from 
the ‘full cost funding’ policy. 
 
6. We recommend that the HRC should maintain discussions with the universities to 
ensure that full grant costs are effectively applied to the infrastructure and facilities 
required by health researchers. The universities should be obliged to report on their 
use of these funds, against agreed performance indicators. 
 
7. We recommend that HRC should be provided with information to enable the 
Council to monitor the effect of the PBRF on health research funding and research 
groups. 
 
8. We recommend that the HRC, in consultation with the proposed health research 
coordinating committee, establish a set of performance indicators for target 
population groups that, as far as possible, allow for international comparison. 
 
9. There is clear benefit to New Zealand in the high standard of assessment and 
evaluation for health research set by HRC and we recommend that these processes 
should be maintained. 
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10. We recommend that HRC should give further consideration to the relationship 
between its project and programme funding, and between programme grants and 
the proposed National Health Research Centres scheme. 
 
11. We recommend that HRC should coordinate the publication of a National Health 
Research Strategy (or Strategies) to complement the New Zealand Health Strategy 
and that the Council be adequately resourced for this task. 
 
12. We recommend that HRC should collaborate with FRST to provide advance 
warning of those health researchers working on technologies or research outcomes 
with potential for commercial exploitation. 
 
13. We recommend that HRC should instigate an international collaboration grant 
scheme for individual health researchers and teams to complement the support and 
grants offered by MoRST and the FRST. These could be targeted for HRC project 
and program grant holders or more widely. Funds from the new ‘Developing 
International Linkages’ output class should be made available for this purpose. 
 
14. We recommend that MoRST review the procedures for reporting current health 
research expenditure data to the OECD and for ensuring that this data is presented 
in a manner that provides for international comparison of research effort. 
 
15. We recommend that the coordinating committee proposed in Recommendation 2 
should have a specific mandate to coordinate and develop a national health research 
reporting strategy and develop performance indicators for monitoring system wide 
outcomes and impact against national strategic objectives. The HRC should provide 
the lead in this activity. 
 
16. We recommend that HRC be mandated to produce a New Zealand health research 
system scorecard report every three years. 
 
The level of investment required 
 
17. We recommend that MoRST adopt a target budget for the HRC’s Output Classes 
(the HROC + Māori OC [health] + SPI OC [health]) of a real increase of 0.01% of 
GDP over the next four years. 
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During the past decade there have been major developments in the way that research 
investments have been monitored and evaluated. While there are differences in the ways 
governments fund research around the world, and a diversity of approaches to evaluation, 
there are a number of common themes that can be observed in national experiences. As the 
importance of evaluation increases, the gap between current practice and best practice 
becomes more significant, and the need for comparative study and methods development 
grows. Current international ‘better-practice’ approaches to research evaluation and 
performance indicators reflect two important considerations. First, they make a clear 
distinction between input, output and outcome indicators and assessments of impact. Only 
limited refinements have occurred in recent years in input and output performance 
indicators. However, quite considerable developments have occurred in relation to the 
development of indicators and approaches for assessing the outcomes and impact of 
research.1 Second, evaluation and reporting mechanisms vary considerably according to 
the intended audience for the reporting. In particular, as nations move toward strategically 
targeting limited government research resources reporting demands at the programme 
level, and for specific stakeholder groups becomes all the more pressing. 
 
Evaluation of Health Research 
  
As part of this on-going process, governments around the world have been reinforcing 
legislation to require research funding agencies to be more specific in reporting their 
research programme outcomes. In this context, the World Health Organisation and the 
OECD have been working for several years on improving the information available on the 
national funding of health research. The US Government Performance and Reporting Act 
(GPRA) for example, which has been in operation for a number of years, has significantly 
changed evaluation and reporting mechanisms for national funding agencies including the 
National Institute of Health (NIH). Under the Bush administration GPRA is already 
steering a new wave of research evaluation. This has led to a considerable refinement of 
research performance indicators within many agencies and across various countries.  
 
The New Zealand Ministry of Research, Science and Technology (MoRST) is committed 
to performing an evaluation of the “effectiveness and efficiency of research carried out 
under the Health Research Output Class (HROC), and report to the Minister on 
achievements against comparable international experiences. The Health Research output 
class is currently administered by the Health Research Council (HRC) of New Zealand, 
which reports on the outcomes of the investment. However, while HRC is the major health 
research purchase agent, MoRST has indicated that the evaluation should consider the 
wider set of assessment objectives related to achievement of goals, past investments and 
future opportunities.  
 
The evaluation of New Zealand’s Health Research output class, reported here, takes into 
account these broader international developments. International comparisons of research 
                                                 
1  See for example European Commission (c2003) 
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funding and strategies are used throughout this report in order to provide an international 
policy perspective against which the New Zealand system can be assessed.  
 
Scope and terms of reference 
 
The evaluation was aimed at assisting MoRST to evaluate the efficiency and effectiveness 
of the research carried out under the Health Research Output Class of Vote RS&T 
(currently approximately  $42 mill. annually). The terms of reference for the evaluation are 
reproduced in Box 1.1. The Australian Expert Group in Industry Studies (AEGIS) at the 
University of Western Sydney was commissioned to carry out a study covering terms of 
reference 2, 5,6,7,8,9 (the shaded areas in the box). The activities and findings from that 
study are presented in the body of this report. Terms of reference 3 and 4 were addressed 
through a separate exercise carried out by MoRST. A report of that work, directed toward 
terms of reference 3 and 4 and the findings with respect to the first terms of reference, is 
attached to this report as Appendix 6. 
 
Box 1.1: Terms of Reference for the Health Research Evaluation 
 
1. Determine the extent to which the investment in health research is contributing 
to the delivery of Government objectives as defined by the Health Research 
output class and make recommendations on opportunities for improvement. 
2. Assess whether the investment in the health research output class is managed 
through an appropriate policy and investment framework and compare this to 
international best practice for investment decision making in health research.  
3. Determine the extent to which research outputs are accessible and assess levels 
of uptake. 
4. Determine the current capabilities, capacity and areas where internationally 
recognised research excellence exists within the system. 
5. Compare the performance and investment in New Zealand health research with 
that of comparable OECD countries, where possible. 
6. Assess the future characteristics of the health research system as defined in 
HRC’s Strategic Plan ‘Vision 2008’; the resources required and benefits to New 
Zealand arising from its implementation. 
7. Assess whether the investment in health research is at a level appropriate to the 
objectives set. 
8. Establish a set of indicators that will allow progress against these strategic 
objectives to be measured. 
9. Consider whether the Government’s investment in health research should be 
managed by a single health research purchase agency.  
Note: Shaded areas identify the terms of reference covered in the body of this 
report. 
 
The evaluation, reported here, relates to the appropriateness of the New Zealand 
Government’s strategic investment and management framework in health research (in all 
its aspects). The benchmark of appropriateness (both for level of investment and 
investment management models) is taken as ‘comparable OECD countries’. The main 
countries selected for international benchmarks are Australia, Canada, Ireland, the 
Netherlands, Sweden and the United States. There is no single ideal comparator country. 
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However, the first five present a range of experiences that offer some similarities including 
similar levels of industrial development, population sizes and characteristics, institutional 
histories, industrial structure and national approaches to public R&D investment. The US 
was included because since the introduction of the Government Performance and Results 
Act (GPRA) extensive effort has been directed toward improving research evaluation and 
reporting, particularly within the NIH (Cozzens 2000). Reference to other countries is 
included, where appropriate, to provide additional points of comparison on specific 
research issues. 
 
The objective of the evaluation was to contribute to a better understanding of the Health 
Research Output Class in order to better inform future policy interventions. The Health 
Research Council (HRC) allocates HROC funding and contributes approximately 65 per 
cent of New Zealand’s public funding for Health Research. The study explicitly considers 
the future organisation and management of Health Research investments, including the 
question of whether there ought to be a single health research ‘purchase agency’. In 
designing the study MoRST has emphasised the need to suggest changes that would be 
incremental in nature rather than a radical redesign of the system’.2  
 
Recent introduction and subsequent development of the Māori Knowledge and 
Development Output Class (2000) and publication of the Māori Health Strategy (2002) are 
important strategic features of the present funding framework. Specific attention has 
therefore been given to the present arrangements for Māori health research in the study.  
 
Recommendations emerging from the study are focused on opportunities and options for 
improving future health research outcomes. The terms of reference have demanded 
consideration of the level of resources that are likely to be required to implement the 
Health Research Council’s ‘Vision 2008’ Strategic Plan and an identification of what 
benefits might be expected from an increased investment. However, by focusing on the 
health research system as a whole we have sought to explore options for improving 
efficiency through coordination and improvements to the general funding framework. The 
study is also directed toward assessment of strategies for the development and application 
of performance indicators for tracking progress against these strategic goals.  
 
It is important to stress that the study is not intended to be a comprehensive inquiry into the 
health research funding system in New Zealand, nor an evaluation of the HRC. Rather, the 
study aims to identify, through international comparisons, aspects of the current health 
research investment system where improvement could be usefully pursued. These 
recommendations will require further consideration by MoRST, the New Zealand 
government and the health research community. In developing these proposals, the authors 
have held discussions and briefings with a range of health research purchase agencies, 
policy makers and performers, including HRC, the Foundation for Research, Science and 
Technology (FRST), the Royal Society of New Zealand (RSNZ), the Ministry of Health 
(MoH), the New Zealand Vice-Chancellors’ Committee, and researchers at Auckland,  
Otago and Massey Universities. A full list of people who contributed at the meetings is 
included in Appendix 4.  
 
                                                 
2  Terms of Reference p.1. 
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Approach to the tasks 
 
The broad tasks presented therefore were to:  
 
1. assemble comparable information and performance indicators collected by  medical 
research funding organisations in other comparable countries;  
2. collect current data, background information and views of stakeholder groups about 
the current arrangements and levels of funding for investing in health research in 
New Zealand; 
3. compare and contrast New Zealand’s health and medical research sector investment 
framework and performance with comparable sectors and agencies in other 
countries; and 
4. make recommendations on opportunities for improvement in New Zealand policies, 
organisational arrangements, levels of investment, evaluation frameworks and 
management indicators for health research.  
 
International data collection 
 
International comparative data was collected through three mechanisms. International data 
sets compiled for OECD countries provide general comparative data. The difficulty with 
these data sets is that fully comparable data is usually well out of date by the time it is 
published, for example the latest OECD health research statistics for New Zealand refer to 
the year 1999. However, more current data for New Zealand was used to provide a 
reference point for comparison with other countries where available.  
 
For the benchmark countries, international reports containing statistical information, 
funding investment strategies, and annual reports were collected from web-sites and 
through direct contact with representatives from health research funding agencies. This 
process yielded background information for the cross-country comparisons. Follow-up 
information from these agencies was collected through e-mail, and in some cases telephone 
contact. A list of international respondents is also in Appendix 4. For Canada and the US 
Professor Susan Cozzens collated additional information in her role as collaborating 
consultant. 
 
New Zealand data collection 
 
Information on the health research system was collected through a variety of mechanisms. 
In New Zealand, data was provided by the Ministry of Research, Science and Technology 
(MoRST), the Health Research Council (HRC) and the Ministry of Health (MoH). 
 
Further information was collected during a series of meetings and discussions in New 
Zealand with representatives from purchases agencies, universities, research groups and 
centres, and government departments. Further interviews were carried out through 
telephone and e-mail correspondence (see Appendix 4). 
 
Throughout the process weekly telephone discussions were held with representatives of 
MoRST and the HRC who assisted the team by providing additional data and names of 
people who could provide relevant inputs. 
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New Zealand in the global research context 
 
The present evaluation of the New Zealand health research system has been carried out in 
the context of international experiences. At a global level, national research policies are 
being formulated and implemented under conditions that are quite different from just two 
decades ago. There have been far-reaching changes in the relationships between science, 
industry and society, in the ways governments fund science, in the institutions that 
distribute funding, and in the organisations that host research laboratories and research 
practice. These changes can be summarised broadly as follows 
 
1. Research has become increasingly multidisciplinary, and interdisciplinary research 
has come to assume a leading rather than supplementary role in scientific research;  
2. The funding of scientific research has become more susceptible to market forces 
and community and political expectations; 
3. International and occupational mobility of scientists has increased; and  
4. New ‘hybrid’ organisational forms in which research is carried out are emerging 
and transforming the boundaries between public/private organisations and between 
disciplines; 
 
A global review of national research strategies and research funding policies shows that 
most OECD countries have been amending their strategies in order to appropriately 
respond to this evolving research environment.3 Flowing on from this is the new wave of 
research investment strategies overseas, which are: 
 
• an increased emphasis on public–private partnerships; 
• the provision of funding support to underpin ‘networks’ and new organisational 
structures that are complementary to project funding; 
• the formation of coordinating mechanisms to ensure lateral links between funding 
agencies and between programs within agencies; 
• a focus on designing funding initiatives that collectively span ‘whole of career’ 
options for scientist’s; and 
• the introduction of common evaluation mechanisms and performance indicators. 
 
The New Zealand research system, as in other OECD countries, is linked to the global 
science and research endeavour and subject to similar pressures for change. However, there 
are a number of socio-economic features that place New Zealand in a particular structural 
position with respect to international health research.   
 
• New Zealand is a small economy with limited economic capacity to fund research 
across all areas of health research; 
• The country’s industrial and business structure, dominated by a large number of 
small companies with historically low investments in R&D, limits the capacity to 
engage the private sector in health research and the commercialisation of research 
outcomes; 
                                                 
3  See for example OECD (2001a). 
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• In spite of the small population New Zealand has a strong scientific education and 
research base and makes a comparatively strong contribution to international 
scientific output; 
• Like many other small nations, New Zealand faces strong international competition 
to retain and attract leading international researchers; and 
• The multicultural characteristics of the population place complex and competing 
demands on achieving equitable health outcomes across population sub-groups. 
 
It is important, therefore, to consider these general features and global trends while 
discussing the Health Research Output Class. New Zealand must not only respond to the 
changing international environment but must also confront these changes in a way that 
maximises outputs and outcomes from the nation’s investment in health research and also 
maximises the capture of benefit from global advances in health research. This may 
demand new ways of thinking about health research policies and management systems. 
 
The report is organised in three parts: current status and environment for health research 
investment (Chapter 1 and 2); international benchmarks (Chapters 3, 4, and 6) and the 
future vision for health research investment (Chapters 5, 6, 7 and 8) Chapter 2 proceeds 
with a brief overview of the New Zealand health research investment framework. In 
Chapter 3 a review of the health research systems in six other OECD countries is presented 
and some general observations are made about international trends and New Zealand’s 
contemporary position vis a vis these trends. Chapter 4 provides a more detailed analysis 
of international levels of health research investment, again drawing some comparison with 
the current situation in New Zealand. Chapter 5 turns to the current strategic framework for 
health research investment in New Zealand, while Chapter 6 provides some international 
comparisons and conclusions in relation to New Zealand’s specific commitment to 
developing Māori health research capability. In Chapter 7 a number of issues are 
developed that flow from the international comparisons and responses from New Zealand 
health research stakeholders. A number of recommendations are offered here for 
improving the present structural arrangements and coordination mechanisms. Finally, in 
Chapter 8 the main observations are summarised and presented together with the 
recommendations developed through the earlier sections of the report. 
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New Zealand has developed a particular approach to the funding and management of 
health research that in several aspects differs from the situation in comparable OECD 
countries. This chapter provides a brief introduction to the health research investment 
system in New Zealand and shows the roles of the main institutional ‘actors’. Specific 
programmes of relevance are discussed in more detail throughout the report.  
 
The current structure of health research support in New Zealand is the outcome of major 
changes to the public research system over the last 15 years that mirror broader public 
sector reform in the country. At the core of the reform is the application of ‘principal-
agent’ theory: ‘the idea that interchange between parties can be characterized as a series of 
contracts, where one party, the principal, enters into agreements with another, the agent, 
who agrees to perform tasks on behalf of the principal, in return for compensation’ (Bale 
and Dale 1998). The catalysts of these reforms, as applied to science and research, were the 
Beattie Committee (which reported in 1986) and subsequent lobbying by the Science and 
Technology Advisory Council – STAC (Palmer 1994). The overall thrust of the reforms 
has been to separate the organisational responsibilities for policy advice, funding and 
delivery of research, science and technology (RS&T) in order to create clear lines of 
accountability.  
 
This separation of responsibilities is more marked than in the benchmark countries in this 
report. It can be argued that it has had the effect of making New Zealand health research 
investment activities more strongly compartmental than in many of the comparator 
countries in the current study, at a time when organisational boundaries between funding 
agencies in other countries are breaking down as a result of growing coordination and 
collaboration. 
 
Recent evolution of the research investment system 
 
The Ministry of Research, Science and Technology (MoRST) was created in 1989 as the 
main organisation responsible for RS&T policy. A separate organisation, the Foundation 
for Research, Science and Technology (FRST) was set up by an Act of Parliament the 
following year to manage the Government’s funding of RS&T and to advise on national 
research priorities. FRST remains the largest ‘purchase agent’ for research, with other 
specialist funding organisations for health research (the Health Research Council of New 
Zealand – HRC), for fundamental research (the Marsden Fund, set up in 1994 and 
administered by the Royal Society of New Zealand), and for technology (the Technology 
New Zealand programme established in 1997, within FRST. 
 
Parallel reforms took place in the science organisations (Palmer, 1994). Focused, 
performance oriented operating agencies replaced a system formerly ‘dominated by a small 
number of large government departments with mixed roles and direct funding’ (MoRST, 
1994: 2). In 1992, ten new Crown Research Institutes (CRIs) were created from the former 
Department of Scientific and Industrial Research (DSIR – founded in 1926) and research 
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institutes in other ministries (including the Communicable Disease Centre in the Ministry 
of Health)4.  The CRIs and other ‘science providers’, such as universities and research 
associations, were drawn into competition for contracts for contestable funds from the 
‘purchase agents’ with the goal of achieving a more open and flexible research system. 
Importantly, ownership of the CRIs (and other ‘Crown Companies’) is vested in the 
Treasury, not in MoRST. However, the current  CRIs play a relatively minor role in health 
research , with most of the active health researchers based in New Zealand’s seven 
universities, notably the University of Auckland and University of Otago. 
 
Recent years have seen reform of the university sector bringing greater scrutiny of research 
performance. Funding for academic research is becoming largely divorced from student 
load and is moving towards a system which rewards performance in research and research 
training, and is assessed by specific criteria. Seven Centres of Research Excellence (CoRE) 
– two of them in health – have been established under a new fund. 
 
MoRST has been the main coordinating agency for New Zealand’s public sector R&D 
through the 1990s through a series of planning and priority setting activities.  In 1995, the 
government adopted a goal of increasing public sector investment in science from 0.6 per 
cent of GDP in 1993 to 0.8 per cent of GDP by the year 2015. This goal specifically 
included funding of health research (MoRST, 1995: 37). In 2000, MoRST consolidated its 
science and research funding into a series of output classes based on research disciplines or 
research objectives. The Output Classes represent specific parliamentary appropriations 
(‘line items’ in Australian government parlance). These replaced an omnibus Public Good 
Science Fund with allocations based on strategic priority setting against objectives. The 
PGSF did not incorporate health research funding and thus health research was explicitly 
excluded from the National Science Priorities and from MoRST’s strategic planning until 
the late 1990s.5
 
Table 2.1 shows the current Output Classes under Vote RS&T and their funding 
allocations for 2003-04 (Minister of Research Science and Technology 2003). 
 
                                                 
4 A list of other R&D agencies within the Health Ministry prior to 1990 may be found in Science and 
Technology Advisory Committee (1988: 20-21) 
5 Science policy and research priorities (including health) were however coordinated at Cabinet level (Palmer 
1994). 
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04 ($ mill) 
% of Vote 
RS&T 
Knowledge Investments  150.95 27.1% 
Output Class O1: Marsden Fund  RSNZ 32.79 5.9% 
Output Class O2: Non-Specific Output Funding   FRST 28.53 5.1% 
Output Class O3: Supporting Promising Individuals  FRST, HRC, 
RSNZ 
14.55 2.6% 
Output Class O4: Promoting an Innovation Culture  MoRST, 
RSNZ 
2.72 0.5% 
Output Class O6: New Economy Research Fund (NERF) FRST 63.88 11.5% 
Output Class O11: Māori Knowledge & Development
Research (est. 2000) 
FRST, HRC 5.48 1.0% 





Economic Investments  238.95 42.9% 
Output Class O7: Research for Industry  FRST 185.04 33.2% 
Output Class O8: Technology New Zealand  FRST 44.03 7.9% 
Output Class O9: Grants for Private Sector R&D  FRST 
Merged with 
OC O8 in 
2003-04 
- - 
Output Class O10: National Measurement Standards  IRL 5.08 0.9% 
Output Class: Pre-seed Accelerator Fund (est. 2003) FRST 4.80 0.9% 
Environmental   88.62 15.9% 
Output Class O14: Environmental Research  FRST 88.62 15.9% 
Social  48.82 8.8% 
Output Class O12: Health Research  HRC 42.23 7.6% 
Output Class O13: Social Research  FRST 6.59 1.2% 
System investments  29.46 5.3% 
Output Class O5: Research Contract Management  FRST, HRC, 
RSNZ 
17.38 3.1% 
Venture Investment Fund - Governance & Operation NZVIF 1.22 0.2% 
Other MoRST 10.86 2.0% 
TOTAL   556.80 100.0% 
 
 
The health research investment system 
 
In common with countries such as Australia and the United Kingdom, New Zealand 
constituted a body with specific responsibilities for health research in the first half of the 
20th century. The Medical Research Council (MRC) was established in 1937 as a 
departmental committee within the Ministry of Health. The MRC gained statutory status as 
an autonomous agency in 1951. In 1990, the then Minister for Health abolished the MRC 
and legislated to set up the Health Research Council of New Zealand (HRC) as a Crown 
entity owned by the Minister of Health.6 This move reflected the wider reforms of New 
                                                 
6 One of STAC’s recommendations had been the establishment of a National Research Council with transfer 
of some funds from other agencies, including MRC. The proposal that won the day however was that of the 
Stewart Review (1989) that led to the foundation of the HRC, funded through Vote Health (Palmer 1994).  
Science for Life 21
  
Zealand’s public research system. Like many medical research agencies internationally, the 
HRC took on a broader responsibility for public health research and its application at that 
time: its statutory mandate is to support research not simply in medicine, but in all areas of 
biomedical and public health. The 1990 Act also gives the Council statutory responsibility 
in relation to Māori health research and health research ethics. As the Council notes, this 
‘saw a major shift in the focus of the organisation, broadening the remit and substantially 
increasing the investment in the more applied end of the spectrum, particularly public 
health research’ (HRC, 2002a: 91)  
 
In 1998, HRC’s core funding (amounting to, $20 million) was transferred from Vote 
Health to Vote Research, Science and Technology. Its main source of funding is the Health 
Research Output Class (HROC) administered by the Ministry of Research, Science and 
Technology (MoRST). The Health Research Council is the sole purchase agent for HROC 
and the principal funding body for health and medical research in New Zealand. The 
Council acts as the national coordinating body for health research. HRC’s overall strategies 
are set by formal agreements with the Ministry of Health and through priorities and 
allocations attached to MoRST’s Output Classes. As a Crown entity, the Council is 
responsible for how it meets the statutory responsibilities within its mandate, giving regard 
to the views of the Minister (HRC, 2002a). As such, the Council sets its own strategies 
following nationwide consultation with a broad range of stakeholders. HRC also enters 
into an ‘output agreement’ with MoRST, which is renewed annually.  
 
As noted above, MoRST has established a specific output class for health research. The 
Health Research Output Class accounts for 7.6 per cent of Vote RS&T committed 
expenditure for 2003-04. In addition, HRC has access to a share of funding through several 
other output classes, namely Supporting Promising Individuals, Māori Knowledge and 
Development Research, and Research Contract Management. Together, these classes 
amount to a further 6.7 per cent of Vote RS&T commitments. HRC receives 14 per cent of 
the SPI Output Class and 40 per cent the Māori Output Class. HRC’s total envelope is 
equal to 8.3 per cent  of Vote RST. 
 




• The purpose of HROC is: ‘to support research programs that have the greatest potential to 
improve the health and quality of life of New Zealanders’ 
• ‘The objective of this output class is for RS&T to improve the health status of New 
Zealanders’  
• The nominated outputs are: 
o ‘Knowledge and understanding of the factors influencing health status, including 
health disparities between New Zealanders’; and 
o ‘Technology, products and services for improving health status and reducing health 
inequalities’. 
As Box 2.1 shows, the objectives of the HROC are focussed as much on terms of benefit to 
the nation as knowledge generation. In recent years, the HRC has moved from a system of 
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disciplinary based funding to a portfolio investment model which comprises both 
disciplinary and outcome focused objectives. In 1999 the Council developed and 
implemented an outcome-focused Research Portfolio framework for its investment in 
research. The Research Portfolio framework has been reviewed and ‘fine tuned’ 
subsequently with consequential change in the scope and priorities. The current Portfolios 
(Box 2.2) and their contents are expected to remain stable for the next three years. The 
Council has given high priority to the development of health research capabilities of 
relevance for Māori , Pacific and other population groups identified as priorities in the 
New Zealand Health Strategy. Since 2000, Māori Health Research has been supported via 
MoRST though a new Output Class.  
 
Box 2.2  HRC Research Portfolios, 2003 
 
 
• Biological Systems and Technologies 
• Communicable Diseases 
• Determinants of Health 
• Health and Independence of Population Groups 
• Health Sector Management and Services 
• Injury and Rehabilitation 
• Mental Health and Neurological Disorders 
• Non-Communicable Diseases 
• Rangahau Hauora Māori (Māori Health Research and Development) 
 
 
HRC has also negotiated a number of innovative Partnership and Joint Venture 
arrangements, initially with the Ministry of Health and a range of public sector agencies, to 
leverage funding in applied health research from sources other than MoRST. The major 
Partnerships and Joint Ventures are shown in Box 2.3 
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• Environmental Health Joint Research Portfolio 
• Immunisation Joint Venture 
• Māori Health Joint Venture 
• Exploring the Māori Health and Disability Workforce Joint Venture 
• Māori Knowledge and Development Research 
• Mental Health Research & Development Strategy 
• National Diabetes Research Strategy 
• Occupational Health and Safety Joint Research Portfolio 
• Pacific Health Joint Venture 
• Primary Care Joint Venture 
• Problem Gambling Research Initiative 
• Socio-economic Determinants of Health Joint Research Portfolio 
Planned: 
• Cancer Control 
• Disability 
• Rehabilitation 
• Food, Nutrition and Health 
• Biotechnology 
 
Source: HRC Investment Strategy, 2003/04 
 
Around 35 per cent of health and medical research is funded outside the HRC. The Royal 
Society of New Zealand (RSNZ) administers the Marsden Fund for fundamental 
research (financed by a special MoRST output class and overseen by the Marsden Fund 
Council). Marsden funds are specifically not targeted for particular research disciplines or 
social objectives. Grants are large and fund both international linkages and postdoctoral 
researchers, but the success rate is low (around 10 per cent) and funding is ‘one off’. They 
may be better regarded as ‘prizes’ for excellent science.  
 
The Ministry of Education’s Centres of Research Excellence (CoRE) fund also provides 
significant support for health researchers and has provided a large injection of capital 
funds. Although there has been a staged move towards full funding of research projects by 
the purchase agencies, academic researchers also receive substantial support through Vote 
Education’s funds to universities. Increasingly, these university funds are being allocated 
on the basis of research performance through a performance based research funding model 
(PBRF).  
 
As noted, the Government’s principal research purchase agent is the Foundation for 
Research, Science and Technology (FRST). FRST is responsible for many of the  output 
classes shown in Table 2.1, notably those relating to industrial technology development, 
the new economy and the environment. Table 2.2 shows the Foundation’s emphasis on 
economic and environmentally oriented research and technology, with three-quarters of its 
investment in these two areas. Most of the Foundation’s remaining investment is in 
‘knowledge’, but again focused on areas like knowledge based industries with potential 
economic return, or in capability building scholarships and networks. Less than two per 
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cent of FRST’s investment is for ‘social’ objectives (including health). FRST reports nil 
expenditure against HROC in 2003-04. FRST does however play an important role in the 
application of health research in areas such as biotechnology, and through its investment 
programmes it has provided support to some of New Zealand’s best health researchers. 
FRST has also commenced funding clinical trials of pharmaceutical products.  
 






(approx. % of 
FRST funding) 





Economic Goal  
(54%) 
• Focus on value-added exports:  
• Add value within existing 
sectors 
• Springboard from existing 
strengths  














• Focus investment on key 
national priorities (in 
environmental strategies)  
• Be at the forefront, anticipating 
and discovering the 
environmental issues of the 
future  
• Engage key stakeholders in 





Social Goal  
(<2%) 
• Invest to support the 
Government’s seven social 
research themes  
• Take a catalytic role to 
leverage others’ investment 
Health Research  






• Create knowledge networks 
and pathways  
• Focus basic research in areas 
likely to create new 
knowledge-intensive 
enterprises 
• Contribute to Māori 
advancement and development  




























Note: * Funding for HROC in 2002-03 was $1.1 million. 
Source: FRST (2003) 
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A recent report by Investment New Zealand identifies several areas of excellence within 
the field of biomedical R&D within public research groups and biotechnology companies 
(Box 2.4).  
 
Box 2.4  Biomedical R&D strengths identified by Investment New Zealand 
 
• Oncology/cancer 
• Diabetes and cardiovascular disease 
• Neurological diseases 
• Immunological diseases 
• Biomedical imaging and bioengineering 
• Infectious diseases 
• Osteoporosis and bone health 
• Eye research 




Non-government sources of health research funding include Lotteries Health Research, 
national charitable organisations such as the Cancer Society, the National Heart 
Foundation, the Neurological Foundation, the Multiple Sclerosis Society and local 
foundations such as the Canterbury Medical Research Foundation (Richards 2000). The 
Malaghan Institute of Medical Research is an independent health research organisation, 
which in 2001 had a capital endowment fund of $2.7 million. The big disparity between 
New Zealand and other OECD countries lies in the R&D activities of the business sector, 
which invests less than one-third of the proportion spent in most OECD countries. Public 
biomedical research funding has laid the basis for New Zealand biotechnology companies 
including Genesis R&D, NeuronZ (a University of Auckland spin-off company), BrainZ, 
EndocrinZ, Pacific Edge Biotechnology, BLIS Biotechnology and ProActa Therapeutics 
Ltd (also based on University of Auckland research) (HRC 2003a; Richards 2000). 
International companies are investing in New Zealand’s top health research groups. 
Pharmaceutical companies contract research participation in trials, but are being 
discouraged from broader investment in part by government purchase arrangements for 




In common with most of the comparator countries, New Zealand has an independent 
organisation for health research funding within a plural system for health research support. 
There is a long-established and effective research council for health and medical research 
the  HRC which is the principal, but not sole, actor and the HROC is the largest, but not 
only, source of funds. Health research investment has remained separate from the 
aggregation of the majority of government research purchasing within the FRST. While in 
the early 1990s health research was excluded from MoRST’s priority setting exercises, a 
closer relationship between MoRST and HRC has existed since 1998, and with it the 
potential for closer collaboration in relation to national research priorities and joint action 
with other purchase agents. Notwithstanding the ‘output class’ framework, emerging areas 
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of opportunity (like biotechnology and clinical trials) are blurring the boundaries between 
the responsibilities of the different purchase agents (HRC and FRST). 
 
Where New Zealand differs notably from the larger OECD countries is in the relatively 
weak business (and non-profit sector) investments in health research and the strong 
concentration of research capability within the university sector (notably within the 
University of Auckland and University of Otago medical schools). 
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3. International Benchmarks I: Comparative National Health 
Research Investment Systems 
 
Choice of benchmark countries 
 
The present evaluation of the New Zealand Health Research output class draws on the 
experiences of health and medicine research systems in other countries. In this context the 
study has sought to make comparisons mainly with the smaller OECD countries that have 
some socio-economic features in common with New Zealand. There is, of course, no 
directly comparable system. Each country has unique historical economic and institutional 
experiences. Nevertheless, it is possible to make some general observations about levels 
and sources of funding, policies, and mechanisms for managing investment while taking 
into account the structural differences.  
 
In Chapter 4 we make some international comparisons of national levels of health and 
medical research funding in terms of health research as a proportion of GDP, as a 
proportion of total research funding and as expenditure per capita of population. Before 
presenting those comparative data it is necessary to describe the structural arrangements 
for funding health research in the comparator countries. The main benchmark countries 
used for this analysis are: Australia, Canada, Ireland, the Netherlands, Sweden and the 
United States. The principal countries selected for comparisons of health research 
investment levels with New Zealand are the same, with the addition of the United 
Kingdom. The countries were selected as benchmarks in consultation with MoRST and 
HRC largely because of the similar scale and structure of their health research systems. 
Clearly, with the larger countries (particularly the USA and UK), due regard must be given 
to the absolute size of their research systems. The comparisons in Chapter 4 include data 
on a range of other OECD countries where these are helpful and readily available.  
 




Like New Zealand, Australia has a long history of commitment to and investment in health 
research. The National Health and Medical Research Council (NHMRC) was set up in 
1936 (Australian Science and Technology Council 1978-1979), becoming a statutory body 
in 1992. Competitive grants for general academic research were introduced in 1966, and 
extended in 1988 with the establishment of the Australian Research Council (ARC). 
Several federal agencies thus fund health research. The major ‘purchaser’ is the NHMRC, 
but ARC and the Cooperative Research Centres (CRC) Program also play a role as do a 
range of other agencies and the State governments. Commercially oriented R&D is 
supported through AusIndustry’s programs (although only those in pharmaceuticals and 
biotechnology are specifically health related). 
 
The federal government continues to give strong emphasis to health and medical research. 
‘Promoting and maintaining good health’ is one of four National Research Priorities (NRP) 
announced in December 2002. Four specific goals – infant and child health, ageing, 
preventive healthcare, and the social and economic aspects of health – are identified as 
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contributing to this priority. Research into biotechnology and genomics is included under 
other priority areas. The national research priorities make no specific mention of health 
research relating to or by indigenous Australians.7  
 
Research issues currently under consideration by the Australian federal government 
include coordination mechanisms in relation to research priorities and collaborative 
research, and provision for research infrastructure.  
 
National Health and Medical Research Council (NHMRC) 
 
NHMRC is the major ‘purchaser’ of health research Australia with a current annual budget 
of nearly A$400 million. It is responsible for an estimated 32 per cent of Commonwealth 
Government expenditure on health R&D (National Health and Medical Research Council 
(2003c). NHMRC funds research undertaken in universities (45 per cent of its grants) and 
in other institutions including medical research institutes (38 per cent), teaching hospitals 
(13 per cent) and other health service providers. In addition, the Council has responsibility 
for the development of evidence-based health advice and provision of ethical guidelines for 
health and medical research (National Health and Medical Research Council (2003c). 
Specifically, the Council’s statutory obligations under the NHMRC Act are: 
• To raise the standard of individual and public health throughout Australia;  
• To foster the development of consistent health standards between the various States 
and Territories;  
• To foster medical research and training and public health research and training 
throughout Australia; and  
• To foster consideration of ethical issues relating to health.  
 
NHMRC comprises several Committees, which report through the Council to the federal 
Minister for Health and Ageing. These are: the Research Committee (RC), the Australian 
Health Ethics Committee (AHEC) (both specified in the NHMRC Act the Health Advisory 
Committee (HAC), the Licensing Committee, the new Aboriginal and Torres Strait 
Islander Forum and several Expert Committees. The Research Committee merges the 
functions of the former Strategic Research Development Committee (SRDC) (National 
Health and Medical Research Council ( 2003c). 
 
NHMRC’s research investment activities have three main strategic goals: world-class 
knowledge creation, world-class research capacity (facilities and infrastructure, 
responsive work force) and translation of knowledge for community benefit (policy and 
practice, commercial development). The scope of the NHMRC’s main research schemes is 
shown in Table 3.1.  
 
                                                 
7 http://www.dest.gov.au/priorities/default.htm, 24/2/2004 
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Table 3.1: Main research investment activities of NHMRC  
 
Scheme (No. and value of new grants in 2003, success rate in 2002) 
NHMRC Project Grants (412, A$158.1 mill., 23% success rate. 57% of application were rated 
‘fundable’) 
Investigator-initiated project that is thought capable of providing solutions to the research questions 
within a relatively short time frame. More project grants are now for 4 or 5 years. 
Program Grants  (16, A$118.2 mill., 35%) 
Substantial, long-term support to proven, multi-disciplinary research teams to collaborate to solve 
complex problems, contribute new knowledge and novel solutions at a leading international level in 
important areas of health research. 
Strategic Research Development (30, A$19.1 mill.) 
Centres of Clinical Excellence (8, A$16 mill.) 
Enabling Grants (5, A$6.2 mill.) 
Development Grants 
Provide pre-seed development of research proposals. .  
Public Health Capacity Building Grants and Priority Driven Research 
Established to build critical mass in health services and population health research. 
Program in Medical Genomics 
Provides a platform to apply biotechnology to important areas of health and medical research. 
Research Fellowships (48, A$26.7 mill., 28%) 
Highly competitive, providing funding to the most distinguished health and medical researchers. 
Selection criteria include the achievement of health-related outcomes and are interlinked with the 
translation of research findings into health policy and practice. 
Industry Fellowships (26, A$5.6 mill.) 
Provide valuable experience in industry for researchers. 
Practitioner Fellowships (31) 
Allow health practitioners to remain active or to become active in research. 
Burnet Awards (2, A$3.8 mill. – 2002) 
Established to bring expatriate health and medical researchers of international standing back to 
Australia. Awarded to Nobel prize-winner Peter Doherty (immunology) and Tony McMichael 
(population health) 
Career Development Awards (59, A$15.7 mill., 29%) 
Build on previous postdoctoral support schemes by increasing the duration of the award and 
providing support for clinical and public health researchers. 
Howard Florey Centenary Fellowships (20) 
2 year fellowships for researchers returning from overseas 
Training (Postdoc.) Fellowships (86, 50%) 
Postgraduate Scholarships (163, A$9.8 mill., 54%) 
Access to additional travelling awards 
Source: National Health and Medical Research Council (2003b, 2003c), Pettigrew (2004). 
 
In line with recommendations in the comprehensive Health and Medical Research 
Strategic Review - the Virtuous Cycle (‘Wills Review’) in 1999, NHMRC’s grant funding 
has nearly doubled, to A$301 mill. in 2003, with further increase planned (National Health 
and Medical Research Council 2003b:131). 
 
The Council has been phasing out block grants to the major medical research institutes, 
which were seen as a barrier to contestability and collaboration. There has also been a shift 
from small project grants to larger project and programme grants. Project grants accounted 
for 47 per cent of grant funding in 2003 compared with over 60 per cent in 2000. Funding 
for ‘cross-discipline, international level collaborative high-impact research’ has more than 
doubled, mainly through the five-year Programme Grants. NHMRC has increased the 
programme grants budget from 7.5 per cent of funding in 2000 to about 18.5 per cent in 
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2003 (National Health and Medical Research Council 2003b). Funding for strategic 
research has increased to around A$20 million, and increases are also seen in 
Development, Collaborative and Partnership Grants, from less than A$50,000 in 2000 to 
more than A$19 million in 2003. The Partnership Grants (to date in the areas of injury, 
mental health and diabetes) are intended to align NHMRC’s priorities with those of other 
stakeholders.   
 
Research priorities and collaboration 
 
Following the Wills Review the NHMRC adopted a three-tiered framework for its strategic 
research program, as follows: 
 
• Tier 1: the areas of ageing; mental health; systems of care for chronic diseases; oral 
health; and Aboriginal and Torres Strait Islander health.  
• Tier 2: links the research priority areas as they relate to health services research, 
socio-economic determinants, rural health and palliative care. 
• Tier 3:  considers the need for capacity building, or whether targeted research is 
required. 
 
By discipline area, by far the majority of new awards in 2003 were in Basic Science (52 
per cent) and Clinical Medicine and Science (34 per cent).  
 
Research priorities have reflected national health priorities and, more recently the National 
Research Priorities. The Council has also identified priority areas, most notable Aboriginal 
and Torres Strait Islander health. The federal and state governments have nominated seven 
National Health Priority Areas. These are: asthma, cancer control, cardiovascular health, 
diabetes mellitus, injury prevention and control, mental health, and arthritis and 
musculoskeletal conditions. In 2003, over 60 per cent of NHMRC funding was dedicated 
to research in these priority areas (National Health and Medical Research Council (2003a).  
 
NHRMC sees itself as the lead agency in relation to the ‘Health’ NRP. In response to the 
NRP initiative, NHMRC established Strategic Research Networks (SRNs) in each of three 
health-related areas: Healthy Start to Life, Ageing Well, Ageing Productively and 
Preventive Healthcare. The Council has borrowed the concept of ‘Consensus Conferences’ 
from the US NIH with a view to developing further SRNs (National Health and Medical 
Research Council (2003a). Development of these priority areas will involve ‘cooperation, 
collaboration and co-funding’ (Pettigrew 2004), which has already commenced with the 
Australian Research Council as partner (see below). The NHMRC has many other formal 
and less formal collaborative partnerships within Australia and overseas.  
 
The NHMRC still makes a huge investment in investigator-driven research project and 
programme grants, scholarships and fellowships, predominantly in basic health science and 
clinical research. These investments have the objective of knowledge generation and 
building a world-class health research capability. Increasingly, the Council is emphasising 
the application of research, such as through research centres, and is targeting priority areas 
through collaborative partnerships and other means. These priorities are steered by national 
health and research priorities and through the Council’s own stakeholder consultations. 
NHMRC has been quite prepared to champion research priorities such as indigenous health 
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which are not specifically on the government agenda. Overall, the Council has managed to 
embrace application driven collaborative research investment quite convincingly, while at 
the same time continuing to underpin Australia’s health research knowledge creation 
capability. Its challenge over the next few years will be in strengthening interdisciplinary, 
multi-institutional, and cross-sectoral centres and partnerships that address research 
priority areas.  
 
Australian Research Council  
 
The Australian Research Council’s grant budget is on a par with NHMRC’s, amounting to 
nearly A$300 mill. in 2002-03. About 5 per cent of ARC’s funding is for research aimed at 
promotion and maintaining good health. Following Ministerial direction, the ARC 
allocated A$162 million, or 34 per cent of its funds in the 2003 funding round (over the 
five years to 2007), to priority areas including biomaterials and genome/phenome research 
(primarily plant genomics). In 2001 the ARC allocated around 4 per cent of its new 
funding to the priority area of ‘Promoting and maintaining good health’ with the 
proportion increasing to 6.4 per cent in 2003. ARC is also funding the new National Stem 
Cell Centre of Excellence jointly with Biotechnology Australia (Australian Research 
Council 2003c). The Chair of NHMRC is an ex officio member of ARC’s Board.  
 
Cooperative Research Centres Program 
 
The Cooperative Research Centres Program (CRC Program) is the Commonwealth 
Government’s largest investment in cross-sector (industry-university-government) R&D 
collaboration. The CRC Program is at heart a collaboration between different R&D sectors 
and institutions: universities, Commonwealth and State government research authorities, 
individual firms, and industry-led intermediaries such as the rural R&D corporations. Over 
the last 13 years it is widely credited with ‘changing research cultures’ and promoting 
increased and more effective cross-sectoral, multidisciplinary and multi-organisational 
research, technology development and commercialisation.  
 
Now within the Education, Science and Training ministry, the CRC program currently 
supports nine centres in the health and medical area, with a new Centre in Oral Health 
successful in the 2002 funding round (Table 3.2). All CRCs are proposal driven, and 
assessed on the quality of their science, partners and strategies for application. The 
outcomes of the health related CRCs range from commercially applicable technologies 
(such as the cochlear implant and diagnostic technologies) to public health initiatives for 
Aboriginal populations.  
 
Unlike the new Commonwealth centres of excellence, the CRCs are fully proposal driven 
rather than linked to national research priorities. Applications are assessed by one of two 
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Table 3.2: Australian Cooperative Research Centres in Health (2004) 
 
CRC for Aboriginal Health 
CRC for Asthma 
CRC for Cellular Growth Factors 
CRC for Chronic Inflammatory Diseases 
CRC for Cochlear Implant and Hearing Aid Innovation 
CRC for Diagnostics 
CRC for Discovery of Genes for Common Human Disease 
Oral Health CRC (new) 
Vision CRC (formerly Eye Research and Technology) 
CRC for Vaccine Technology 
 
Over the life of the entire programme, about 11 per cent of the researcher/years within 
CRCs has been related to health, with clinical research and public health research in about 
equal proportions (Turpin, Wixted et al. 2003). Under the NRP framework, the CRC 
Program calculates that A$128 million, or around 10 per cent of Commonwealth funds to 
the Program, will be dedicated to health research over the life of the current centres. This 
breaks down as shown in Table 3.3.  
 
Table 3.3: CRC contribution to NRP over the life of current centres 
 
National Research Priority Per cent of Commonwealth funds for CRC Program 
a. A healthy start to life 1.9% 
b
c
. Ageing well, ageing productively 5.1% 
. Preventive healthcare 2.4% 
Total 9.4% 
 
Indigenous health research  
 
Although health research for indigenous Australians is not mentioned within the overall set 
of national research priorities, implementation agencies recognise its importance. These 
agencies include the Australian Institute of Health and Welfare (AIHW), which provides 
statistical and other data for health research,8 and the Australian Institute of Aboriginal and 
Torres Strait Islander Studies (AIATSIS), which has a long history of involvement in 
indigenous health research. The NHMRC identifies Aboriginal and Torres Strait Islander 
Health in its Tier 1 strategic research program. The Council also hosted an Aboriginal and 
Torres Strait Islander Research Agenda Working Group (RAWG), which formulated the 
NHMRC ‘Road Map’ as a programme for health research of relevance to Australia’s 
indigenous peoples.9
 
Infrastructure and overheads 
 
                                                 
8 http://www.dest.gov.au/priorities/plans/AIHW.pdf, 24/2/2004 
9  www.health.gov.au/nhmrc/research/srdc/indigen.htm, 4/3/2004 
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The issue of ‘marginal funding’ of academic research by research councils and research 
corporations is again under review in the context of the development of a national research 
infrastructure strategy. In the past, the government has tended to prefer a model of research 
performance based block funding to universities, presumably in part because any move to 
full cost funding would require a substantial ‘clawback’ of institutional funding from the 
major research universities. As a result, in the view of the ARC, ‘institutional and 
competitive funding mechanisms operate in a fragmented and unduly complex way within 
the university sector’ (Australian Research Council 2003b:3). Currently,  
 
the competitive funding allocated by the ARC and the NHMRC covers only a part of the 
direct costs of the projects, programs, centres and fellowships that these agencies support, 
and very little or none of the indirect costs. The grants and centres programs of these 
agencies do not fund the salaries of Chief Investigators, which often are a significant 
component of the full costs of a research activity. Similarly, the ARC and the NHMRC 
meet none of the costs of project-specific infrastructure, nor those associated with 
infrastructure overheads. In universities, these costs are met by institutional block grants 
and other sources of funding, the allocation of which may be unrelated to ARC- and 
NHMRC-sponsored research outcomes. (Australian Research Council 2003b:32 ).  
 
A further problem is that funding awarded competitively by the NHMRC to medical 
research institutes and other non-University organisations does not attract Commonwealth 
infrastructure funding in the same way that universities do (National Health and Medical 
Research Council (2003b). 
 
In its submission to the infrastructure review, the ARC has proposed that responsibility for 
allocating funding for minor and project-specific infrastructure be transferred from 
Education to the ARC and NHMRC, and that a coordinated mechanism for funding 
medium and major infrastructure (both capital and recurrent costs) be established to be 
jointly managed by the two research councils. ARC has also advocated a fully contestable 
model of funding for research infrastructure accessible by universities, government 
research agencies and other research institutions. The ARC submitted that project-specific 
infrastructure overheads should be paid at a rate of at least 40 per cent of the associated 
grant (Australian Research Council 2003a:13). 
 
The National Research Infrastructure Taskforce reported in March 2004, with a range of 
recommendations about investment in major research infrastructure. The taskforce also 
advanced a set of research infrastructure funding principles for adoption by all research 
funding agencies, universities and government laboratories. These deal with coordination 
and collaboration in the government’s funding of infrastructure, and do not prescribe the 
level of infrastructure funding that should be made by the research councils. However, a 
further review of Australia’s higher education research policies has recently recommended 
that ‘that the Government provide increased funds to the Australian Research Council, the 
National Health and Medical Research Council and other granting bodies to allow them to 
provide increased funding to cover overheads associated with research projects’ (DEST 
2004: 54). This suggests that the Australian research councils will move in the direction of 
meeting a higher proportion of overheads and infrastructure costs.  
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Commercially Oriented Medical Research 
 
AusIndustry administers a range of incentives for research and technology development 
within businesses, most of which are not specifically targeted at biomedical companies. 
The exceptions are the new Pharmaceuticals Partnerships Program (P3), commencing in 
July 2004, which aims to increase high quality pharmaceutical R&D activity in Australia 
throughout the value chain including biotechnology, originator and generic medicines 
companies. Participating companies will receive thirty cents for each additional dollar they 
spend on eligible R&D in Australia up to a maximum grant amount of A$10 million. The 
Biotechnology Innovation Fund (BIF) (now closed to new entrants) funded 
commercialisation of promising biotechnology at the ‘proof-of-concept’ stage. 
 
The research councils have a mandate to support the scientific and technological base of 
commercial applications, but steer away from direct involvement in commercialisation. 
The NHMRC’s position is quite clear: it ‘has no direct function in the commercialisation of 
discoveries… Nonetheless the NHMRC has increasingly supported research that 
demonstrates commercial potential’ (National Health and Medical Research Council 
(2003b:10). In 2001-02 the NHMRC and the ARC commissioned a joint survey with the 
CSIRO of research commercialisation activities in Australian universities, medical 
research institutes and CSIRO divisions. Biotechnology companies such as Proteome 
Systems Ltd (PSL) have been established on the basis of technologies funded by ARC in 
universities.  
 
State government investment in health research 
 
Australia’s States are primarily responsible for the health care system. The larger States 
make substantial provision for health research, which tends to complement that provided 
by the Commonwealth agencies. In New South Wales, for example, NSW Health and 
NSW State Development offer a range of competitive health research grants including 
Capacity Building Infrastructure Grants, R&D Infrastructure Grants, Health Promotion 
Demonstration Research Grants (DRGS) and BioFirst Awards. The DRGS funds Area 
Health Services to conduct rigorously designed health promotion intervention research. 
Funding is modest – DRGS for example has a budget of around A$0.3 mill. in 2004-05.  
 
Under the A$68 mill. BioFirst strategy, A$6 million has been allocated to provide ‘top-up’ 
funding to attract biotechnology researchers to NSW. It has also provided infrastructure in 
two of NSW’s medical precincts – Westmead and St. Vincent’s.10 The intention of these 
BioFirst Awards was to attract 15 expatriate Australians or international experts to NSW 
within five years. The NSW Parliament’s Standing Committee on State Development has 
recently completed an inquiry into science and commercialisation in NSW. The Committee 
criticised the BioFirst program for attracting only five researchers in its first 2.5 years and 
for being too research (rather than commercially) oriented. In 2003, the Minister for 
Science and Medical Research (a new portfolio) initiated a review of medical and health 
research, its terms of reference including priorities for health research funding in the State. 
The parliamentary Standing Committee has recommended dedicated administrative 
                                                 
10 http://www.biofirst.nsw.gov.au/, 25/2/2004 
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support in order to make the Science and Medical Research portfolio effective.11 A 
Ministerial Advisory Council on Medical Health and Research (MACMHR) contributes to 
the coordination of health research in NSW.  
 
In summary, NSW is placing great emphasis on new initiatives in health research and 
biotechnology, experimenting with new funding and organisational structures that are still 




In recent years, coordination has centred on research priority areas and ad hoc cooperation 
between agencies. Attention has now turned to formal organisational coordination of 
activities of the research councils and other science agencies, and between the federal 
government and the states.  
 
Consistent with their missions, all Australian Government research agencies and funding 
bodies are expected to implement the National Research Priorities announced in 2002. 
Each agency has been required to produce an implementation plan showing their 
commitment to appropriate goals.  
 
In 2003, the Minister for Education, Science and Training instigated a review of the scope 
for greater collaboration between Australia’s main publicly funded research agencies and 
universities, chaired by Donald McGauchie. The McGauchie report, released in March 
2004 recommended that a Strategic Research Council (SRC) be established to enhance 
collaboration and coordination across the research system. As the CEO of the ARC puts it, 
‘the nature of research has changed and research is now addressing global and national 
issues which require enhanced collaboration and sharing of resources’ (quoted in Illing, 
2004). European and Scandinavian research councils (such as Sweden’s Council for 
Planning and Coordination) are seen as role models. The intention is for an overarching 
body with advisory, coordination and investment roles to engender greater collaboration 
between research agencies and sectors. The proposed mandate of the SRC includes 
providing policy advice (especially independent advice on cross-boundary issues), 
complementing the roles of existing advisory bodies and research councils (ARC and 
NHMRC), setting broad research policy directions, overseeing implementation of the 
National Research Priorities, and assisting in developing a more unified approach to global 
markets. McGauchie also proposes that SRC should be responsible for a new contestable 
Collaboration Fund of A$500 million over 10 years. The Fund would finance world class, 
centres of excellence involving cross sectoral collaboration.12
 
There is already significant collaboration between NHMRC and ARC in relation to cross-
disciplinary research. The councils are currently discussion appropriate funding models 
and projects in two nominated health related research areas: ‘Thinking Systems/biological 
programming’ and ‘Ageing Well, Ageing Productively’.13 The latter topic is already one of 
NHMRC’s Strategic Research Networks (SRNs).  
                                                 
11 ‘NSW report calls for science system overhaul’. Australian R&D Review, Feb 2004, p 10. 
12 ‘Reports reveal directions for new research system’, Australian R&D Review, March 2004, p 1.  
13 ‘ARC and NHMRC to jointly fund projects’. Australian R&D Review, Feb 2004, p2. 
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Federal-State cooperation in health research investment is achieved through the Priority 
Driven Research (PDR) Program under the aegis of the Australian Health Ministers’ 
Advisory Council (AHMAC). Established in response to recommendations by the Wills 
Review, PDR commenced with a pilot program of A$5 mill. in 2001-02 and received A$13 
mill. in ongoing funding from AHMAC in 2003. The second round of funding allocated 
A$4 mill. to research priority areas including future demands for aged care, high risk 




There are many parallels between the health research investment systems in Australia and 
New Zealand. The ARC (although larger and less elite) has some comparable features with 
New Zealand’s Marsden Fund in the proportion of ‘quality led’ health research investment 
that it funds, while, to some extent  the role of AusIndustry parallels FRST’s commercially 
oriented activities. New South Wales provides an example from a small jurisdiction where 
responsibility for health services and policy is separated organisationally from health 
research funding.  
 
The Australian health investment system is at least as pluralistic as New Zealand’s. 
However, an important difference is that the Australian federal research councils are not 
simply ‘purchase agencies’ and, particularly since amendments to ARC’s legislation in 
2001, have a very significant research policy advisory function.  
 
The NHMRC is responsible to the Minister of Health, while the ARC and CRC programs 
come under Education. Coordination is always an issue. Arrangements have been effective, 
with cross membership of research council boards, and federal coordinating bodies at the 
ministerial and interdepartmental levels of government. Even so, collaboration is still seen 
to be inadequate and organisational changes are being considered. The way that Australia 
has handled Federal-State coordination, while not an issue in New Zealand, gives examples 
of the interleaving of health research support initiatives at the central and local level.  
 
 
Health Research Investment in Canada  
 
Medical research and Public health research 
 
Canada has a complex system of funding sources for health and medical research. 
Although the Federal Canadian Institutes of Health Research (CIHR) is the most easily 
recognised component of the system, there are a number of other agencies involved. For 
the 2002-03, government appropriations for CIHR amounted to $651.2 million15. 
 
General research infrastructure to support R&D is provided by the Canada Foundation for 
Innovation (CFI).16 This is an independent corporation created in 1997 by the Government 
                                                 
14 ‘New round of priority research funding’. Australian R&D Review, Feb 2004, p 19. 
15  CIHR Performance Report 
16 http://www.innovation.ca/index.cfm  
Science for Life 37
  
of Canada to fund research infrastructure. The CFI’s mandate is to strengthen the ability of 
Canadian universities, colleges, research hospitals, and other non-profit institutions to 
carry out world-class research and technology development. The CFI has a budget of 
C3.65 billion and funds up to 40 per cent of each project’s infrastructure costs. These funds 
are invested in partnership with eligible institutions and their funding partners from the 
public, private, and voluntary sectors who provide the remaining 60 per cent of a project’s 
cost. Based on this formula, the total capital investment by the CFI, the research 
institutions, and their partners, will exceed C$10 billion by 2010. 
 
CFI also serves to support health research. For example the British Columbia Cancer 
Agency17 has received grants between C$25 and C$30 million from CFI. In addition CFI 
has a special category for infrastructure support for research hospitals. 
 
Another important initiative of the Canadian Federal Government in recent years has been 
the establishment of the Research Chairs program.18 In 2000, C$900 million was allocated 
to establish 2,000 research professorships (Canada Research Chairs) in universities across 
the country”. Canadian universities both nominate Canada Research Chairs and administer 
their funds19. Universities are allocated Chairs in proportion to the amount of research 
grant funding they have received from the three federal granting agencies: NSERC, CIHR, 
and SSHRC in the three years prior to the year of the allocation. Of the total 2000 Chairs, 
1880 are regular allocations, distributed as follows: 
 
• 846 Chairs (45 per cent) for research in natural sciences and engineering;  
• 658 Chairs (35 per cent) for research in health sciences;  
• 376 Chairs (20 per cent) for research in social sciences and humanities. 20 
 
‘CIHR’s 13 “virtual” institutes are not buildings or research centres, but networks of 
researchers from every possible discipline, brought together to focus on important health 
problems’21. As one example the Institute for Aboriginal Peoples’ Health (IAPH) will fund 
excellent research in topics as diverse as health promotion strategies, diseases and injury 
and ethical considerations within research and care issues. Mostly, funding decisions are 
made at the level of the CIHR but the Institutes, like the IAPH, do have their own funding 
for strategic projects and capacity building. 
 
The Canadian Provincial governments and not-for profit foundations also make a 
significant contribution to health research funding. A number of provincial governments 
have a ‘foundation’ to allocate their funding22. They fund about health research to an 
amount equivalent to about 41 per cent Federal Government’s expenditure. Table 3.4 
summarises the sources of funds for health related R&D in Canada. In addition Canada, 
like Sweden, has a considerable proportion of health research funded by the business 
sector. The proportion of business sector funding in Canada is similar to Sweden but 
                                                 
17 http://www.innovation.ca/projects/index.cfm?websiteid=145  
18 http://www.chairs.gc.ca/
19 http://www.chairs.gc.ca/web/program/index_e.asp   
20 These statistics apply to the 1035 Canada Research Chairs awarded from December 2000 to October 2003. 
21 http://www.cihr-irsc.gc.ca/e/institutes/9466.shtml  
22 For example, the Michael Smith foundation – British Columbia, http://www.msfhr.org/; the Alberta 
Heritage Foundation for Medical Research http://www.ahfmr.ab.ca/  
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considerably more than New Zealand. Table 3.5 shows the source of public sector funding 
for Canadian health research. 
 
Table 3.4: Gross domestic expenditures on R&D (GERD) in the health field1, 2002p 
(C$ mill.) 
 












Federal government 140 0 9 537 6 692 
Provincial 
governments 
0 42 5 218 16 281 
Business enterprise 0 0 1,085 260 9 1,354 
Higher education2 0 0 0 1,228 0 1,228 
Private non-profit 0 0 0 327 25 352 
Foreign 0 0 476 26 1 503 
Total 140 42 1,575 2,596 57 4,410 
1 As data are not provided specifically by “Health Field”, this is STC’s best estimate. 
2 Includes teaching hospitals. 
P – provisional. 
Source: Statistics Canada 2003 Estimates of total expenditures on research and development in the health 
field in Canada, 1988 to 2002p. 
 
Table 3.5: Non-business contribution to health research in Canada 
 
Non-business as % of total health related research 57.9 
Federal % of non-business health related research 27.1 
Provinces % of non-business health related research 11.0 
Higher Education % of non-business health related research 48.1 
Non-profit % of non-business health related research 13.8 
  
Provinces % of Federal funds health related research 40.6 
Based on Table 3.4. 
 
Commercially Oriented Medical Research  
 
CIHR has a dual responsibility for funding knowledge creation and knowledge translation. 
It directly supports commercialisation through three programs23. The CIHR Small- and 
Medium- Sized Enterprises (SME) Research Program is a jointly funded partnership 
between CIHR and numerous Canadian biotechnology companies. The program 
encourages the development of innovative therapies. The CIHR SME program also 
strengthens Canada’s technology-transfer capacity by providing support for research 
commercialisation in university institutions. The Proof of Principle (POP) Program 
supports research projects that require additional time and support to validate discoveries 
and thereby improve the likelihood of their ultimate commercialisation. The Intellectual 
Property Management (IPM) Program strengthens the ability of institutions to manage 
their research knowledge, attract potential users and promote the professional development 
                                                 
23 Information from CIHR (2002) Annual Report 2001-2002 Building for better health Ottawa, CIHR pp22 & 
23. 
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of personnel involved in intellectual property management. The program is managed 
jointly by Canada’s three granting agencies: CIHR, the Natural Sciences Engineering 
Research Council of Canada (NSERC) and the Social Sciences Humanities Research 
Council (SSHRC). 
 
Another avenue for assistance is Technology Partnerships Canada (TPC24). This program 
invests directly in efforts to develop and refine technology, pursue breakthroughs, build 
business alliances, and provide opportunities for highly skilled individuals. Technology 
Partnerships Canada (TPC) offers two main programs25 The TPC R&D program supports 
pre-competitive projects across a wide spectrum of technological development, including 
environmental technologies, life sciences, information and communications technologies 
and advanced manufacturing. Support for small to medium-sized companies with projects 
valued under C$3 million is provided through the TRC-IRAP initiative. 
 
The Canadian Networks of Centres of Excellence program26 promotes partnerships among 
universities, industry, government and non-governmental organizations.27. An important 
coordination feature is that NCE centres are supported and overseen by the research 





Canada’s federally funded innovation system is very complex with a large array of 
different funding sources for research and related activities. This raises challenges for 
coordination. Coordination is primarily managed through structural ties for assessment and 
evaluation at the program level. This occurs at two levels: 1) coordination between 
programs; and through 2) joint funding and administration of a special program. 
 
An example of the first approach is the performance based funding which links success in 
applications for research grants to other programmes. An example of the second type of 
coordination is the Networks of Centres of Excellence, which is funded and administered 




Canada presents a considerably larger system than New Zealand. Like Sweden, Canada 
provides significant direct investment to the research infrastructure at universities. In the 
case of Sweden the allocation is disciplinary based. In Canada it is provided through 
research chairs, along broad disciplinary lines, i.e.. natural science and engineering; health 
sciences; and social science and humanities and via direct infrastructure support from CFI. 
 
                                                 
24 http://tpc.ic.gc.ca/en/invest-health.html  
25 http://tpc.ic.gc.ca/en/about-program.html  
26 http://www.nce.gc.ca  
27 http://www.nce.gc.ca/about_e.htm  
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Health Research Investment in Ireland 
 
The Irish research system 
 
Total public expenditure on S&T in Ireland is classified under five broad headings: 
 
• Research and development activities; 
• Other S&T activities; 
• Education and health; 
• Other public service activities; and  
• Economic and social activities. 
 
The budget for research and development activities (i.e. the public sector component of the 
research funding system) was €342 million in 2001. This represents 23.6 per cent of the 
total S&T budget. The Irish system has continued to grow rapidly, increasing from €296 
million in 2000. 
 
Funding health research 
 
The Department primarily responsible for health research is the Ministry of Health and 
Children. The Department of Enterprise, Trade and Employment is also responsible for 
National agencies such as Science Foundation, Ireland (SFI), and the Irish Council for 
Science, Technology and Innovation (ICSTI). These agencies also contribute to the health 
research investment through infrastructure, project funding and policy advice. The other 
important agency is the Higher Education Authority, under the Department of Education 
and Science, which also funds ICSTI. 
 
The majority of health research funding in Ireland is provided through the Health Research 
Board which comes under the responsibility of the Minister for Health. The HRB was 
established in 1987 with the following functions. 
 
• to promote, assist, commission or conduct medical, health and health services 
research; 
• to promote, assist, commission or conduct such epidemiological research as may 
appropriately or necessarily be conducted at national level and to assist and support 
other health agencies with such research; and 
• to liaise and co-operate with other research bodies in Ireland or elsewhere, in the 
promotion, commissioning or conduct of relevant research. 
 
The HRB expenditure has increased rapidly over the past few years, from €5 million in 
1997 to €22.5 million in 2002. The Post Graduate Medical and Dental Board allocated a 
further €5 million in 2001. Total government expenditure for science and technology 
expenditure for the ‘health’ objective health was €24,093,000. As the HRB has pointed 
out, the introduction of SFI and the funding provided through the Higher Education 
Authority’s Program for Research has greatly enhanced the infrastructure available for 
health related research (HRB 2002)  
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In 2001 the Minister for Health and Children released a new strategic document to guide 
health research funding, Making knowledge Work for Health – a strategy for health 
research. This document emphasised a government commitment to ‘investigator-led, 
bottom-up research, funded competitively and following national and international peer 
review and proposed significant increases in overall funding (HRB 2002).  However, in 
spite of the growth in the health research budget ICSTI have proposed that health funding 
targets will not be achieved and that health research generally remains ‘under-funded in 
terms of GDP/expenditure on health relative to other countries and has not kept pace with 
the overall increase in health funding over the past five years’ (ICSTI 2003a).  
 
Commercially oriented medical research 
 
In 2000, the Government established Science Foundation, Ireland (SFI) as a sub-group 
within Forfás: The National Policy and Advisory Board for Enterprise, Trade, Science, 
Technology and Innovation.  SFI specifically targets biotech and ICT and emphasises the 
basic building blocks, the scientists, keeping them in Ireland and ensuring the health of the 
science system. SFI also Supports Centres, Institutes and equipment and operates a Basic 




The Irish Council for Science, Technology and Innovation (ICSTI) advises the 
Government on the strategic direction of science, technology and innovation (STI) policy. 
Its advice encompasses all aspects of STI policy including: primary, secondary and third-
level education; scientific research; technology and research, development and innovation 
in industry; prioritisation of State spending and public awareness of STI issues. In 2001 the 
Council completed three priority areas of work: 
 
1. Commercialisation of research 
2. Biotechnology 
3. Research evaluation 
 
The growing number of agencies involved in funding or administering health related 
research funding has created debate around how best to coordinate the various agencies 
and their activities in order ‘ maximise synergies and reduce duplication of effort and 
funding’ (HRB 2002:6) As one step toward achieving this an ‘agreed statement’ was 
signed in 2001 by the HRB, the higher Education Authority, the Irish Research Council for 
Science, Engineering and Technology, the Irish Research Council for Humanities and 
Social Sciences and Enterprise Ireland. The HRB was nominated to chair meetings of this 




Ireland presents a country that has rapidly increased its research funding capacity and from 
a comparatively low base. Although the overall health research budget remains small by 
international comparison it has increased at a faster rate than most other small countries.  
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Many of the structural features evident in the Irish system can also be observed in New 
Zealand. For example, they have moved away from a disciplinary based funding and 
toward strategic investments in priority areas. The support for biotechnology and 
innovation through the ICSTI reflects similar strategies adopted by NERF in New Zealand. 
 
The HRB performs a key role in Ireland in coordinating health research overall and is 
consistent with an enhanced coordinating role proposed in this report for the New Zealand 
HRC. 
Health Research Investment in the Netherlands 
 
The Dutch research system 
 
In the Netherlands public research funding is organised both along disciplinary lines and 
through various crosscutting support arrangements for the commercial and social 
application of knowledge and in support of S&T careers and infrastructure. The result is a 
highly pluralist system for funding, performing, evaluating and setting directions for health 
and medical research. The system appears productive and effective. The number of 
scientific publications per researcher exceeds the European average, and while the 
Netherlands has a similar share of international scientific publications to Australia (around 
2.5 per cent of world total), their impact is higher than all countries save the USA and 
Switzerland (Netherlands Observatory of Science and Technology 2000).28  
 
Basic and strategic health research 
 
The Dutch national research council, the Netherlands Organisation for Scientific 
Research (NWO) under the Ministry of Education, Culture and Science, is responsible for 
about 20 per cent of total university research funding, although funding is only delivered 
through its Research Councils. Eight research councils within NWO represent the branches 
of science and humanities: There are several research institutes in the health field in the 
Netherlands, such as the National Institute for Public Health and the Environment (RIVM); 
these are financed directly by the Ministry of Health, Welfare and Sport rather than by 
NWO through ZonMw. The Royal Academy (KNAW) and government TNO and KNAW 
have their own institutes carrying out health related research (see below).  
 
Traditionally, NWO’s role has been to award investigator initiated proposals, but from the 
early 1990s has adopted a more strategic role: ‘it has also taken up the responsibility for 
stimulating research in areas of socio-economic relevance, wants a larger share of funding 
to go to multidisciplinary research and, increasingly, allocates resources under “large grant 
schemes”, and in some instances with co-funding of government ministries and industry’ 
(Van der Meulen and Rip 2000). As NWO acknowledges, ‘[t]he awareness of the fading 
distinction between scientific and social inspiration has complicated NWO’s policy 
environment’.29 NWO continues to recognise that its ‘core business’ is ‘quality: 
                                                 
28 Impact is measured by the citation impact score, defined as the number of citations received from ISI listed 
publications, 1994-98. The Netherlands’ impact score is 1.23, compared to the world average of 1.00. 
Slightly less than 40 per cent of Netherlands’ publications outputs are in biomedical and health sciences. Of 
these by far the largest group is in Clinical Medicine, which has an impact score higher than the international 
average.  
29 http://www.nwo.nl/nwohome.nsf/pages/NWOP_5SRCB6_Eng [16/2/04] 
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challenging, high risk science’ (Netherlands Organisation for Scientific Research (NWO) 
1995). From 2002, a new career development scheme supports 150 researchers a year. This 
represents a substantial increase in career support from NWO. This ‘new-style’ 
Innovational Research Incentives Scheme is in collaboration with the universities and the 
Royal Netherlands Academy of Arts and Science (KNAW) and is also known as the ‘Veni, 
Vidi, Vici’ programme, as it supports researchers at three stages in their career.30 NWO 
also offers career development schemes for women researchers (Apasia) and non-native 
Dutch researchers (Mosaic). 
 
ZonMw, the Netherlands Organisation for Health Research and Development, is the 
NWO’s medical and health research council, and also has a formal relationship with the 
Ministry of Health, Welfare and Sport (VWS). ZonMw was created through the 
amalgamation of ZON, the Health Research and Development Council within the Health 
Ministry, and NWO’s former Medical Sciences Council.  
 
ZonMw sees its mission as follows:  
 
• To renew the system of health research and health care in the Netherlands; 
• To operate integrated programs of research, development and implementation; and  
• To intermediate between practice, policy and research.31 
 
ZonMw supports research in the areas of health, prevention and care, covering basic 
scientific research through to applied research and development. ZonMw runs both 
proposal driven (‘open response’) and targeted special research initiatives. Fellowships, 
clinical research training grants, group and equipment grants are examples of the main 
instruments of support. Research is organised according to clusters (with broad average 
funding in recent years): 
 
1. basic science and industrial innovation (€32.7 mill.). 
2. research support for disease prevention (€24.0mill.). 
3. support for research for ‘long lasting care’( €8.8 mill.). 
4. support for research and development for health care and cure including demand 
and societal factors (€8.4mill.).  
5. support for research for quality and efficiency & effectiveness in health care and 
cure (€13.0 mill.) 
 
The total spend is around €87 mill. The annual budget for science-driven research is about 
€21 million.  
 
ZonMw’s assessment procedures focus exclusively on scientific quality, including career 
perspectives for new researchers and track records for established investigators. An 
application is structured in two stages. Applicants first write a short Expression of Interest 
(success ratio 15 per cent). This is judged on quality and the researchers either invited to 
                                                 
30 http://www.nwo.nl/nwohome.nsf/pages/NWOP_5SRC5E_Eng [16/2/04] 
31 Edvard Beem, ZonMw, pers. comm. 
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apply or advised that an application is unlikely to succeed. The success ratio for the second 
stage of applications is 37 per cent.32  
 
The role of ZonMw has changed significantly over the last decade, paralleling 
developments within many health research councils internationally, including in New 
Zealand. These changes are summarised by Beem (pers. comm..)as follows:.. Health care 
and health research systems have become more strongly integrated compared to the former 
situation where the Health Ministry funded the former and NWO funded individual basic 
biomedical research projects. In parallel, a closer working relationship has developed 
between the Medical Faculties in the universities and the Academic hospitals, which 
formerly operated independently. Over the next decade ZonMw has set its sights on further 
integration of health R&D, strengthening health R&D infrastructure, implementation of 
R&D results (and translation of public health and health care needs into R&D 
programmes), and promoting a greater international orientation for Dutch health R&D. To 
achieve these goals, ZonMw aims to double its budget over the next decade. 
 
The Netherlands Royal Academy of Arts and Sciences (KNAW) is responsible for a 
range of national biomedical research institutes and centres, including the Institute for 
Brain Research, the Interuniversity Cardiology Institute and the Ophthalmic Research 
Institute. KNAW has a discipline advisory Council for Medical Sciences and committee 
for Biochemistry and Biophysics. The Academy offers a range of stipends, overseas study 
and conference grants for medical researchers.33 KNAW sees itself as a protector of basic 
research and plays a specific role in the evaluation of the quality of research (Rip and Van 
der Meulen 1995). KNAW accredits medical research schools and carries out discipline 
reviews in conjunction with the Association of Universities in the Netherlands (VSNU). 
The Council has recently reported on the impact of applied health research (Council for 
Medical Sciences 2002).  
 
Commercially oriented medical research 
 
The Technology Foundation (STW) has operated within NWO since 1990. STW is 
independent, but acts as the knowledge transfer agency for NWO. STW funds university 
research (and research in selected technology institutes) that meets two criteria: it must be 
of high scientific quality and directed towards practical application or utilisation i.e. ‘the 
embedding of the results in society’.34 Each criterion carries equal weight in the 
assessment. STW’s budget in 2002 was about €46 million. Funding comes from the 
Ministry of Economic Affairs (EZ) (40 per cent) and from the Ministry of Science and 
Education (60 per cent), the latter via NWO. About 40 per cent of completed proposals are 
funded and it is firm STW policy to maintain the success rate at this level. The application 
process takes no longer than six months, and applications are considered at any time. 
Typical project funding is €0.4-0.5 mill.  
 
STW welcomes applications from all fields, including health, medical and biotechnology. 
STW runs two programme streams. The first and largest the Open Technology Programme 
                                                 
32 Stéfan Ellebroek, ZonMw, pers. comm. 2003. 
33 http://www.knaw.nl/cfdata/disciplines/medicine.cfm [16/2/04] 
34 http://www.stw.nl/stw/networking.html [10/02/2004] 
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(OTP), with over 85 per cent of budget, is for proposer driven projects in any field, while 
the second is for specific programmes nominated by STW (11 per cent of budget), the 
remaining 3 per cent of programmes are determined by NWO/EZ. These may arise from 
‘critical masses’ generated in the OTP. Projects are collaborative in that researchers 
develop their proposals in consultation with people in industry and nominate industry or 
social representatives for a ‘user committee’, set up for each project by STW. Most project 
grants last 4-5 years and can fund equipment, PhD students and equipment. The 
Technology Foundation and the university jointly own any intellectual property from the 
project. Any royalties are returned to the project leader. One successful project has been 
the development of a novel prosthesis for leg amputees. Research into drug delivery and 
rheumatism diagnostic kits has led to new start-up companies.  
 
The Netherlands Organisation for Applied Scientific Research (TNO) Institute for 
Prevention and Health is organised around two research clusters: the biomedical cluster 
(Pharma), which develops knowledge for the pharmaceutical and biotechnology markets, 
and the ‘care’ cluster, which is geared towards public market issues (TNO Prevention and 
Health 2002). 
 
‘BioPartner’ is a Dutch government initiative, under the Ministry of Economic Affairs, 
that provides support for several stages of commercial development of the life sciences. 
While most assistance, such as networks, risk capital and ‘BioPartner Centres’, which are 
incubator building with some shared facilities, is aimed at start-up companies, BioPartner 
will also support researchers in public universities and laboratories to collaborate with 
start-up companies or to set up their own enterprises. For example, ‘First Stage’ grants are 
available for them to develop a feasible business plan from their research idea. The scheme 
also supports the purchase of specialised equipment for joint use by public sector research 
and start-up companies. The equipment is usually housed in the university or public 
laboratory.35  
 
‘Senter’ is branch of the Ministry of Economic Affairs (EZ) with a brief to promote 
technology, energy, environment, exports and international cooperation. Senter manages 
grant schemes on behalf a number of government agencies. In addition, Senter supports 
national collaborative initiatives (for example in genomics), as well as sponsoring Dutch 
involvement in European and international aid projects in biomedicine and public health. 
Senter acts as a brokering agency by providing companies with information on Dutch and 
international grants and assistance, and provides a link between companies, universities, 




Real cooperation is apparent between NWO, STW, Senter and BioPartner (STW 2003). 
Collaboration has started in the field of ‘Genomics Technology’, a sub-section of the 
Innovation Oriented Research Program Genomics (IOP Genomics) which is run by Senter. 
IOP Genomics and STW have each allocated €2 million for technology research in the 
                                                 
35 http://www.biopartner.nl/asp/content.asp [10/02/2004] 
36 http://www.senter.nl/asp/page.asp [10/02/2004] 
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field. STW is also co-operating with ZonMw within the Tissue Engineering programme. 
Many STW grant recipients have been awarded BioPartner ‘First Stage’ grants.  
 
A sectoral Advisory Council on Health Research (RGO) is established to advise the 
government (primarily the health and education ministries) on strategic issues. The RGO’s 
main task is ‘to set priorities for research aimed at the solution of problems in health and 
health services and to give recommendations on financial and infrastructural matters’. A 
recent report, for example, investigates the knowledge infrastructure for public health and 




The Dutch health research support system exhibits all the elements found in New Zealand, 
with the addition of a large government research institute (TNO) and specialised 
biomedical commercialisation agencies. The system has undergone many of the same 
changes faced in New Zealand: a system initially organised along the 
basic/strategic/applied divide, represented by KNAW/NWO-MW/STW and TNO, but 
which is now addressing social (and to some extent commercial) application of health 
research at all levels. This has required a high degree of cooperation and coordination. 
Dutch policy researchers have explained the coordination challenge as a process of 
‘heterogeneous aggregation’ (Van der Meulen and Rip 2000). They note,  
 
The real importance however rests on the development within these interactions of shared 
frames of references and co-development of what can be called hybrid knowledge 
reservoirs: knowledge that comprises the scientific insights as well as practical knowledge 
and experiences, and last but not least insights how these two are interrelated (in some 
cases in a way that they are difficult to distinguish). Such hybrid knowledge reservoirs are 
needed to create effective communication and the ability of societal actors to become real 
users’(Van der Meulen and Rip 2000). 
 
The level of coordination in the Netherlands and the mechanisms for achieving it – such as 
the presence of a cross-Ministry advisory council on health research – may offer some 
useful lessons for New Zealand –. This is discussed further in Chapter 7.  
 
 
Health Research Investment in Sweden 
 
The Swedish research funding system 
 
Sweden maintains a pluralistic research funding system with numerous independent 
financiers. The situation is similar to the Netherlands but with a higher proportion of 
funding provided by private foundations and the business sector. Like New Zealand, most 
public funded research in Sweden takes place in the universities. The public sector (other 
than higher education) accounts for only around 3 per cent of national R&D expenditure. 
However, unlike New Zealand, a large proportion of national research funding is provided 
and carried out by the private sector. Nearly 70 per cent of all Swedish research funding 
originates from the private sector. 
                                                 
37 http://www.rgo.nl/pdf/summary-publication-39.pdf [16/2/04] 
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Public funding is directed through two main mechanisms: through direct appropriations to 
higher education institutions, allocated to specified scientific fields; and by means of 
appropriations to Research Councils and sectoral research agencies to be distributed 
through competitive funding programs and investigator led bids. The strategy underlying 
this dual system is to provide a ‘well-funded’ collaborative research environment in the 
university system while at the same time providing flexibility through a competitive 
submission based processes.  
 
Basic research  
 
Funding to universities is allocated directly to universities across eleven ‘scientific fields’. 
The strategy is to provide a sound infrastructure base across the disciplines. Medical 
research at universities represents the largest single concentration of government funds by 
field of research to universities. Total government research investment for medicine in 
2003 was equivalent to €435 million38 including the higher education allocation and 
government R&D grants (Statistics Sweden 2003). This investment accounted for 60 per 
cent of all medical research (Billig 2004). The Swedish Research Council has a funding 
base of around €262.8 million, approximately 16 per cent of which is distributed to 
medical research.  
 
In 2001 a number of general reforms were introduced to increase interdisciplinary and 
cross-sector collaboration across the system. The reorganised Swedish Research Council 
now comprise of three research councils: humanities and social science; natural and 
engineering sciences; and medicine. In addition the SRC maintains an education 
‘committee’. The strategy behind these changes was to ‘strengthen researcher control’ and 
‘promote collaboration between different fields’. (Swedish Institute 2001) 
 
The SRC holds responsibility for funding basic research and maintaining an international 
standard of research capability and excellence. It is also responsible for providing research 
policy advice. The Scientific Council for Medicine supports medical research throughout 
the field of medicine: medicine, pharmacology, odontology and healthcare sciences. 
During 2001, the Council for Medicine disbursed nearly €38 million for medical basic 
research. In addition, it administered nearly €3.3 million from other sponsors of joint 
research programmes. 
 
Apart from the SRC there are other agencies that contribute to health and medical research. 
These include: 
 
• The Swedish Council for Working Life and Social research  
• The Swedish Foundation for Strategic Research 
• The Knowledge Foundation 
• The Swedish Foundation for Health Care Sciences and Allergy Research 
 
Sweden’s county councils and municipalities also finance R&D in health care. A 
significant component of medical research in Sweden is funded through non-government 
                                                 
38  These figures are based on a 2003 exchange rate of 9.13 SEK. 
Science for Life 48
  
foundations. For example, the Swedish Cancer Society distributes approximately €32.8 
million annually.  
 
Commercially Oriented Medical Research 
 
The Swedish Agency for Innovation Systems aims to promote sustainable growth in 
business through innovation. It is a new agency financing ‘needs based and development to 
support ‘innovation systems, sustainable development and growth’. Some of these funds 
support R&D in medical related fields. It should be noted, however that the business sector 
accounts for around 70 per cent of all R&D carried out in Sweden and approximately 40 
per cent of medical research. For this reason there is a strong emphasis placed on creating 




Coordination of medical research as carried out two levels. The SRC has a coordinating 
role for its three councils and education committee. The SRC also has the general task of 
providing the government with research policy advice as well as promoting research 
cooperation. At a higher level, overall responsibility for the coordination of research policy 





A major distinguishing feature of the Swedish health research system is the high 
proportion funded by the non-government sector, including firms and foundations. 
However, like New Zealand the majority of publicly funded research takes place in 
universities. The Swedish system could be characterised as a dual system, supporting 
disciplinary based clusters through university research funding and by investigator led 
funding through a peer reviewed grants based system. 
 
Recent discussion in Sweden has drawn attention to a relative decline in Swedish health 
research funding. It has been pointed out that medical research has not kept pace with 
growth in other disciplines. On the other hand there is evidence of an increase in the 
number of new biotechnology companies(Billig 2004).  
 
A new strategy, Medical Research – for health, quality, Health Care and economic growth  
is currently under discussion(Billig 2004).. The target identified in the draft strategy is to 
double the amount of funding for project support and to increase the level of funding 
among the top 10 per cent of projects.  
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Health Research Investments in the United States 
 
The US funding system 
 
The outstanding feature of the US system is its sheer size and the strength of the private 
sector in funding and carrying out research as well as providing a platform of research 
users. A consequence of the size of the economy and the history of medical research is the 
size and complexity of the National Institutes of Health (NIH). However, in spite of these 
major structural differences there are some useful lessons that might be drawn from the US 
experience. 
 
Responsibility for basic biomedical research 
 
The U.S. National Institutes of Health have lead responsibility for basic biomedical 
research in the United States. NIH consists of 27 institutes and centres, some focused on 
disease categories and some on general resources for biomedical research. The total budget 
requested for NIH for the coming fiscal year is US$28.8 billion, of which about 11% will 
be spent on NIH in-house laboratories and the rest in extramural grants to universities and 
medical schools. Because the NIH is so big, it is often asked to take on missions beyond 
basic research, and NIH directors have varied in their willingness to do so. The current 
director, Dr. Elias Zerhouni, has a roadmap for the biomedical enterprise that stresses 




Beyond NIH, the U.S. Department of Health and Human Services includes about US$1 
billion in research spending in more specifically applied agencies. The Veterans’ 
Administration, for example, funds some health on issues relevant to those who have 
served in the military. The Agency for Healthcare Research and Quality supports health 
services research. Another US$1 billion or so is spent for health research outside HHS, for 
a total of US$30 billion requested in the next fiscal year’s budget. 
 
Public health research 
 
The Centers for Disease Control and Prevention (CDC) has lead responsibility at the 
federal level for public health. It includes some research components, including intramural 
laboratories. The National Institute of Occupational Safety and Health (NIOSH), for 
example, is housed within the CDC, as are the laboratories that isolated and sequenced the 
SARS virus. 
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Commercially-oriented medical research 
 
All biomedical research in the United States is available for commercialisation under the 
provisions of the Bayh-Dole Act. Even NIH intramural researchers are allowed to consult 
with industry. Some specifically commercial programs include the Small Business 
Innovation Research Program at NIH, the new Institute of Biomedical Imaging and 
Bioengineering at NIH, and portions of the Advanced Technology Program at the National 
Institute of Standards and Technology in the Department of Commerce. Biomedical 
inventions may also be commercialised in the SBIR programs of other agencies, such as 
Defense. Similar approaches can be observed in other countries such as the Swedish 
Agency for Innovation, the STW in the Netherlands, the ICISTI in Ireland as well as HRC 
and NERF in New Zealand. 
 
Minorities health research 
 
The US has in place a strategic research plan and budget directed toward ‘the reduction 
and ultimate elimination’ of health disparities (NIH 2002). The strategy includes increasing 
participation of minorities in clinical research and ‘increasing the number of minority 
clinical and basic medical scientists in the system. The strategic plan focuses on three key 
goals: research; research infrastructure; and community outreach. The strategic plan also 
reflects work in progress toward development of a methodology the NIH can use to 
determine the amount of resources currently supporting health disparities research. NIH 
has established a Committee on Minority Health and Health Disparities Research 
Definitions and Application Methodology. However, under the US approach all minorities, 
including American Indians are combined to form a single target group under the ‘health 
disparities research’ policy.  
 
New Zealand appears to have progressed further in strategic development for Māori health 
research and has already achieved significant outcomes in building a Māori health research 
community. The HRC has also been involved in the formulation of performance indicators 
for Māori and Pacific Health research through involvement in the PBRF. Considerable 
progress has been made in New Zealand in developing mechanisms for assessing research 
outcomes and impact from health research directed toward Māori. Further, indicators to 
monitor the number of Māori and Pacific researchers across the system have been used by 




Most of the health research enterprise is located within the Department of Health and 
Human Services, which provides some coordination. Interagency working groups tend to 
form in specific disease or problem areas. All the parts of the medical research enterprise 
in the United States are ultimately, but very loosely, coordinated by the White House 
Office of Science and Technology Policy, which works closely with the White House 
Office of Management and Budget. Most of health spending is authorized through the 
Subcommittee on Health of the House Committee on Energy and Commerce and through 
the Senate Committee on Health, Education, Labor, and Pensions. 
 
Evaluation and GPRA (Government Performance Reporting Act) 
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Annual Performance Plans include performance goals that can be assessed through 
objective/quantitative measures and performance goals based on descriptive achievement 
criteria. Where objective/quantitative measures can be used, performance assessment is a 
process, principally, of comparing data on actual achievement with the target levels stated 
by the Annual Program Performance Plans. Where such measures are not available or 
judged not useful, GPRA (Government Performance Reporting Act) provides for an 
agency to define performance goals that rely on criteria that are descriptive in nature.  
 
NIH has organized its performance goa1s under three Core GPRA Programs: 
• Research Program 
• Research Training and Career Development Program 
• Research Facilities Program 
 
NIH also focuses on communicating scientific results, promoting the efficient transfer of 
new drugs and other technologies, and providing effective research leadership and 
administration. Six goals for the Research Training and Career Development Program 
support research training and outreach designed to ensure a continuing supply of well-
trained scientists. Eight goa1s for the Research Facilities Program focus on modernizing 
and improving intramural and extramural research facilities to ensure that the nation' s 




The US presents the world’s largest national research system. There are few direct 
comparisons that can be made at a system level with New Zealand. However, there are 
some areas that provide some useful benchmarks. First, health research has only recently 
been brought under the national evaluation spotlight, through GPRA. New Zealand on the 
other hand has a quite well developed and transparent system for funding and reporting on 
output. The move to full cost recovery costing in New Zealand and the processes in place 
for assessing full-cost provide an opportunity to develop a robust and transparent 
evaluation system. The US has moved in the same direction and considerable effort has 
gone into developing methodologies for identifying strategic research inputs and outcomes. 
As this work deepens in the US new indicators for evaluation may emerge. 
 
 
Summary Observations on International Health Research Systems 
 
The review of country experiences emphasises a number of common features. There are 
significant socio-economic differences across the countries but there are some lessons that 
can be drawn from strategies, implementation and evaluation mechanisms and 
coordination. 
 
While a variety of funding mechanisms are in place and managed by various agencies in 
other countries there is, as in New Zealand, usually a dominant agency (or in the case of 
Sweden, sub-council) carrying major responsible for national health research. Typically, 
other complementary agencies are focused on innovation and commercialisation, in 
collaboration with the private sector. The level of complexity and number of agencies is 
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largely a factor of size. The sheer size of the US contribution to health research presents 
the most complex system in terms of the numbers of agencies involved. However, even in 
comparatively small countries, such as Ireland, other funding mechanisms are in place to 
complement the work of the core funding agencies. The New Zealand system is consistent 
with this model. A key issue – one that most countries are grappling with – is the best way 
to manage the boundaries between funding mechanisms and the agencies administering 
them. 
 
Thus, Australia has just raised a proposal for a cross-cutting Strategic Research Council to 
improve collaboration and coordination and to oversee the implementation of national 
research priorities. In Canada, collaboration can take the form of joint funding and 
administration of particular programmes, notably the Networks of Centres for Excellence. 
In Ireland, the Health Research Board chairs an interagency coordinating group on health 
research. The health research council in the Netherlands has become more strategically 
focused and collaborative, and there is also an sector council for health research to advise 
relevant ministries. Sweden has a longstanding research Council for Planning and 
Coordination. 
 
The funding strategy within all countries has shifted, to varying extent, away from 
disciplinary based models toward broad objective based. The main distinction that 
predominates in funding strategy is not so much between disciplines but between 
biomedical science, clinical science and public health. The emphasis is thus on strategic 
objective rather than scientific base. A further distinction is between research supporting 
innovation in partnership with other sectors, especially the business sector, and research 
focused on centres of excellence.  
 
All countries covered in the review have introduced new strategic plans for health research 
during the past four years. These reflect growing demands to account for the returns and 
value derived from research investments and to establish formal and transparent evaluation 
systems. In most countries changes have been introduced into the structure and 
mechanisms for health research funding. Sweden, for example, have revised their Research 
Council structure, Ireland has introduced a new agency for innovation research and the 
Netherlands have combined the activities of ZON (the Health Research and Development 
Council) with NWO’s former Medical Science Council to create ZonMw (the Netherlands 
Organisation for Health Research and Development). 
 
There is a trend in the benchmark countries towards building in infrastructure costs to 
investigator led research investments. New Zealand has progressed further down this path 
than other comparable countries. The full-cost-funding system as implemented by the HRC 
in New Zealand has not been achieved to the same degree in other countries (see Appendix 
2). Its implementation provides a well-defined and transparent process for accounting for 
the various elements of total research cost some of which are provided through different 
investment mechanisms and agencies. The process provides for clarity between financial 
contributions from different sectors. It consequently provides a sounder base for evaluating 
the relationship between specific research inputs and outcomes. An important issue for 
New Zealand university based research is to ensure that with the introduction of full cost 
funding adequate resources are available for carrying out high quality medical health 
Science for Life 53
  
research as well as maintaining the appropriate infrastructure within the university system 
on which it depends. 
 
A feature of the most recent wave of strategic plans is an emphasis on target populations. 
New Zealand appears well ahead of the comparator countries in this regard. For example, it 
is now more than a decade since the Māori health research strategy was initiated. HRC also 
has extensive health research and capacity building programmes for Pacific peoples. The 
US, in contrast, has only now established a committee to define a methodology for 
accounting for research investments for minorities (see Chapter 6).  
 
Research councils in all the benchmark countries support some combination of investigator 
led health research based on excellence and to varying extent relevance. In this regard, the 
HRC is closely in line with international practice. The New Zealand peer review system 
for health research is clearly of a high international standard, is transparent and is very 
highly regarded. Key stakeholders unanimously expressed confidence in this element of 
the system. The peer review system as it is currently in place identifies a considerably 
larger proportion of excellent fundable research projects than is presently funded under 
present budget constraints. Further, the HRC has clearly developed investment strategies, 
linked to target objectives for health outcomes. The HRC’s research investment strategy 
and related issues are discussed in more detail in Chapter 5. 
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The question of the appropriate level of investment in health research in New Zealand is 
best considered by examination of investment decisions made in other countries that are 
facing similar health challenges. This chapter analyses the funding of health and medical 
research in New Zealand and a range of comparable industrialised (OECD member) 
countries. 
  
Because the variations in the structure of research and investment systems (see Chapter 5), 
no single indicator of funding can be used as a definitive measure of the level of research 
funding. Thus a range of different measures of comparison has been developed to 
‘benchmark’ New Zealand’s health research investments against the comparator countries. 
 
The analysis is divided into three sections. The first compares the overall funding of health 
and medical research in the comparator countries; the second investigates the degree to 
which national competitive grants fund health research; the third provides a brief analysis 
of the cost structures for medical research funding councils, since this affects the validity 
of comparisons based primarily on expenditure by the councils. Detailed notes on data 
used in the analysis can be found in Appendix 1. Each of these measures has particular 
benefits and limitation. These are discussed in Box 4.1. 
 
Box 4.1: Measures of comparison: the pros and cons  
 
1. Source of data 
 
There are several choices – government budget data and survey data from institutions conducting 
research (e.g. the universities) are the main examples. The appropriate choice depends on the 
purpose. This report is an evaluation of the Health Research Output Class – a government budget 
item – so we are interested in equivalent government budget data from other countries. 
 
2. Basis of indicators 
 
There are several types of data and different means of transforming data into comparable indicators 
for cross-country comparison. 
 
(a) Health research expenditure as percentage of Gross Domestic Product (HR/GDP). 
This is the most widely adopted indicator. It is easy to use and can be applied to different research 
fields, sectors of activity (government, business, natural sciences and social sciences etc) and can 
be done for most countries. Data compiled by international organisations emphasise this indicator. 
 
Limitation 1: is that when it is applied to particular funding categories, then there is an assumed 
equivalence of purchasing power. So for example the HRC expenditure as percentage of GDP 
when compared to other health research funding bodies does not take account of the HRC having to 
pay the universities a full cost overhead rate.  
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Limitation: 2 comes with the use of GDP as a denominator. If a country has a rapidly growing 
GDP then the ratio may fall – because it is difficult for Governments to expand research 
expenditure faster than GDP growth. 
 
2. Share of Government expenditure on R&D devoted to a health research.  
 
This approach overcomes the vicissitudes of GDP. It may also obviate the cost structure 
comparison problem (provided that all agencies are on the same cost basis). Thus this indicator is 
not without merit and has been included in this report, but it is not without difficulties. 
 
Limitation 1. Finding cross-country comparable tables of Government S&T budgets can be very 
difficult (see OECD’s approach in Box 4.2). Each country has idiosyncrasies in how they report 
budget funds. As this indicator is not used often by international sources it has to be extensively 
researched (as has been done for this report) but there is a risk of double counting or missing data. 
Limitation 2. The indicator provides a good measure of the importance accorded to health research 




Overall health research investment in OECD countries 
 
Government outlays on health research – official OECD data 
 
The first benchmark used in the level of government budget appropriations or outlays on 
R&D (GBAORD) in respect of health research. Before presenting the comparison, it worth 
noting how these data are derived (see Box 4.2). The validity of the comparison is 
influenced by the structure of national health research organisations, in particular, whether 
the primary purpose of an organisation is health research (if not, its funding may not be 
included). Where possible, the OECD also includes estimates of government funding of 
health research through other channels such as general university funding (GUF), ‘non-
oriented’ research,39and R&D expenditure in hospitals. The OECD’s detailed guidelines on 
the derivation of health R&D data from GBAORD are reproduced in Appendix 5. 
 
                                                 
39 Formerly termed ‘advancement of knowledge’, i.e. research with no specific objective in mind other than 
advancement of knowledge– in this case advancement of knowledge in health and medical sciences. 
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Box 4.2: OECD calculation of GBAORD on health research. 
 
The data on central government (eg federal) support for R&D are derived from budgets and are 
referred to as government budget appropriations or outlays for R&D (GBAORD). GBAORD can 
be broken down by socio-economic objectives (SEO), such as the protection and improvement of 
public health which is defined as follows: “This category covers research aimed at protecting, 
promoting and restoring human health broadly interpreted to include health aspects of nutrition and 
food hygiene. It ranges from preventative medicine, including all aspects of medical and surgical 
treatment both for individuals and groups and provision of hospital and home care to social 
medicine and paediatric and geriatric research.” (Frascati Manual, OECD, 2002). The GBAORD 
health category is used here as a proxy for total central government funding of health R&D. 
However, it should be borne in mind that it only covers programmes for which health is the 
primary objective. Furthermore, the classification of programme and institutional funding depends 
on how governments present their R&D priorities as well as on the formal mandate of the 
institutions concerned. For example, long-term research may be the responsibility of a medical 
research body classified in health objectives (e.g. the National Institutes of Health in the United 
States) or of a general research council whose funds are mainly awarded for the advancement of 
research (e.g. the National Council for Scientific Research in France). Arrangements for funding 
R&D in hospitals also vary between countries. To address some of the limitations mentioned above 
and to provide a more complete picture of health related R&D, funding of medical sciences via 
non-oriented research and general university funds (GUF) are included when available as are other 
relevant funds, notably general support for R&D in hospitals. (OECD 2001b: 34) 
 
Table 4.1 presents the official OECD data (direct GBAORD) on health research funding 
through government budgets in terms of absolute expenditure (as a proportion of GDP) and 
annual growth rates in expenditure over the last 5-7 years. As the OECD data for New 
Zealand are for 1999, we have added an estimate for New Zealand for 2003 based on HRC 
data. Countries are ranked by level of expenditure. The same data presented graphically 
makes it easier to grasp the differences in the relative levels of funding (Figure 4.1) and 
growth rates (Figure 4.2). 
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(% of GDP) 2002 
Average annual growth 
rate, 1995-2002 
United States 0.23 9.17 
Iceland 0.10 26.68 
OECD (2001) 0.10 .. 
United Kingdom (2001) 0.10 2.18 
Finland 0.07 0.13 
Korea 0.06 .. 
France 0.06 3.38 
Canada (2000) 0.06 8.64 
Australia (2001) 0.06 11.69 
EU (2001) 0.05 .. 
Portugal 0.05 15.13 
Italy (2001) 0.05 1.17 
Norway 0.05 4.52 
Spain (2000) 0.04 8.19 
   
   
New Zealand (OECD 1999) 0.04 .. 
New Zealand HRC 02-03 
   (AEGIS estimate) 0.036  
New Zealand Health research 02-03 
   (AEGIS estimate HROC + SPIOC + 
Maori OC + Marsden) 0.04  
Japan 0.03 11.15 
Germany 0.03 3.46 
Denmark 0.02 7.76 
Netherlands (2001) 0.02 5.93 
Greece 0.02 5.98 
Switzerland (2000) 0.01 .. 
Sweden 0.01 -2.05 
Mexico (2001) 0.01 -2.66 
Belgium (2001) 0.01 -6.72 
Ireland (2001) 0.01 21.1 
Austria 0.01 -0.56 
Slovak Republic 0.01 -5.69 
Source: OECD 2003. Notes: Growth rate: Australia, Belgium, Ireland, Italy, Mexico, Netherlands, 
United Kingdom (1995-2001); Canada, Spain (1995-2000); Finland (1997-2002); Iceland, 
Sweden, Switzerland (1998-2002). 
Note The Aegis estimate includes funding from the Māori Knowledge Output Class and the 
Supporting Promising Individuals Output Class. This table does not take into consideration factors 
such as the differences in the overheads payment rate by research council in different countries. 
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Figure 4.1: Health R&D (direct GBAORD) for selected OECD countries (2002) 































Source: data from OECD 2003. NZ 02-03 calculations based on data from MoRST and Statistics New 
Zealand. 
Note: This table does not take into consideration factors such as the differences in the overheads payment 
rate by research council in different countries. 
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ce: OECD 2003  
Note: New Zealand is excluded here because it was not in the OECD tables. 
 
At the gross level, the data appear to suggest the following conclusions.  
 
• New Zealand in 1999 spent 0.04 per cent of its GDP on health research reported 
through Government budget expenditures. This amount was well below that of the 
USA and UK only two thirds of the expenditure by Australia and Canada (0.06 per 
cent) in the same year, but amounted to twice that of the Netherlands (0.02 per 
cent) and 2-3 times that of Sweden (note comments on Sweden below) and Ireland. 
New Zealand’s expenditure was below the average for European Union countries 
(2001).  
 
• Between the mid to late 1990s and early years of this century, life sciences became 
an important area for increased investment in research by government. Some 
countries rapidly expanded their health research capacity. Countries with annual 
growth rates in excess of 10 per cent included Ireland and Australia. Canada, the 
USA and the Netherlands experienced growth rates exceeding five per cent 
annually. Of the benchmark countries, only Sweden experienced a decline in 
funding, however this is largely an artefact of the OECD data set (see below). 
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OECD data evaluated 
 
The validity of these conclusions rests on the comparability of the official OECD data. 
Such gross comparisons between countries can be misleading if the characteristics of their 
research systems are not taken into consideration. It is worthwhile therefore to examine the 
derivation of the data for the benchmark countries in greater detail (Box 4.3) 
 
Box 4.3: Review of the limitation of OECD ‘direct GBAORD’ data for the benchmark 




The OECD reports Australia’s medical research funding as 0.06%GDP. This result appears to be 
on the high side if the NHMRC (the main funding body in Australia) alone is being considered. 
The 2001 result of 0.06 per cent of GDP would represent A$402.6m – whereas The Australian 
Government (Nelson 2003) reports A$247m and NHMRC (2003: 15) estimates the indicator to be 
about 0.035% of GDP. The latest data suggest that Australia has now climbed to nearly 0.05 per 
cent GDP for the NHMRC alone (NHMRC 2003). However, there are sources of direct funding 




The Direct GBAORD figure of 0.06 is quite close to our calculation of the CIHR budget plus other 
Federal Government programs. 
Ireland 
 
The OECD reports Ireland’s government medical research funding as 0.01 per cent of GDP. Based 
on data from the Health Research Board40 of Ireland and the Central Statistics Office41 of Ireland 
the apparent health research expenditure for 2001 was 0.013 and probably42 reached around 0.015 
in 2003. 
 
                                                 
40 HRB (2003) 
41 http://www.cso.ie/  
42 In communications from HRB it is known that the budget for ‘2004 is EUR20.552 million, which 
represents an increase of 3-4 per cent on last year’ and the GDP statistics were incomplete – therefore a 
conservative estimate of the average of the 2nd and 3rd quarter GDP was used to calculate 4th quarter GDP and 
thus provide a recent estimate for Ireland. 





The OECD reports the Netherlands’s public medical research funding as 0.02 per cent of GDP. 
ZonMw, the main medical research funding organisation, has a budget of €87 mill split between 
the following clusters. 
 
 Table 4.2:  Funding clusters in ZonMw, 2002 
 
 Basic science and industrial innovation    (€32.7 mill.). 
 Research support for disease prevention    (€24.0mill.). 
 Support for research for ‘long lasting care’  ( €8.8 mill.). 
 Support for research and development for health care  
 and cure including demand and societal factors   (€8.4mill.). 
 Support for research for quality and efficiency &  
 effectiveness in health care and cure    (€13.0 mill.) 
 
In general this level of funding would result in quite a low percentage of GDP for the Netherlands. 
However data on Dutch Government expenditure on medical research in 1997 looks to double the 
level of expenditure. If this structure remains accurate then the OECD data might be accurate. 
 
 Table 4.3: Health Research Expenditure in the Netherlands, 1997 
         US$.mill. 
 Medical faculties      312 
 MHRC [medical and health research council]   60 
 Other governmental expenditures    67 
 Pharmaceutical industry      338 
 National charity funds      78 
 Total        855 
 Total health expenditure (trillion USD in 1997)   32.6 
 




For New Zealand, the OECD reports funding of 0.04 per cent of GDP43 in 1999, which would 
equal $39.07 million. MoRST in its Progress and Achievements report (2003) does not itemise 
HRC funding for 1999, but for 2000-01 the Health Research Output Class was allocated $33.4 
million (0.03% of GDP). The HROC has received $38.4 million (01-02) and $39.7m (02-03), 
representing 0.036% of GDP in 2002-03. For 2003-2004 the HROC class was allocated $42.2m 
from the budget. The OECD data perhaps includes the Marsden Fund expenditure on health 
research, which the HRC44 has estimated to be approximately $6m. Therefore the New Zealand 
data reported by OECD may be accurate, although including more than just the funding for the 
HROC (HRC).  
 
                                                 
43 GDP data from Statistics New Zealand website. 
44 HRC 2002 p10 





The OECD reports Sweden’s medical research funding as 0.01% GDP, which is extraordinarily 
low by international standards. The Swedish Research Council’s expenditure for Medicine was 382 
million SEK in 2003 equal to 0.016 per cent of GDP (2002). This is reasonably close to the OECD 
estimate. However, it is important to note that in Sweden the university system receives significant 
stand alone funding. Statistics Sweden reports that government outlays for research in the medicine 
field of science is 3923 million SEK in 2003 or 0.15% of GDP. There would appear to be an order 
of magnitude difference between OECD and Swedish national data, which would put Sweden in 
the upper rank of public investors in health research. This conclusion shows the importance of 





The OECD reports the UK’s medical research funding as 0.1% GDP. This level of expenditure 
cannot be accounted for by the expenditure of the Medical Research Council alone. Official data 
(see Appendix 1) show MRC’s budget as fluctuating between 0.035 and 0.04 per cent of GDP over 
the last 10 years, implying that MRC accounts only 40 per cent of government expenditure on 
health research. However, the UK as a large economy has complex array of public programs 
supporting health research, including some of the other Research Councils, and therefore and it is 




Direct GBAORD of 0.24 appears reliable. In 2004 the budget for NIH was US$28 bill.  
 
Although the derivation of the data in Table 4.1 is sometimes unclear, it does not seem to 
be a fair reflection of government expenditures on health research for at least some of the 
benchmark countries (notably Sweden and the Netherlands). However, the OECD has 
attempted to compensate for the problems of research funding sources by adding in ‘other’ 
government sources of funding, which are indicated in Box 4.2 and described in detail in 
Appendix 5. As can be seen form Table 4.4, this addition has the effect of promoting 
benchmark countries, notably Sweden and the Netherlands, and other countries such as 
Germany, to significantly higher levels of expenditure. The OECD omits comparable 
figures for ‘other’ health R&D outlays for Australia and Canada. We have calculated proxy 
figures and included them in Table 4.4, but note that these data are not strictly comparable 
with the OECD-sourced data.. In the case of New Zealand, we cannot calculate a reliable 
‘Other’ figure. However the total New Zealand health research effort in the universities 
(from all funding sources, not solely government) was equivalent to 0.076 per cent GDP in 
2002.45 This would place an upper limit on ‘Other’ of around 0.035 per cent of GDP (since 
the Direct Health GBAORD must be subtracted). 
 
                                                 
45 Statistics New Zealand reported university health research expenditure of $93.3 mill. (Statistics New 
Zealand and MoRST 2003). 
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Table 4.4: Health R&D (direct GBAORD and ‘other’) for selected OECD countries 
(2002) 
 







United States 0.24 0.01 0.24 
France (2001) 0.06 0.14 0.19 
Austria 0.01 0.17 0.18 
Canada (2001) (AEGIS 
estimate for ‘other’) 46 0.06 0.12 0.18 
Sweden 0.01 0.16 0.17 
Finland (2000) 0.07 0.08 0.15 
Netherlands (1999) 0.03 0.12 0.15 
United Kingdom (2000) 0.10 0.03 0.13 
Germany (2000) 0.03 0.08 0.11 
Denmark (2001) 0.04 0.04 0.08 
Australia (DATE) (AEGIS 
estimate for ‘other’)47 0.06 0.053 0113 
New Zealand (1999) 0.04 See text 0.06 
Spain (1999) 0.03 0.03 0.06 
Greece (2001) 0.02 0.03 0.05 
Ireland (2000) 0.01 0.01 0.02 
Source: OECD 2003 except as noted 
Note. AEGIS estimates for Canada and Australia ‘Other’ category. The OECD estimates that New 
Zealand in 1999 had total expenditure of 0.06% GDP - see text. 
 
What, then, is the most appropriate comparator for HRC and HROC in New Zealand – 
direct GBOARD, direct + ‘other’, or a third, adjusted figure? Table 4.5 summarises our 
judgements and comments on the data. 
 
                                                 
46 Health expenditure data from Statistics Canada 2003 and GDP data from 
http://www.statcan.ca/Daily/English/040227/d040227a.htm  
47 Australian GUF RFCD Medical and health sciences $360,414,000 (ABS (2002) 8111.0 Research and 
Experimental Development Higher Education Organisations Australia 2000. GDP 2000-2001 = 
$671,120,000,000 (ABS (2003) 5204.0 Australian System Of National Accounts 2002 – 03 Canberra, ABS.) 
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Table 4.5 Most appropriate expenditure indicator for federally funded health research 
funding agencies like HRC 
 
Benchmark country Appropriate 
comparator 
(Govt health 
R&D as of 
GDP) 
Derivation and comments 
Australia 0.06 Direct GBAORD: is probably a fair estimate, even though 
NHMRC alone is somewhat lower.  
Canada 0.06 Direct GBAORD of 0.06 is quite close to the CIHR 
budget plus other Federal Government programs. 
Ireland (2000) 0.01 Direct GBAORD: HRB has a small budget. 
Netherlands 0.15 Direct GBAORD + other funds: because there are multiple 
national agencies involved. This may overstate the 
situation but is better than the ‘direct GBAORD’ funding 
figure. 
New Zealand (2002) 0.036 
 - 0.04
Current estimates by AEGIS. HRC by itself is about 0.036 
but including estimates of other health related (SPI, Maori 
and Marsden) = about 0.04. 
Sweden 0.17 Direct GBAORD + other funds: because of the funding 
structure for the universities. 
USA 0.24 Direct GBAORD: because the federally funded NIH 
receives its funds direct each year from the US budget. 
Other Federal funding in the USA is comparatively small. 
  
EU average 0.05 Direct GBAORD: The EU 15 consists of a number of 
small and larger member countries. This appears to be a 
fair estimate of an average for the group of countries. 
OECD average 0.10 Direct GBAORD, despite some limitations: Data on ‘other 
funds’ are unavailable. The reader should note that most 
countries spend less than this average indicating the 
significance of the larger players i.e. the USA and the UK. 
The OECD average would be higher if expenditures in 




• If the OECD data selected in Table 4.5 are an appropriate comparator of 
government expenditure on health research then it can been seen that New 
Zealand’s public investment in health research is under-funded by comparison 
with most of the benchmark countries. 
 
• Of the benchmark countries only Ireland invests a lesser proportion of GDP in 
health research funded by Government than does New Zealand.  
 
The OECD data allow a calculation of the additional investment that would be required to 
bring New Zealand to a funding level comparable with that of particular benchmark 
countries or groups of countries. In 2003 dollars, an increase in health research funding by 
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an amount equivalent to 0.01 per cent of GDP would represent an additional investment of 
$12.7 million.48
 
It is essential to note that the comparisons above do not take into account an important 
difference between New Zealand and the benchmark countries. The level of overhead costs 
funded through HRC grants has in recent years grown to be substantially higher than in 
comparable research councils in the benchmark countries. This must be factored into any 
comparison of current funding levels and of target levels for future funding. Before 
considering the issue of cost structures, however, we examine other possible comparisons 
of government health research funding.  
 
 
Per capita comparisons of health R&D funding 
 
Another way of developing funding indicators is to compare countries on the basis of per 
capita expenditure. Figure 4.3 shows per capita funding on health research for selected 
OECD countries on the basis of the most recent year available. Except for Sweden, these 
data cover funding through the research councils only. These data are not ideal, but due to 
a lack of internationally comparable ‘field of science’ data they are the most directly 
comparable. The data have a tendency to bias the comparison in favour of New Zealand 
because the other countries have very substantial other sources of funds apart from 
research council funding.   
 
The data for the Netherlands is only on the basis of research council (ZonMw) expenditure 
and with the inclusion of ‘other’ funding would be higher. As discussed above, in the 
Swedish system, much of the research money is channelled through the universities and so 
the research council and total expenditure are included in the separately on Figure 4.3.  
 
Figure 4.3: Health research funding per capita for selected OECD countries (PPP 
USD) 
0 10 20 30 40 50 60 70 80 90
USA










                                                 
48 Based upon New Zealand’s GDP of $127 bill. for 2003. 
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The data in Figure 4.3 show a similar ranking to those in Table 4.1. On the basis of per 
capita funding, the UK’s rank falls below that of Australia and Canada, and is fairly 
comparable with that of New Zealand. The UK data appear the most out of line. MRC 
funding in 2002 was equal to US$519m but for a population half as big again as Canada, 
whilst Canada was investing US$437m. Such a calculation is supported by Billig (2004). 
 
• On the basis of Figure 4.3, New Zealand would need to expend US$10 per 
capita to bring health research investment to the level of Australia, and US$14 
per capita to bring it to the level of Canada (a doubling of expenditure).  
 
 
National research grant schemes and Health R&D  
 
As has been noted already, funding for health research has been increased rapidly in some 
countries. This has translated into substantial increases in funding per capita to health 
research councils in some benchmark countries, notably Canada and the UK, in the past 
few years (Billig 2004).  
 
Another way of understanding the national priority given to health research is to analyse it 
within the context of other research competitive grant schemes with each country. These 
are often managed through research councils such as HRC.  
 
Such analysis has a few difficulties. The two primary ones are: 
 
1) identifying ‘relevant’ research grant schemes; and  
2) understanding the context of each system of funding – particularly as 
mechanisms for general university funding (GUF) vary markedly. 
 
The following section examines trends in competitive grant and research council funding 




The research granting organisations are reasonably easily identifiable in Australia, the 
research councils do not generally pay high overheads rates and GUF is still a significant 
source of funding for research expenses (see Chapter 3). In Australia, the NHMRC has a 
lesser share of Federal grants and science and innovation investment than its counterpart in 
New Zealand. As can be seen from Figure 4.4 the NHMRC’s share has grown, especially 
following the 1999 Wills Review, as has the government’s overall emphasis on 
competitive grant funding for research.  
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1994-95 1995-96 1996-97 1997-98 1998-99 1999-00 2000-01 2001-02 2002-03 2003-04
%
NHMRC as % of total research grant funding
NHMRC as % government S & I
Research grant funds as % of all Gov't S & I
 




In Canada, health research expenditure is on the increase as a percentage both of federally 
funded research system grants and as percentage of government investment in science and 
innovation (Figure 4.5). Interestingly, health research makes up about the same share of 
overall government support for research, science and innovation in Canada as it does in 
Australia but the health research share of research grants is much higher in Canada than in 
Australia.  
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Research funding as % of all Gov't S & I  




Sweden’s research council for medicine receives a budget share fairly similar to that of 




The United Kingdom an interesting case where grant based funds have been rapidly rising 
as a share of total government expenditure on S&I funds. In part this reflects a move 
towards full cost funding through the research councils, as is the trend in New Zealand. 
The Medical Research Council (MRC) has received substantial increases in funding in 
recent years, yet its share of Government Research grant money has dropped as a 
proportion over the last few years (light bar in Figure 4.6). This is despite the fact that 
MRC’s share of Government expenditure on the science and innovation having been about 
the same since the middle of the 1990s.  
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MRC as % of R&D grants MRC as % of S & I R&D Grants as percentage of S & I  
Sources and notes: see Appendix 1. 
 
Comparison with New Zealand 
 
It was not possible to construct a comparable time series for New Zealand. However, Table 
4.6 provides a broad comparison with the other benchmark countries of gross share of 
competitive grant funding and of government budget for science and innovation.  
 
Table 4.6: Health research share of research grants 
 
 New Zealand Australia Canada Sweden UK
 HRC NHMRC CIHR
Medical in 
SRC MRC
Health research as % of research 
grants 15.5 10.5 19.5 16.0 17.0
Health research as % of S & I  *8.1 7.5 8.0 n/a 5.0 
Notes: * See Table A1.4 for components of Vote RS&T included Figure is equivalent to the other reported 
comparisons in this section.  
 
New Zealand’s health research expenditure as a share of research grants is lower than that 
of Canada, but higher than in Australia. HRC’s expenditure as a share of Vote RS&T is on 
a par with Government support for science and innovation in Canada and Australia. These 
examples suggest that HRC’s funding is a comparable proportion of the federally funded 
research system as its counterpart agencies research councils in the benchmark countries. 
This analysis is not inconsistent with the earlier evidence that New Zealand is under-
funding health research in comparison with other countries because it is known that New 
Zealand overall government expenditure on R&D is less than for comparator countries. 
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However, before drawing such a conclusion definitively, one needs to bear in mind the cost 
structures build into various research councils’ grants. By ‘cost structure’, we mean the 
level of direct costs (such as the salary of researchers) and indirect costs (overheads) of 
research projects that are funded by the research council, rather than through other 
channels, such as general university funds.  
 
Evidence on trends in New Zealand Health research expenditure 
 
HRC makes the point that taking into account the costs associated with the full cost 
funding (FCF) of projects, funding to the organisation as represented by the share of GDP 
has been in long term decline. The funding in real dollar terms (when full costs 
implementation and inflation are excluded) has been static since 1996-97. This evidence is 
corroborated by data on R&D performed in New Zealand’s higher education sector. 
 
The Ministry of Research, Science and Technology published R&D statistics for the year 
1997-98 (MoRST 1999). It reported R&D expenditure by the socio-economic objective 
health research for that year in the universities of $94.1m (or 0.097 per cent of GDP). 
However for higher education R&D by the same socio-economic objective for the year 
ended 31 December 2002, Statistics New Zealand, reported expenditure of $93.3 mill, or 
only 0.076 per cent of GDP (Statistics New Zealand and MoRST 2003).49
 
Therefore expenditure on health R&D within the universities has fallen in absolute terms 
and as a proportion of GDP between 1997-98 and 2002. Using the Reserve Bank of New 
Zealand’s50 inflation calculator, for health R&D to have kept pace with inflation during 
this period expenditure would have had to have stood at $104.4 mill. in 2002. This 




Macro level indicators of funding are an important measure of comparative activity but 
they can be deceptive. Hidden by the comparisons are the actual cost structures faced by 
the different agencies. Research buying power is greatly influenced by government policy 
towards the contestable grant funding and by the level of overhead and infrastructure costs 
built into the grants. There are two micro indicators that have been collected for this 
project to help identify the amount of research that each research agency obtains from its 
investment, taking into account other contributions of funding.  
 
The results of a survey of the health research councils in the benchmark countries (Table 
4.7) shows that the research purchase agencies in New Zealand, and HRC in particular, are 
being called on to fund a higher proportion of the full cost of the research they support. Or, 
to look at it another way, each dollar of HRC investment leverages fewer dollars from 
other public sources than would be the case in Australia or Canada. As support for full cost 
funding (FCF) is being introduced progressively, this is less of an issue for the benchmark 
comparisons than for future funding targets.  
                                                 
49 On the basis of Dec quarter 2003 reporting of GDP by Statistics NZ: 1997-98 health research $94.1m 
(0.0967% GDP) [GDP $97.23b]; 2002 health research $93.3m (0.0759 % GDP) [GDP $122.8b] 
50 http://www.rbnz.govt.nz/statistics/0135595.html 
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• Institutional overhead costs. New Zealand’s universities directly charge research 
granting bodies an overhead rate on research project salary costs. This overhead 
rate is developed from an auditable process but is on a ‘full cost basis’. 
Internationally, the practice of charging projects at a full cost rate is rarely used and 
even having any on-cost component is not universal. 
• Chief investigator salary payments. In New Zealand’s system of full cost 
payments principal researchers are paid for their time on projects. In some systems 
these researchers are not paid out of project grants. As it would be expected that 
these faculty would have high direct salary costs and thus high overheads – 
including or not including payments for their time could significantly impact on 
project funds availability.  
 
Table 4.7: Summary of research grant cost structure in selected OECD countries 
 
Country Overhead charge rate Chief Investigator payments 





New Zealand 114+ 
Sweden 30% 
United Kingdom 46%, with proposal to rise to 65% 
USA Variable 50%av 
Source: The data for were collected from the individual health research councils in each country. Full text of 
the responses is at Appendix 2. 
 
A current estimate of the implications of the implementation of full cost funding (FCF) in 
New Zealand is that by 2006-07 (when most grants will receive FCF) HRC would need to 
receive $16.5 million in additional funding each year than its current budget to be in 
exactly the same position. As this re-financing is already assumed, future international 
comparisons will show New Zealand’s government health research investment increasing 
by about 0.01 per cent of GDP towards 0.05 per cent but of course without any additional 
capacity being created.  
 
To maintain a real increase we propose that the funding target recommended in the current 
report be augmented by a further amount to cover the implications of FCF. In determining 
an appropriate loading, we use HRC’s estimates. The estimate of $16.5 million represents 
an amount equivalent to nearly 40 per cent of HROC funds for 2003-04. We have therefore 
applied a loading of 40 per cent to suggested future targets for health research investment 
in New Zealand. Should the estimates of the cost of FCF prove incorrect, we note that our 
recommendations are for a real increase in funding over and above the implementation of 
FCF on health research grants.  
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Conclusions and recommendation 
 
Three main observations can be made on level of health research funding in New Zealand 
by comparison with the benchmark countries.  
 
• Taking all the comparisons into account, New Zealand’s current level of public 
investment in health research is substantially lower than almost all the benchmark 
countries. Of these countries only Ireland spends less, proportionally, on health 
research and development. 
 
• Most of the benchmark countries are increasing their investment in health 
research – some by as much as 20 per cent per annum. By contrast, there is no 
evidence of sustained increase in health research investment in real terms in New 
Zealand in recent years Indeed, national data on health research in the university 
sector provide clear evidence of a decline in New Zealand’s expenditure on health 
research, as a proportion of GDP. 
 
• The cost structures of many of the comparator health research funding agencies are 
lower than those of the HRC. The move towards full cost funding (FCF) will lead 
to a spurious improvement in the ‘health research as a per cent of GDP’ indicator. 
Given that the overall envelope of health research funding available to the HRC in 
New Zealand is already comparatively smaller than in most of these countries, the 
cost structure in New Zealand means that the HRC’s capacity to purchase high 
quality health research is all the more limited. 
 
Any target for investment is arbitrary. In the New Zealand case the problem of suggesting 
a target increase is particularly difficult. Even were the HRC to receive no more funds 
beyond FCF supplementation, the international comparisons would improve - but with no 
additional research being done than is now being conducted. Our estimate is that FCF 
supplementation alone would make it appear that New Zealand funding eclipses the level 
of the EU (15) and trends towards that of Australia within a couple of years.  
 
On the other hand, we know that (a) the level of research funding reported in the 
universities fell by over $11 million in real terms between 1997 and 2002 and that (b) the 
EU (15) average (which includes a basket of small and large countries) for direct funding 
is about 0.01% of GDP ($12.7 mill.) higher than the current New Zealand position. Under 
normal circumstances, we consider that the EU (15) average (not an average based on the 
expanded EU (25) as it will soon become) would represent a reasonable benchmark 
because of the mix of developed economies it represents. The OECD average is too 
strongly influenced by the high funding nations such as the USA and there are problems 
identifying the real level of government expenditure in other potential benchmark countries 
such as the Netherlands. We have chosen Government health research outlays as a 
proportion of GDP as the appropriate indicator for comparison, since a figure related to 
GDP is the best measure of a country’s ability to invest. On this basis, New Zealand’s 
investment would need to increase by about 0.01 per cent of GDP from the current level of 
about 0.4 per cent. However, as noted above, a target of 0.05 per cent does not allow for 
the effects of FCF of research grants by HRC, either in the current comparison, or in any 
future increase. 
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We therefore suggest that (a) the target be set as a real increase of 0.01 per cent, and (b) a 
loading be added to this target to cover the probable costs of FCF on the increase.  
 
We recommend  
 
• that MoRST adopt a target budget for the HRC’s Output Classes (the HROC 
+ Māori OC [health] + SPI OC [health]) of a real increase of 0.01% of GDP 
over the next four years. 
 
We note that for the year 2003 such a target would have required a real increase above full 
cost funding supplementation of about  $17.8 million, calculated as $12.7 million (0.01 per 
cent of GDP, 2003) + $5.1 (40 per cent loading on this sum to cover FCF on the new 
funds). By itself, an increase of $12.7 million above FCF would not in the current funding 
model deliver the full benefits required. 
 
Noting the lack of currency of the New Zealand health research data published by the 
OECD and the implication of full cost funding on international comparability, we 
recommend: 
 
• That MoRST review the procedures for reporting current health research 
expenditure data to the OECD and for ensuring that these data are presented 
in a manner that provides for international comparison of research effort. 
 
In the medium term the health research performance indicator reports should compare 
funding on the basket of small to medium sized countries and including non-agency public 
sector funds (ensuring Sweden is included). We expect that over the next few years with 
increased interest by WHO (via its Department of Research Policy and Cooperation)51 and 
the OECD better data will become increasingly available. During 2003, alone, there was a 
noticeable improvement in data availability. 
                                                 
51 World Health Organisation.  Health Research System Analysis Initiative, Department of Research Policy 
& Cooperation.  http://www.who.int/rpc/researchsystemsanalysis/index.en.shtml 
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5. The Vision: Where is New Zealand’s health research going? 
 
Strategy and Priority Setting  
 
As noted, the bulk of health research investment in New Zealand is channelled through the 
HROC, almost all of which is allocated by the HRC. The HRC’s strategic planning 
processes and nominated priorities are thus central to any consideration of the 
appropriateness of national health research goals and the resources required to achieve 
them. This section attempts to assess the future characteristics of the health research 
system as defined in the Health Research Council’s Strategic Plan ‘Vision 2008’, the 
benefits to New Zealand arising from its implementation the scale of resources likely to be 
required for its implementation. 
 
Before considering these strategies in detail, it is important to recognise that HRC’s 
strategies sit within a broader environment of planning firstly for RS&T and secondly for 
health. The funding envelope for HRC is set by MoRST through the budget allocations to 
the output classes that HRC has access to. These are primarily HROC, but also include the 
Māori Knowledge and Development Research OC and Supporting Promising Individuals 
OC. Clearly, the lever of funding for specific activities has a strong influence on overall 
priorities, for example in supporting HRC’s Māori Health Research portfolio.  
 
The second influence on HRC’s priorities is the policy of the Ministry of Health. The 
Minister of Health transmits an annual ‘letter of expectations’ to the HRC. The HRC is 
also required to furnish an annual Statement of Intent (SOI) for the financial year, which 
the Minister is required to approve. The SOI describes the output classes in place and the 
performance indicators used to measure their achievement. While these are potentially 
substantial ways that the Minister can steer HRC’s priorities, they have not been used in 
this way. The way that the Ministry of Health has more strongly influenced HRC’s 
priorities is through the New Zealand Health Strategy (NZHS), although the Strategy 
barely mentions the contribution of research.  
 
• HRC has adopted its research priorities following broad consultations between 
the Council, MoRST, MoH, District Health Boards and their constituencies. 
There may be benefit in making this process a more explicit one (HRC 
Strategy 1d) and setting HRC’s priorities in the context of a national ‘Health 
Research Strategy’, coordinated by HRC  
 
 
HRC’s Strategic Plan ‘Vision 2008’ 
 
IMPORTANT NOTE: The details of HRC’s Strategic Plan documents are 




HRC’s Strategic Plan ‘Vision 2008’, which is currently under development, sets out 
strategic goals for the Council. These are:  
Science for Life 75
  
 
1. Maximising New Zealand’s potential to conduct excellent and relevant health 
research 
2. Fuelling the engine for health R&D through investment in people 
3. Bridging the gaps in careers for health research 
4. Ensuring that health research contributes to improved health and wellbeing 
for all New Zealanders  
5. Taking advantage of New Zealand’s unique opportunities 
6. Using cross-sectorial research partnerships to produce knowledge of benefit 
to New Zealand   
7. Global connections: strengthening networks, adding value and raising New 
Zealand’s profile  
8. Ensuring that the economic benefits of health research are captured for New 
Zealand 
9. Ensuring New Zealand has the infrastructure to support high quality health 
research 
 
Appendix 3 shows the goals, strategies and performance measures in detail (note that this 
is based on an earlier draft of ‘Vision 2008’).  
 
The sections, which follow, consider the future characteristics, resources and benefits 
implied by each goal. The comments made are intended to assist in achieving the 
maximum benefit from the strategies proposed by HRC.  
 
GOAL 1: Excellent and relevant research 
 
Focus on excellence and relevance 
 
The health research councils in all the countries surveyed were set up with mandate to 
select and fund the highest quality research. In any field, poor science is a poor investment, 
nowhere more so than where it may affect human health interventions. The study found no 
evidence in any country of health research councils reducing the level of peer assessment 
of research proposals or of reducing the emphasis on excellence. The HRC’s 
comprehensive peer review system for assessing the scientific excellence of research 
proposals is central to maintaining the quality of research funded and is of a clear and 
continuing national benefit and receives strong endorsement from the research community. 
The system is of necessity resource intensive, as international experts play a large part in 
the assessment. However the operation of best practice assessment and evaluation 
processes within HRC is also vital in leveraging funding from other sources, such as 
international partners.  
 
• There is clear benefit to New Zealand in the high standard of assessment and 
evaluation for health research set by HRC and this assessment process should 
be maintained. 
 
In common with overseas health research councils, HRC is now giving greater weight to 
the relevance and application of research that has been assessed as of high scientific 
excellence. The HRC has four statutory committees, two of these – Biomedical Committee 
Science for Life 76
  
and the Public Health Committee – being disciplinary based. In the past these Committees 
have apparently operated largely independently. Over the last few years, the HRC has 
introduced an investment portfolio model (Research Portfolio) to augment the discipline 
based allocations of funds. The portfolios currently in place are shown in Box 2.2. 
(Chapter 2). 
 
HRC’s Research Policy Advisory Committee (RPAC) has overseen the development and 
modification of the portfolios. Each portfolio has a Portfolio Advisory Group (PAG) that, 
along with wider consultation, has helped shape the scope of each portfolio. An RPAC 
member commented that the portfolio process has improved priority setting, but that there 
were few ‘discretionary’ funds available once funding for core outputs had been allocated. 
The HRC retains the two discipline based committees. 
 
The benefits of this approach are several. First, it has made it possible to implement 
specific national research priorities, such as that for Māori Health Knowledge and 
Development. Second, it has allowed HRC to establish and monitor output oriented 
priority areas, such as Health Sector Management. Third, in the process, it has engendered 
greater collaboration between the biomedical and public health activities of the Council. 
 
HRC’s development of outcome oriented investment portfolios is in line with international 
developments. It could be argued that HRC portfolios are not yet as ‘outcome oriented’ as 
they could be – i.e. they comprise both social objectives (potential outcomes) and health 
disciplines (which do not necessarily specify particular outcomes). This is the case for 
comparable agencies overseas, such as the virtual institutes within Canada’s CIHR (see 
Appendix 1). We would expect that all health research councils will increasingly move 
towards investment programmes based on health outcomes in line with the trend towards 
‘application based’ research structures.  
 
HRC’s dual assessment process of quality (through discipline based panels) and 
application (by reference to criteria of relevance) is also in line with models overseas. Such 
a process was in early use by the US NIH and has been subsequently adopted by many 
health funding agencies. Most overseas research councils have retained and strengthened 
their discipline based panels for the purpose of assessing research excellence. Australia’s 
NHMRC is an example where discipline based assessment panels have replaced former 
regionally based panels.  
 
The move to outcome oriented Research Portfolios has entailed resources for advisory 
committees (RPAC) and an extensive national consultation process that has underpinned 
priority setting. Monitoring and modifying the portfolios in the future will require similar 
consultation and analysis which can be justified by the benefits of an outcome focused 
strategy. 
 
• HRC’s move towards investment portfolios focused on health outcomes is in 
line with trends in the benchmark countries and should receive continued 
support.  
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Investment in Research Portfolios 
 
‘Vision 2008’ argues for increased funding for all of the nine investment portfolios 
(Strategy 1a). HRC notes that, with the exception of Rangahau Hauora Māori , all 
Portfolios are significantly over-subscribed with research deemed fundable. Across all 
portfolios, the 2001/02 funding allocations covered 55 per cent of fundable proposals while 
in 2002/2003, this figure was only 40 per cent. The success rates for fundable proposals 
was lowest in Non-Communicable Diseases, the largest Portfolio, where the proportion 
funded fell to 27 per cent in 2002/03 compared to 56 per cent in the previous year. 
 
The argument for any increase in funding relies variously on justifications of quality, 
importance for broadly based health research capabilities or capability building and 
national relevance of the research. For example, an increase in funding for research into 
Non-Communicable Diseases could be justified on the basis of providing stability of 
funding for an existing, productive community of researchers as well as the relevance to 
national priorities in combating diseases such as cancer and diabetes. Increase in funding 
for Māori Health Research is driven by a specific national research priority and identified 
funding. The case for funding Pacific health research rests on an identified need, and the 
requirement to build research capability to meet that need. 
 
• HRC’s case for increased funding would be strengthened if the Council set 
quantitative or qualitative targets and timelines for some of the key 
performance indicators. For example, the target numbers of fellowships or 
scholarships, or the number of world-class research groups identified who 
were likely to be eligible for Programme Grants. 
 
In discussions with researchers, much emphasis was given to ‘success rates’ in winning 
HRC grant funds. Most Research Portfolios are significantly over-subscribed with research 
deemed fundable by the HRC. The data suggest that the Council could spend at least 
double the current annual budget on high quality research – a level not uncommon in the 
benchmark countries. Success rates in grant applications do appear to have declined, 
fuelling, as one researcher commented, ‘the cycle of disappointment’.  
 
The study surveyed research councils in the benchmark countries about their grant 
application success rates. Their responses are summarised in Appendix 2, Table A2.3. It is 
difficult to draw robust conclusions based on year-to-year data from one research council, 
let alone make valid international comparisons. Factors influencing outcomes include the 
quality of the pool of applications (which may be affected by perceptions of the success 
rate), and whether there is a ‘first stage’ culling process (as in the Netherlands ZonMw), 
which of course inflates the ‘second stage’ success rate. It is not common for research 
councils to set target success rates. The Netherlands STW effectively does so for 
‘complete’ (i.e. second stage) proposals. Several councils have a policy of a fairly high rate 
for scholarship applications (often around 50 per cent of qualified applicants). For research 
grants, it seems common for research councils to fund around 40 per cent of proposals that 
make it past the first stage of assessment. Raw success rates (percentage of total 
applications) vary widely 
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The view was put to us by researchers was that HRC’s support for biomedical research is 
‘teetering on the sub-critical’ and cannot provide the prospect of a reasonable chance of 
continuing funding for the best researchers. The most compelling argument therefore is 
that such increase is required to retain existing research capability in the country and to 
build up the research teams and facilities that would attract expatriate and overseas 
researchers. The HRC in its Strategic Plan argues for an increase of the order of $10.5 mill. 
in 2004-05 to achieve sustainable outcomes. The HRC has the assessment processes in 
place to handle some increase in grant applications that might flow from such an increase. 
Substantial resources may be wasted on preparing and assessing high quality research 
proposals for which there is little prospect of funding.  
 
• An increase in resources for HRC’s current research project grant, research 
programme grant, and scholarship and fellowships schemes is necessary to 
ensure the sustainability of New Zealand’s capability in world class health 
research.  
 
A discussion of the level of funding required to restore the ‘health’ of the health research 
system may be found in Chapter 8. In summary, there is no simple calculation. The case 
for increased funds therefore rests on international comparisons of the level of funding that 
overseas agencies with a similar health research funding mandate require to achieve their 
objectives.  
 
Where there are specific national priorities that HRC is required to fund, the solution 
adopted for Māori Health Research is probably the most appropriate – i.e. specifically 
earmarked funding, at least in the ‘development’ phase of support.  
 
Investment in Research Programmes 
 
HRC’s Research Programmes are six-year contracts that support research teams with a 
track record of high achievement recognised by their peers, in contrast to the three-year 
research project contracts. HRC Programmes are awarded to well-established, world-class 
research groups. The Programmes amalgamate at least three project grants and can provide 
assistance for multidisciplinary teams, for research training and for international 
collaboration. The initial requirement for success in winning three separate projects is an 
uncommon practice overseas, and could be a potential disincentive to some applicants. 
 
According to HRC, funding for research programmes of research is highly oversubscribed. 
In the2002/03 funding round 16 programmes were submitted but only six were funded due 
to lack of resources. The only portfolios that did not include a programme component were 
Health Sector Management and Services and Communicable Diseases. The twelve 
programme components in Non-Communicable Diseases suggests that there is greater 
critical mass of well-established research teams working on issues of primary relevance to 
this portfolio (such as asthma, cancer, diabetes and bone disease). 
 
HRC has set a target for programme funding at 50 per cent of total grant expenditure, 
provided this does not reduce the funds available for project grants below $20 mill. per 
annum. Currently 33 per cent of grant funding is allocated to programmes. This implies an 
absolute increase in programme funding, which requires specific justification. Certainly, 
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overseas research councils have been moving to increase the proportion of longer term 
funding they provide to established health researchers. In Australia, the NHMRC budgets 
about one-fifth of grant monies on research programmes. By some standards, then, the 
proportion of HRC programme funding is already relatively high.  
 
HRC’s research programme funding provides longer stability of funding for research 
groups, and provides opportunities for synergy between interrelated, often 
multidisciplinary projects. They also provide greater opportunity for research training 
activities.  However, we believe there would be a stronger case for increased programme 
funding if the research programmes had a character that was clearly differentiated from 
project grants. Practice in other countries has been to provide programme grants to 
established teams of researchers that are not tied to specific projects, but rather to an 
agreed research theme. Options for consideration could include four or five year project 
grants, ‘conversion’ of several projects to a programme grant, rolling programmes 
reviewed after 3, 5 and 7 years, and programme grants for broad themes of research. A 
further use of programme funding is to promote the formation of new, multidisciplinary 
research teams. 
 
• HRC should give further consideration to the relationship between its project 
and programme funding, and between programme grants and the proposed 
National Health Research Centres scheme.  
 
Development of competitive advantages 
 
The development of competitive advantages means adequately supporting world-class 
research groups as identified by their peers. There is clear benefit in identifying and 
provided support to such teams – the Dunedin Multidisciplinary Study is an oft-quoted 
example of world recognised research investment.  
 
• The Strategy could usefully indicate how world class research groups are to be 
identified (e.g. through bibliometric studies, through the PBRF assessment 
exercise or otherwise) and what preferential support these groups should 
receive.  
 
Practice in some countries (e.g. Canada) has been to tie success in one research funding 
competition with matching funds from another source. This is one model that HRC could 
follow for the identified research groups. This strategy perhaps better fits under Goal 4. 
 
Working with other agencies 
 
A coordinated and collaborative approach to the strategic management of all New 
Zealand’s health research effort is clearly essential given the small scale of the system. The 
other countries reviewed operate with a similar range of funding organisations. What is 
noticeable however is the greater extent of formal interagency cooperation and 
collaboration than appears to be the case in New Zealand. There is a more convincing case 
for HRC to be the lead agency in relation to assessing and approving clinical trials, on the 
basis of the expertise that the Council commands and the scientific rigour required for 
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effective trials. Again, FRST is starting to fund extensive clinical trials, so the issue is one 
of coordination and collaboration.  
 
• We do not believe a substantially increased concentration of research funding 
through HRC would automatically produce benefits in terms of the coherence 
and coordination of health research. Rather the challenge is to make the 
various funding agents and policy departments work more effectively together 
within a plural system, as is the case in many of the benchmark countries.  
 
The performance measure proposed (per cent of health research funding flowing through 
HRC) is not as appropriate as indicators that measure the degree of cooperation between 
purchase agents.  
 
GOAL 2: Investment in people 
 
Re-establishment of fellowships and scholarships 
 
In 2003-04 the HRC is offering the following career development awards: 
(i) Masters Scholarships for Māori and Pacific graduates 
(ii) PhD Scholarships for Māori and Pacific graduates 
(iii) Postdoctoral Fellowships for Māori and Pacific graduates 
(iv) Sir Charles Hercus Health Research Fellowship 
 
As part of the requirement to pay increased overhead costs to the universities (see Chapter 
7) several other types of fellowships and scholarships formerly funded by HRC have been 
transferred to the universities. We consider that, while universities may use these funds for 
fellowships and scholarships, HRC has a crucial role in supporting health research careers 
(including technical staff and clinical practitioners) and should be the prime purchaser for 
scholarships and fellowships in health research. The overseas research councils studied all 
provide forms of direct support for researchers in their careers. There is some evidence that 
the level of support is increasing. In Australia, for example, the NHMRC proposes to 
increase the proportion of funding for ‘people’ from 21 per cent of its funds in 2000, to 30 
per cent in 2005 (National Health and Medical Research Council 2003c). 
 
Prior to the introduction of full cost funding, HRC spent up to 10 per cent of its budget on 
scholarships and fellowships. The comparable figure for Australia’s NHMRC is closer to 
20 per cent. HRC estimates the resources required to reinstate the scholarships and 
fellowships nominated in ‘Vision 2008’ as around $1.2 mill annually.  
 
• HRC requires additional funding to invigorate its fellowship and scholarship 
programmes (including biomedical and public health training awards). 
Overall, the target for the proportion of HRC expenditure on ‘people’ needs to 
be set at 20-30 per cent of budget if it is to reach norms common in some of the 
overseas research councils studied.  
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Career development programmes for Māori and Pacific peoples 
 
HRC has made substantial progress in both of these national priority areas, particularly for 
Māori career development programs. The HRC has identified serious Pacific research 
workforce capacity issues which the Council is trying to address thorough its partnership 
strategies and strategies such as the new Pacific Placement Programme (dependent of 
funding increases in 2004-05) and Summer Studentships. These are innovative attempts to 
develop capability without lowering standards required of health researchers. They deserve 
appropriate earmarked funding.  
 
• There is benefit in having separately identified funding for both Māori and 
Pacific health research career development programmes. 
 
Linkage of fellowship and research funds 
 
HRC proposes to provide grants of up to $125,000 over three years for successful 
scholarship and fellowship applicants. This approach is fairly common in the benchmark 
countries, where success in one competitive funding round provides either parallel funds or 
the ‘entry ticket’ of eligibility for them. At the institutional level, an example is in the 
allocation of Canada Research Chairs (see Chapter 3).  
 
GOAL 3: Health Research Careers 
 
HRC’s aim is particularly to retain and attract experienced mid-career researchers. The 
intention is to offer a senior fellowship, similar to Australia’s Burnet fellowship; to expand 
the Sir Charles Hercus Fellowships (4 year postdoctoral) to at least eight fellows by 2005; 
and new awards for Māori PDFs and a clinical research fellow. HRC also funds the Foxley 
Fellowships and Summer Studentships. 
 
There is obvious benefit to New Zealand in each of these proposals. For example, a Burnet 
Fellowship has brought Nobel laureate Peter Doherty back to Australia. The Burnet 
fellowships commenced in 2001. 
 
The level of investment required for ‘star’ fellowships is quite small in relation to the 
potential benefit. Outlay is around A$0.4 mill. per fellowship year in the case of the Burnet 
scheme. Evidence suggests that expatriate researchers are attracted not by salaries, but the 
opportunity to work with world class colleagues and facilities. Rather than announce 
‘generic’ fellowships, as the contestable pool of researchers is small, a more effective 
strategy may be to target particular individuals and negotiate a package which comprises 
salary, facilities and supporting researchers and staff. The estimated cost is $0.8-1.0 mill. 
per annum per fellowship.  
 
We understand that HRC is no longer funded for public health and biomedical Career 
Development Awards. The tertiary institutions are now responsible for career development 
in these areas. As indicated under Goal 2, these fellowships should be brought back under 
the control of HRC, with additional funding if necessary.  
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GOAL 4: Improved health and well-being 
 
There is clear benefit in linking HRC research investments with national health goals in 
relation to medicine, public health and disability/rehabilitation. Indeed, this must be one of 
HRC’s major goals. There is a strong nexus between HRC’s priorities and national health 
planning, but one which could be made more explicit to both policy makers and the 
research community.  
 
The New Zealand Health Strategy (NZHS) comprises 61 overall objectives and 12 ‘priority 
health gain areas’. These include: Reducing smoking; Improving nutrition; Reducing 
obesity; Physical activity; Suicide; Alcohol and illicit drugs; Cancer; Diabetes; Oral health; 
Violence; Mental illness; and Child health services. Surprisingly, the Strategy makes scant 
mention of the contribution of research to achieving its objectives. However, we were told 
that the daughter strategies in preparation for several of the main priority areas do or will 
address the role of research in their achievement. Some of these are more detailed policy 
documents. Others are active programmes of R&D: the Mental Health R&D Strategy, 
developed through HRC and MoH, is an example of the latter.  
 
The HRC has the statutory responsibility to advise the Minister of Health on national 
health research policy. Section 34a of the Health Research Council Act 1990 requires that 
‘the Council shall set up formal mechanisms of liaison to develop a national health 
research strategy for New Zealand’. The HRC notes that the NZHS is a good measure of 
national health research priorities because it was based on an extensive consultation 
process in which a broad range of stakeholders, including the HRC, participated. Certainly, 
the government’s health strategy has been ‘fundamental’ to the HRC’s development of the 
research portfolios in the sense that the Council has aligned its strategies with the NZHS. 
However, there are a number of important research areas that are not covered by the 
NZHS, such as evaluation of health sector reforms. Conversely, there may be health 
priorities that do not require substantial research before action can be taken.  
 
We consider that there is a strong case for a published national health research strategy 
(or strategies) to complement and extend HRC’s existing nine strategies, which refer to the 
Council’s own activities. 
 
• ·We consider that there should there be more explicit articulation between the 
New Zealand Health Strategy (NZHS) and health research priorities. This 
could be achieved by nominating specific research priorities/needs within 
future NZHS or through separate published national health research 
strategy(ies). We recommend (see Recommendation 4) that HRC should 
coordinate these strategies. This would require adequate resources for HRC to 
carry out this task.  
 
GOAL 5: Unique opportunities 
 
The strategies under this goal address two concerns. The first is to ensure the application of 
health research by and for Māori , Pacific peoples and particular target groups in society. 
These may be termed ‘needs driven’ opportunities. The second is to exploit New Zealand’s 
competitive advantage in particular areas of world class research, such as foetal 
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development models and very long term epidemiological studies (‘strength driven’). The 
rationale and benefit for each is rather different, as are the strategies that could be 
effectively adopted. In the first case, the benefit lies in improved health outcomes for 
significant population groups, social equity, and expanding the pool of qualified 
researchers from different cultures. HRC comments that research capacity appears to be a 
major barrier to funding more research of relevance to Pacific peoples and people with 
disability. Capacity and capability building strategies are therefore appropriate, which is 
different from the requirement in established areas of strength. The issue of indigenous 
health research is further discussed in Chapter 6.  
 
In the second case the benefits deriving from a competitive advantage in health research 
may be commercial exploitation, or scientific reputation. (See also GOAL 1: Development 
of competitive advantages).  
 
• HRC should collaborate with FRST to provide advance warning of those 
health researchers working on technologies or research outcomes with 
potential for commercial exploitation.  
 
GOAL 6: Using cross-sectoral research partnerships 
 
The HRC’s Partnership Programme is being used effectively to deliver cross-government 
solutions for evidence-based health practice. This Goal also recognises the need to work 
together with Foundation for Research, Science and Technology (FRST) on development 
of co-investment opportunities and to recognises and capture of sector convergence 
opportunities which flow from discoveries in the life sciences sector.  
 
These strategies reflect a ‘top down’ approach to cross sectoral research partnerships, 
which is clearly an effective approach in areas of national priority and immediate user 
needs. The HRC’s Partnership Programme has been used most innovatively and effectively 
to leverage funding from sources apart from the HROC.  
 
Most of the benchmark countries have also established schemes to support ‘bottom up’ 
(research partner/user) driven cross sectoral research partnerships. 
 
• Support for ‘bottom up’ cross sector partnerships or centres is a significant 
gap in HRC’s health research investment strategy, one which is likely to 
require substantial additional funding to rectify.  
 
This need could be met through support for National Health Research Centres (see Chapter 
7) to complement existing CoREs and FRST consortia. HRC has indicated that it supports 
the establishment of National Research Centres in principle as a strategic initiative, but has 
indicated that it cannot provide funding support in 2003-04 given the current funding 
environment (HRC 2003e: 14). The issue of partnerships and cross-sectoral research 
support is discussed further in Chapter 7.  
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GOAL 7: Global connections 
 
New Zealand’s small size and geographic location mean that international collaboration is 
especially important. HRC is supporting international networks and partnerships through 
specific international initiatives in joint research funding, clinical trials and 
epidemiological studies, and through research programme grants. These initiative are 
appropriate and of benefit, but could be usefully extended. Given the scope for potential 
strategic linkages, they obviously require careful selection.  
 
• HRC should instigate an international collaboration grant scheme for 
individual health researchers and teams to complement the support and grants 
offered by MoRST and the FRST. These could be targeted for HRC project 
and program grant holders or more widely. 
 
• Funds from the new ‘Developing International Linkages’ output class should 
be made available for this purpose.  
 
The estimated cost of these initiatives would be of the order of $0.5 – 0.75 mill per annum.  
 
GOAL 8: Capturing economic benefits of health research  
 
As currently stated, Goal 8 in relation to ‘ensuring the economic benefits of health research 
are captured’ would not be achievable without a substantial reorientation of HRC’s 
activities. HRC’s investments are undoubtedly essential to ensuring the health research 
capabilities that underpin economic benefit, and the Council should certainly invest in 
research that may have significant economic potential. However, under current 
arrangements, schemes that aim to derive direct economic benefit from research are 
managed by the FRST. This follows the practice in countries such as the Netherlands 
where support for near-commercial application is the responsibility of separate government 
agencies with specialist expertise. Collaboration between FRST and HRC towards this and 
other goals should be strongly encouraged (Appendix 3, Strategy 1d). We suggest that this 
goal be reworded to reflect current arrangements.  
 
HRC notes that the majority of intellectual property arising from HRC-funded research in 
2001-02 arose from contracts funded under the Biological Systems and Technologies, and 
Non-Communicable Diseases Research Portfolios. This emphasises the need for adequate 
funding to these commercial ‘seed’ areas of fundamental research. As indicated above, we 
see this as HRC’s appropriate contribution to national economic benefit in medical 
biotechnology and other areas, not the support of ‘near commercial’ development (except 
in respect of clinical trials). Internationally, the trend is for ‘commercialisation’ agencies to 
provide support for academic researchers to test the economic potential of their research. 
An example is the ‘BioPartner’ programme in the Netherlands. Biotechnology is a field 
where innovative collaborations between research councils and more commercially 
oriented technology funding agencies are emerging. The new Stem Cell Centre of 
Excellence in Australia is an example.   
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• HRC has a crucial role in supporting research with commercial potential and 
supervising clinical trials. These activities require close cooperation with other 
purchase agents, notably FRST.   
 
GOAL 9: Infrastructure for health research 
 
This issue is discussed in Chapter 7. 
 
 
Conclusion: the Future Vision 
 
‘Vision 2008’ is a document that will be central to the development of health research in 
New Zealand over the next five years. HRC is to be congratulated on producing a strategy 
that is soundly based on analysis, recognises the particular contribution that the Council 
makes and is consonant with and responsive to the government’s health and research 
priorities. We consider that the plan should be widely used and publicised, and could 
usefully form the basis for a broader national health research strategy, coordinated by 
HRC which covers not only the activities of the Council but all publicly funded health 
research in the country. This would require close collaboration between HRC and other 
purchase agents and policy ministries. 
 
We found some evidence in our discussions that HRC’s Strategy and the rationale behind it 
does not seem to be widely understood within the research community. ‘Vision 2008’ 
nominates nine Goals and more than 30 specific strategies flowing from these goals. We 
identify two types of goals, one of which is closely related to the Council’s mission, and 
the second of which is essential in fulfilling that mission. These might be termed 
overarching and structural (or instrumental) goals respectively. It is not immediately clear 
from the document the relative importance or ranking that HRC attaches to each of the 
nine goals. We consider there would be benefit for HRC’s stakeholders understanding of 
the Strategy if the Council were to structure and prioritise the goals within the Strategy.  
 
• We suggest that HRC consider presenting the Strategy in terms of overarching 
goals (or missions) and crucial structural goals, possibly such as shown in 
Table 5.1, and give consideration to ranking their importance.  
 
Each of these strategies has clear benefit for New Zealand. It is not however possible to 
quantify these benefits in advance and HRC will undoubtedly monitor their effectiveness 
and impact using appropriate performance indicators (see Appendixes 3 and 5) as the 
Council has with past investments (HRC 2002a). HRC’s performance measures and 
evaluation practices are well developed and appear the equal of those we have examined in 
the benchmark countries. Chapter 7 addresses the specific question of appropriate 
performance indicators. 
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Table 5.1: Suggested overarching goals and structural goals for HRC 
 
Overarching Goals Structural Goals  
Investing in excellent and relevant health 
research 
Fuelling the engine for health R&D through 
investment in people 
Ensuring that health research contributes to 
improved health and wellbeing for all New 
Zealanders 
Bridging the gaps in careers for health research 
Taking advantage of New Zealand’s unique 
opportunities [in health research] 
Global connections: strengthening global 
networks 
Capturing economic benefits of health research Ensuring New Zealand has the infrastructure 
to support high quality health research 
 Using cross-sectorial research partnerships to 
produce knowledge of benefit to New Zealand  
 
Effective implementation of the Strategy will require additional resources, some of which 
we indicate in this Chapter. The resources required to achieve some Goals (such as 
‘excellent and relevant health research) are not specifically quantifiable without reference 
to the level of funding that seems to be required to achieve similar goals in other countries. 
The question of an adequate level of funding to achieve the objectives is discussed further 
in Chapter 8, and summarised in Table 8.1. 
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Because of its treaty with Māori (The Treaty of Waitangi [Te Tiriti o Waitangi]) New 
Zealand Governments have arguably been more sensitive to the needs of the indigenous 
population than many other countries. Health statistics reveal that Māori and other 
population groups (such as Pacific peoples) in general suffer from poorer health than for 
the non-Māori population.52  The Health Research Council has thus devoted significant 
effort in developing a health research capacity within the Māori community - by Māori for 
Māori, and is now extending its model to Pacific peoples.  
 
The three ‘New World’ countries compared through the present study also have identified 
the health of indigenous populations as specific targets for health research investments. 
These are Canada, Australia, and the United States. In spite of specific investments through 
indigenous health programs in these countries health outcome disparities have persisted, 
and in some specific areas widened (NIH 2002). As a response to these disparities health 
research investment frameworks across all four countries have attracted considerable 
attention. This chapter reviews the strategic frameworks and structures in place for such 
investments. 
 
Because of the differences in demographic structures in each country, specific community 
health issues, socio-economic position of minorities in the overall populations and the 
socio-political structures for dealing with ‘minority’ health policies it is problematic to 
make direct comparisons of levels of funding. For example, in New Zealand Māori 
represent 14.7 per cent53 of the population (about 570,000 persons). In Canada ‘First 
Nations’ represent about 3 per cent of the population54 (about 800,000 persons). Australia’s 
indigenous population is estimated to be about 460,140 people, a similar overall number of 
persons to New Zealand, but only 2.4 per cent of the population, more similar to Canada. 
In the US American Indians and the indigenous people of Alaska (AIAN) are considered to 
comprise the indigenous population, but together, they comprise only 0.9 per cent of the 
U.S. population, but approximately 2.6 million persons. Not surprisingly these differences 
contribute to different proportions of funding within each health research system. 
However, it is helpful to review the comparative approaches to indigenous health research 
policies and, as far as possible, the outcomes achieved in terms of the strategic objectives.  
 
By international comparison New Zealand has made significant progress in developing its 
Māori health research strategy. Māori health research has been identified as a high priority 
issue by the HRC for over a decade. Current information suggests that the complementary 
objectives of capacity building, and project, programs and partnership have begun to show 
good returns on investment. 
                                                 




54 http://142.206.72.67/02/02a/02a_009_e.htm  
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New Zealand, like some of the comparator countries described in this chapter, has also 
identified other priority population groups as part of their overall health research strategy. 
As this ‘target group’ strategy develops there are two areas where New Zealand might 
draw some useful lessons from other countries. 
 
Australian health research investments and strategy for Aboriginal and 
Torres Strait Islander peoples 
 
In Australia funding for health research to benefit Aborigines and Torres Strait Islanders 
(ATSI) is provided through a number of agencies. The National Health and Medical 
Research Council has recently put together its Roadmap document. In addition, funding is 
allocated through the CRC program, The CRC for Aboriginal Health, The Australia 
Institute of Aboriginal and Torres Strait Islander Studies (AITSIS) as well as funding 
provided through individual State Governments and the higher education system more 
generally.  
 
Because of the multiplicity of agencies involved it is difficult to identify the total overall 
level of Aboriginal health research investments in Australia. The level of State 
Government expenditure is particularly difficult to determine because it is often provided 
through a range of state government programs. 
  
The NHMRC has a number of legislated roles in terms of contributing to national 
indigenous health research policy. These include advising on government and the 
community on matters relating to, the improvement of health, the prevention, diagnosis, 
and treatment of disease and the provision of health care. The Council is also mandated to 
report on issues concerning public health and medical research and ethical issues relating 
to health. Within these roles the Council provides advice and recommendations to the 
Commonwealth on matters concerning, public health research and training, medical 
research and training and the application of the ‘Medical Research Endowment Account’. 
These are essentially the same roles as the HRC performs in New Zealand. 
 
The NHMRC released its ‘Roadmap’ for improving Aboriginal and Torres Strait Islander 
health through research in 2002. The Roadmap outlined what the NHMRC perceived as the 
issues for Australia’s indigenous peoples’ health and provided a proposed research agenda 
for improving the situation. A central plank in the strategy was a nominated target of 5 per 
cent of the Council’s budget for expenditure on health research for Aboriginal and Torres 
Strait Islander peoples. 
 
Roadmap of research 
 
The proposed research agenda framework was comprised of six key elements. These are: 
1. Descriptive research to identify patterns of health risk, disease and death. 
Information derived from this research is intended to inform the development of 
preventive action and treatment.  
 
2. A research focus on the factors and process that promote good-health particular 
during the periods of pregnancy, infancy, childhood and adolescence.  
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3. A research focus on health services to describes the best means of delivering 
preventive, diagnostic and treatment.  
 
4. A research focus on the association between health and related policy and 
programs that otherwise lie outside the direct influence of the health sector. 
 
5. A focus on action research in previously under-researched areas concerning 
Aboriginal and Torres Strait Islander communities.  
 
6. The development of the nation’s Aboriginal and Torres Strait Islander health 
research capacity, with a particular emphasis on raining and practice for and by 
Aboriginal and Torres Strait Islander researchers. 
. 
Outcomes Against Objectives 
 
In 2003 NHMRC directed A$12.7 mill. or 4.2% of funds toward the above objectives. This 
was close to, but short of the target of 5 per cent target identified in the roadmap 
(Cunningham et al 2003). In terms of the overall target population this figure represents 
A$27.6 per head of the Aboriginal and Torres Strait Islander population. Of the A$12.7 
million, 5.3 per cent  (A$680,000) was spent on training and 4.6 per cent on public and 
population health (A$590,000).55 A total of A$2.5 million (19.7 per cent of the A$12.7 
million) was allocated to health research partnerships in mental health. 
In summary Australia has a well structured research agenda that has been developed 
through consultation with indigenous populations and health research stakeholder groups. 
The ‘Roadmap’ identifies the need to develop indigenous research capacity but 
achievements toward this appear weaker compared to advances in New Zealand and 
Canada. Capacity building is clearly underway through many programs such as the 
Menzies School of Health Research, the CRC for Aboriginal Health as well as through the 
NHMRC. However, in Australia there appears a long way to go before Aboriginal health 
research can be defined in the same terms as Māori health research is in New Zealand. 
That is with Māori, for Māori and by Māori, as is set out in the framework that is used to 
purchase Maori health research in New Zealand eg Maori advancement and Maori 
development (explained in the HRC’s Maori Health Strategic Plan and in the HRC’s 
Investment Strategy). 
 
Canada’s research investments in First Nations and Inuit health  
 
Despite improvements in some areas of indigenous health, First Nations and Inuit continue 
to live in poorer environments than the overall population. This disparity places them at 
greater risks and results in poorer health. The prevalence of chronic disease in First 
Nations and Inuit is high and appears to be increasing.56 Although some advances have 
been made in the reduction of mortality and morbidity from infectious disease, the number 
of deaths due to accidents and violence, especially suicide, have risen57.  
                                                 
55 See Table MM, in Cunningham et al 2003. 
56 A Statistical Profile On The Health Of First Nations In Canada 
57 From http://www.hc-sc.gc.ca/english/budget/2000/firstnations.htm





Like Australia, Canada funds health research through a national funding body as well as 
through funding provided by the Provinces. There is a national strategic plan that guides 
indigenous health research. The plan is focused on targeting direct health research 
investments through institutes as well as building indigenous health researcher capacity. 
CIHR funds Native peoples’ health research directly through its ‘virtual institutes’ it also 
funds the Institute of Aboriginal Peoples Health (IAPH) to develop research capacity.58 
IAPH in turn is responsible for the Aboriginal Capacity Developmental Research 
Environments (ACADRE) centres which are intended to play a major role in encouraging 
the development of indigenous researchers. 
The IAPH provides the lead in Canada for developing ‘aboriginal’ health research policy 
and funding strategies. Target health research investment areas include clinical research, 
public health and population research as well as clinical trials and research into health care 
service delivery. The Institute is also responsible for culturally relevant ethical issues and 
international studies into health research and health outcomes of indigenous populations 
world-wide. Canada is also a partner in a tripartite indigenous health research program 
involving Australia and New Zealand. 
 
CIHR has several programs, including open competitions for industry-partnered, proof of 
principle, research, and training projects; and strategic competitions in priority areas 
identified in collaboration with other institutes. IAPH appears mostly to solicit applications 
for research grants in specific areas, such as privacy and aboriginal community-based 
research. 
 
In Canada, as in Australia, it is difficult to identify total national levels of investment for 
indigenous health research. Data are available, however, for CIHR funding to Aboriginal 
Peoples. For the year 2001/2 this amounted to C$4.8 million and represented 1 per cent of 
the CIHR budget. Investment in grants and awards through IAPH amounted to C$320,321, 
most of which was directed toward capacity building.59  
 
In summary CIHR contributes a comparatively small proportion of its overall budget 
directly to Aboriginal health research, but performs a key role in developing health 
research policy. It appears that provincial governments make significant investments but it 
is difficult to identify the total contribution from the provinces. 
 
USA: American Indian and Alaskan Native (AIAN) health research 
 
The health challenges of the AIAN population have been well documented. The population 
sub-group experiences lower life expectancy than other Americans. The chief causes of 
death are unintentional injuries, cirrhosis, homicide, suicide, pneumonia, and 
                                                 
58 See for example  http://www.cihr-irsc.gc.ca/e/institutes/iaph/8668.shtml. 
59  IAPH (n.d.). 
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complications of diabetes.60 The US strategic plan for health in the United States calls for 
eliminating such health disparities and US federal agencies including research agencies are 
consequently required report on their contributions toward this objective.61
 
The major agency funding research for AIAN health is the National Institutes of Health. 
The central organization there is the National Center on Minority Health and Health 
Disparities, but grants and programs exist across the various NIH Institutes. The total NIH 
budget for health disparities research was estimated at US$2.9 billion in FY 2003, but the 
AIAN research component is only one part of this investment.  
The budget of the Indian Health Service, which has responsibility for the delivery of health 
services and which does not have a significant research funding system was  US$2.6 
billion in 2001. 
 
In 2004, NIH had somewhere between 300 and 500 active grants for research on AIAN 
health problems. These were of many different types, from standard grants, centres grants 
and training grants.62 The NIH on latest available figures allocates 10.6 per cent of budget 
to the elimination of health disparities, a proportion of which is directed toward indigenous 
health research (NIH 2002). 
 
NCMHD uses only three types of awards: a loan repayment program for training, and 
‘endowment’ grant to eligible minority-serving institutions, which can be used for a 
number of purposes; and centres of excellence. The centre makes no standard grants. 
 
NCMHD promotes minority health and leads, coordinates, supports, and assesses the NIH 
effort to reduce and eventually eliminate health disparities in the United States. 63 The 
Center supports basic, clinical, social, and behavioural research, promotes infrastructure 
and training, fosters emerging programs, disseminates information, and reaches out to 
minority and other health disparity communities. The overall budget is in excess of 
US$185 million. Three programs form the core of the investment strategy:  a centres of 
excellence program, loan repayments for capacity building among minority health 
professionals; and a research infrastructure program for capacity building in ‘minority’ 
institutions. The NCMHD supports partnership initiatives involving several other agencies. 
There are also cross-cutting programs for minority health research initiatives across 
various NIH Institutes.  
 
The Indian Health Service (IHS)64 is an agency within the Department of Health and 
Human Services. It is responsible for providing federal health services to American Indians 
and Alaska Natives. The IHS is the principal federal health care provider and health 
advocate for Indian people providing health services to approximately 1.5 million 
American Indians and Alaska Natives who belong to more than 557 federally recognized 
tribes in 35 states. Consequently provides input to health research policy.  
                                                 
60 American Indian and Alaska Native Health (CBM 96-6). The data are for 1990. 
61 http://www.healthypeople.gov/. 
62 This list of grants was generated from the NIH database CRISP 
http://crisp.cit.nih.gov/crisp/crisp_query.generate_screen., using the terms American Indian, Native 
American, and Alaska Native, with stem expansion. 
63 http://ncmhd.nih.gov/default.html
64 http://www.ihs.gov
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The Native American Research Centers for Health 
 
The Native American Research Centers for Health (NARCH) grants were established as a 
result of an ongoing collaboration between IHS and NIH. The NARCH initiative is aimed 
at developing a population of Indian researchers and health professionals engaged in 
biomedical, clinical, and behavioural research. Tribal partnerships with academic research 
centres are encouraged as a basis for cooperative competitive research bids on health 
conditions of importance to American Indian and Alaska Native people. IHS is responsible 
for the program overall with funding contributions from NIH's National Institute of 
General Medical Sciences, National Institute of Allergy and Infectious Diseases, National 
Institute of Drug Abuse, National Institute of Dental and Craniofacial Research, and the 
NIH Office of Behavioural and Social Sciences Research. 
 
In summary, overall strategic planning and reporting on minority health research inputs 
and outcomes in the US is a comparatively new development. Government legislation in 
the US requires NCMHD to report to congress with recommendations for a methodology 
that the NIH can apply to determine the actual amount of NIH resources directed toward 
eliminating health disparities. This is an ongoing process but one which New Zealand 
might monitor closely in terms of identifying useful internationally comparable 
performance indicators. 
 
While it is too early to identify outcomes from the US minorities strategies there is 
evidence of progress toward strategic reporting and monitoring for assessing progress 
toward the key goals: research; research infrastructure; and community outreach.  
 
 
New Zealand investments in Māori health research 
Improving Māori health has been identified as an important priority for the New Zealand 
health system.65 As part of that process New Zealand’s HRC has set in place a clearly 
articulated philosophy, policy and practice for the development of Māori health research 
capability. The strategy has been emerging progressively over the past decade and has been 
covered by two successive strategic plans 1998-2002 and 2004-2008 (HRC 2004a). The 
strategic areas for Māori health research development in this plan include: 
• development of the ability of tangata whenua communities to undertake research 
projects; 
• to ensure Māori health research is innovative and opportunities to contribute to 
economic goals are exploited where appropriate; 
• to ensure Māori have the ability to engage in the debate on the development and 
implementation of new health research technologies; 
• to ensure research collaborations with other indigenous peoples are fostered, and 
                                                 
65 See Priorities for Māori and Pacific Health: Evidence from epidemiology, downloaded from the Ministry 
of Health’s Māori Health website http://www.maorihealth.govt.nz/cgi-
bin/p/viewnews.cgi?newsid990594000,42195
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• to ensure Māori ethical issues are part of the debate and discussion on health ethics 
in Aotearoa - New Zealand. 
This will be achieved through the HRC investment framework for Māori research. 
 
• Investment in quality health research and related initiatives. 
• Implementation of a programme of career development awards to build a trained 
Māori health research workforce. 
• Development of strong and meaningful relationships with tangata whenua. 
• Development of partnerships and strong relationships with health and research 
stakeholders to add value to HRC’s investments. 
• Identification and adoption of new health research relevant  to improving Māori 
health and well-being. 
 
The New Zealand HRC has devoted significant effort to delivering a conceptual model 
appropriate for the development of a health research capability for Māori and is now 
identifying actions for Pacific peoples. The framework for investment in Māori health 
research identifies three basic platforms for development: capacity building for a Māori 
research community; investigator led research for Māori health; and program partnerships 
for Māori health. The framework incorporates a national plan locating points of 
contribution from a variety of agencies and research output classes. The key agency in 
terms of planning and research purchasing is the HRC. 
 
(Māori research for Māori and by Māori ) amounted to approximately $4 million for 
2002/3, approximately 7 per cent of the total HRC budget. Research funding can be 
classified in two ways. Firstly research investments through the Māori research portfolio 
(the HRC’s research portfolio for Maori Health Research funded in the annual funding 
round is the Rangahau Hauora Maori Research Portfolio) Current investments in Māori 
Career Development awards amounts to $1.7 per annum. Many of these scholarships are 
for current PhD candidates. Since 1995 the HRC has funded 45 66 PhD scholars, 13 of 
whom have graduated to date.     
 
Another classification for reporting on Māori health research is ‘research that contributes 
to outcomes for Māori ’. A total of $12 million representing 26 per cent of HRC total 
expenditure can be counted in this category and includes HRC’s contribution to the Māori 
research joint ventures with FRST and MoH. Total investments within these classifications 
is presented in Table 6.1. These data also show the progressive growth in investment in 
this portfolio area over the past six years. However, as discussed below it is important to be 
able to consolidate these gains in order to convert these longer-term investments into 
improved health outcomes for Māori . 
 
                                                 
66  Data from presentation to evaluation team (HRC 2004d). 
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Research capability development is described as a progressive process initially through 
research that is relevant for indigenous populations to research through partnerships and 
moving toward research carried out by Māori for Māori (governance).67  
 
Table 6.1:  HRC expenditure (1998/99 to 2003/04) on health research and career 





98/99 99/00 00/01 01/02 02/03 03/0469
Māori Development Research70 1.14 1.29 2.15 1.90 1.85 2.56 
Māori Advancement Research 
71
2.0072 2.005 2.73 4.14 6.00 7.50 
HRC – FRST Joint Research 
Portfolio73
- - - 0.13 0.45 0.70 
HRC – MoH Joint Venture74 - - - - - 0.16 
Total Māori Health Research 3.14 3.29 4.88 6.17 8.30 10.92 
Māori Career Development 
Awards75
0.76 0.71 0.89 0.87 0.85 1.07 
Total for Health Research & 
Awards  
3.90 4.00 5.77 7.04 9.15 11.99 
Total (%) 76 12.3% 10.1% 13.9% 19.4% 24.4% 27.4% 
Source: HRC, 2004 
 
Consolidating and sustaining the Māori health research strategy 
 
During the present evaluation a number of respondents expressed confidence and support 
in the way the HRC Māori research strategy had been developed and its application over 
the past decade. By devoting significant effort to workforce issues, the HRC is developing 
a pool of talent that will eventually be able to generate their own research proposals of 
relevance to their own communities and compete successfully for project funds. There is 
clear evidence that the capability development strategy is shifting from individual awards 
and grants toward more sustainable programs. During the past decade the graduate base 
has increased significantly and, according to the HRC, the number of fundable Māori 
                                                 
67  HRC presentation to the evaluation team 
68 Expenditure which contributes to outcomes for Māori is inclusive of investments in biomedical, clinical 
and public health disciplines. 
69 $ for 2003/04 are HRC’s projected expenditure based on contractual commitments 
70 Māori Development Research is primarily funded from Rangahau Hauora Māori Research Portfolio. 
71 Māori Advancement Research is funded from all HRC Research Portfolios except Rangahau Hauora 
Māori. 
72 Expenditure on Māori Advancement Research shown as estimate 
73 Table shows the funding with JRP administered by HRC 
74 Value of Joint Venture includes both HRC and MoH funds 
75 Māori Career Development Awards include Summer Studentships, Masters and PhD Scholarships and 
Postdoctoral Fellowships 
76 Percentage of HRC expenditure associated with Māori initiatives in Output Classes Public Good Health 
Research, Māori Knowledge and Development and Human Resource Development. 
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research projects has increased. A Māori Health Research Centre has recently been 
awarded funding in open competition. 
 
The challenge for the future will be to maintain career structures and opportunities for 
promising new Māori researchers. As noted in previous chapters the overall level of 
funding for health research in New Zealand has not grown in real terms. Already a 
considerable proportion of fundable projects assessed by the HRC remain unfunded. 
Unless there is growth in the system overall the capacity to consolidate the gains already 
made in Māori health research can only be achieved at the expense of other areas. During 
the interviews for the present study attention was drawn to growing perceptions that Māori 
health research was already at the expense of other research portfolios. Increased 
competition for funding inevitably leads to these sorts of tensions.  
 
We note that in comparison with other national experiences, the development and 
implementation of the Māori health research strategy has met with considerable success. 
However, urgent funding increases for the system overall are now required to consolidate 
the gains already made and reduce unproductive tension within the system.  
 
Although Australia seems to be behind New Zealand in terms of capacity building it has, 
however, a well articulated set of priorities for strategic Aboriginal health research. This 
appears to be the main strength of the Australian Roadmap. As an appropriate pool of 
talent begins to emerge, HRC might consider developing a process that identifies strategic 
research that needs to be conducted in New Zealand. The HRC has already nominated such 
an activity within its plan for Māori health research (HRC 2004f). We endorse the 
approach marked out for these next steps, however, as noted above it will be difficult to 
establish achievable goals for this unless there is growth in the overall system. 
 
• In parallel with this strategic development we recommend that the health 
research coordinating committee proposed elsewhere in this report establish a 




The HRC’s research capacity building for Pacific peoples and other 
proirity population groups 
 
The HRC has now begun to develop a health research capacity building framework for 
Pacific peoples. The Pacific peoples framework is constructed around research 
programmes that are relevant to this group, in partnership with this group and research that 
is for and by Pacific peoples (governance).  
 
• This framework appears thoroughly appropriate and we encourage the HRC 
to continue in this direction. 
 
Alongside Māori and Pacific, the HRC nominates other population groups (older adults, 
children and youth, and people with disability) for attention. It was noted during interviews 
with stakeholders that the disability category, in particular, is languishing. However, 
HRC’s strategy and performance for these groups was not a focus for the present 
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evaluation. However, we draw attention to the need to monitor research outcomes for all 
target sub-groups and in particular, to identify the flow of benefits achieved for the health 
system most generally from research investments targeted toward such groups. 
 
At present HRC is devoting considerable effort in developing research capability for Māori 
and Pacific peoples. However, HRC nominates a number of population groups, some of 
which such as the disability sub-group do not appear to have such well developed strategic 
frameworks. While these population groups remain a defined target for HRC’s funding 
framework similar development strategies should be set in place with similar emphasis on 
building research capacity and evaluation measures.   
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7.  Emerging Issues 
 
In Chapters 5 and 6 the current status of the New Zealand health research strategy was 
discussed. A number of observations were offered including the level of funding required 
to meet the strategic objectives. Both Chapter 3 and 4 provided a base for comparing New 
Zealand’s health research system with the investment frameworks in other countries. It was 
observed that while the New Zealand approach was consistent with international trends and 
indeed, in some areas, was at least equal to or leading international policy practice, there 
were some international lessons that could be drawn to improve the system. Our overriding 
observation from meetings with stakeholder groups in New Zealand is that there are some 
tensions in the system associated with the level of project and program funding available 
for health research. In part, this is also associated with recent changes in funding 
arrangements. While there was general consensus among health researchers that the HRC 
has developed an efficient, transparent and internationally comparable set of procedures for 
delivering funds, there were a number of issues raised as to how the overall health research 
system might be improved. That is the subject of this Chapter. 
 
One of the key tasks set for the present evaluation was to report on whether the investment 
in the health research output class is managed through an appropriate policy and 
investment framework. Associated with this issue was the task of considering whether the 
Government’s investment in health research should be managed by a single health research 
purchase agency. In coming to a position on these issues the present evaluation considered 
(a) the structural arrangement of purchase agencies; (b) coordination between agencies and 
output classes; and (c) the relationship between HRC, MoH and MoRST; and (d) the 
current status of collaborative research; and (e) the role of the higher education system in 
delivering outcomes from health research investments. Each of these issues is discussed 
below together with some recommendations for improvement. 
 
 
Structural arrangement of purchase agencies 
 
The New Zealand health research funding system offers a range of funding options for 
health researchers. The majority of funding is provided through the HRC. Approximately 
60 per cent of all health research in New Zealand is purchased by the HRC, which is 
responsible for all of the Health Research Output Class. Other key purchase agencies that 
also contribute to health research include FRST and the Marsden Fund. It has been 
estimated elsewhere that around 5 per cent of FRST and 20 per cent of Marsden funding 
budgets also contribute to health related research (HRC 2002c). However, while HRC is 
clearly the dominant agency in terms of health research funding, research providers appear 
to be quite discerning in strategically exploiting various funding options. That is, they 
appeared to make quite sharp distinctions between the objectives and strategies directing 
funding from different sources. Thus, while both FRST and Marsden have missions and 
objectives that differ from the HRC and are responsible for different output classes, there is 
potential complementarity. However, there is also the potential to overlap. 
 
In 2002 the HRC put forward a proposal to establish a single specialised health research 
agency (HRC 2002c). It was proposed that all ‘health’ research funds, irrespective of the 
RS&T goal (i.e. knowledge, social/health and economic) should be invested through a 
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single purchase agency. While the core objectives of HRC, FRST and Marsden are 
different there are clearly areas where there is overlap. The HRC refers to this overlap as 
the ‘contested space’. However, based on our interviews, with stakeholders across the 
health research system and our observations from international experiences we believe that 
the contested space is a natural outcome of transgressing disciplinary boundaries in 
research. The HRC, like its counterparts overseas has moved strategically toward a 
multidisciplinary portfolio based strategic approach. Indeed by international comparison 
this has been effectively embedded in strategic planning, policy making and ex-ante 
research evaluation. The effectiveness of this shift from disciplinary to strategic objective 
was evident from some of the health research providers who, for different strategic 
reasons, had received funding separately from Marsden, HRC and most recently FRST. 
One researcher, in particular, noted that his career path from ‘blue-skies researcher’ to 
director of a biomedical company was possible only because of the range of funding 
available.  
 
In addition to HRC, FRST and Marsden, there are various foundations that contribute to 
the overall health research effort. These include the National Heart Foundation, the NZ 
Lotteries Fund and the Medical Research Foundations. Underpinning NZ health research 
are the higher education, the hospital and health delivery systems. While the objectives and 
functions of these agencies are somewhat different they each contribute to the environment 
in which health research is developed and carried out. HRC and Marsden grants, for 
example, have underpinned the formation of a number of new biotechnology companies 
through the 1990s, while NERF grants have reportedly underpinned subsequent 
commercial development (HRC 2002b). 
 
Thus health research in New Zealand, as in most other OECD countries, needs to be 
understood not as a single system but as the product of the intersection of various systems. 
An evaluation of the health research output class and the policies and strategic 
management that drive it need to take into account this inter-sectoral reality. 
 
This multi agency approach is similar to other comparable countries. New Zealand, 
however, is a small country and this, as elsewhere, presents a challenge for determining 
appropriate concentration of investment in the various agencies and how the boundaries 
between agencies and programs should best be managed. In particular, questions emerge as 
to how policy is devised and managed, how it is monitored and coordinated. This boundary 
management not only concerns funding decisions but also the development, 
implementation and evaluation of the overall funding framework. 
 
In Sweden, like New Zealand most research is carried out in the University sector. Basic 
medical research is funded through the SRC Medicine Council which in 2001 disbursed 
SEK 350 million for basic medical research and administered SEK30 million on behalf of 
other agencies. However, this was approximately only 10 per cent of total medical research 
expenditure in the higher education system. The Irish HRB has a comparatively small but 
growing medical research budget. The SFI in Ireland, which has two strategic priorities 
(biotech and IT), performs a complementary role emphasises the basic research building 
blocks: the scientists, ‘keeping them in Ireland’ and ‘ensuring the health of the science 
system’ (ICSTI 2003a). 
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A distinguishing feature of health research in New Zealand is the comparatively minor 
involvement of the private sector. Other countries faced with similar challenges, such as 
Ireland and Australia, has placed considerable emphasis on collaborative programs to build 
bridges between a multidisciplinary science base at universities and the private sector. The 
objective has been to create structures to involve the business sector more directly in the 
national health research effort. Australia has focused on the cooperative research centres as 
a mechanism for achieving this objective. In Sweden and Canada, where there is 
significant involvement of the private sector, collaborative grant programs are used to 
maintain a flow of new knowledge between universities and industry. In small economies 
where there is a need for government interventions to strengthen the role of a weaker 
business sector collaborative funding mechanisms are all the more critical.  
 
• In the light of these observations we recommend (in Recommendation 1) the 
maintenance of diversity in the funding base provided through different agencies. 
However, we also propose an enhanced role for HRC in steering research policy, 
coordination, and evaluation toward strategic national goals. 
 
There are three key issues we consider need to be addressed in order to ensure national 
benefit flows from this diversity: 
 
1. the proportion of health research funding distributed through each purchase 
agency; 
 
2. the level of coordination between agencies, strategies and reporting mechanisms; 
and, 
 
3. the further development of common reporting indicators, taking into account the 
strategies and funding mechanisms of each agency. 
 
Proportional distribution of health research funding 
 
The HRC is now responsible for the entire Health Research Output Class, around $42 
million, as well as approximately $2 million from the Supporting Promising Individuals 
Output Class and $2.2 million from the Māori Knowledge and Development Output Class. 
While definitive figures are not available for health research purchased through FRST or 
Marsden the HRC has estimated amounts of $15-20 million through FRST (New Economy 
Research Fund - NERF) and about $6 million for Marsden. Thus it can be estimated that 
HRC is responsible for around 66 per cent of government’s health research purchase. It 
was pointed out to the evaluation team that HRC funds pure basic research in the 
Biological Systems and Technologies Research Portfolio and that in some cases research 
groups are funded by Marsden, HRC and FRST. From our international review this is a 
common experience, reflecting the multidisciplinary contributions of the biological 
sciences and the ebb and flow between basic and applied research. It is our view that a 
proportion of somewhere between 60 and 70 per cent of health research (broadly defined) 
through the HRC is appropriate and that the balance allocated through FRST and Marsden 
are appropriate proportions to allocate to innovation/new economy and pure basic research, 
respectively. By international comparison this appears an appropriate mix. As discussed 
below, the critical issue is to maximise coordination of investments and to maximise the 
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contribution of HRC in areas such as clinical trials where the Council has particular 
expertise and responsibilities.  
 
The recent introduction of fully costing project and program grants, while an important 
development, places new responsibilities on universities for maintaining appropriate levels 
of creativity and flexibility. In this context the role of project and programme grants 
through the HRC, and to some extent Marsden and FRST, in offering complementary but 
diverse options for research investment, is all the more critical for maintaining a dynamic 
health research system in New Zealand.  
 
• A single research agency, responsible for funding all health research, broadly 
defined, would not be in the best interests of the New Zealand research system 
overall. However, we propose an enhanced role for HRC in the coordination, 
strategic planning and evaluation of health research. 
 
Coordination (between purchase agencies and output classes) 
 
Maintaining diversity in funding streams and maintaining direction in strategic objectives 
requires coordination. A point to note from the Swedish system is that FRN maintains a 
strong policy and coordinating role across multiple funding options. In Ireland the SFI 
seeks an integrated approach by offering funding support for centres, institutes and 
equipment, project grants and partnerships. In cases where these various ‘blocks’ are 
funded through a single agency allocations can be coordinated within that agency. But 
where there are cross agency complementarities, such as between biotechnology and health 
research, there is a need for inter-agency coordination 
 
In New Zealand the major focus of the HRC is on project grants with a complementary and 
growing emphasis on programmes and partnerships. While infrastructure, including 
personnel and equipment costs are required to be identified through the full-cost funding 
requirements, it is the universities that finally allocate the infrastructure resource. This 
raises the need to ensure coordination and reporting on final inputs and monitoring and 
evaluation outcomes. In particular we note a need to:  
 
1. enhance coordination between the research purchase agencies whose investments 
contribute to health research; as well as,  
 
2. coordination across other relevant Votes such as higher education and output 
classes such as Māori knowledge and development. 
 
Our discussions with stakeholder groups suggest that while there is a level of coordination 
between agencies at a senior planning level, coordination is weaker at the program or 
portfolio level. Clearly some important advances have been made in strategic portfolio 
areas such as Māori heath and mental health. The challenge, however, is to press such 
strategic program development further. 
 
• In our view coordination could be strengthened both between purchase 
agencies and at strategic program levels by ensuring HRC more central in the 
development and coordination of the national health research strategy. This 
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would require deepening the structural relationship between HRC, MoRST 
and MoH. 
 
Proposals for achieving this are discussed below. 
 
Enhancing the relationship between MoRST, MoH and HRC 
 
The three key agencies concerned with health research and policy are HRC, MoH and 
MoRST.  In essence HRC serves two interrelated but separate interests: national delivery 
of health services including public health research (MoH) and national science for 
underpinning advancements in science and innovation, including new insights into health 
and disease and health services (MoRST). While HRC currently makes a major 
contribution in all areas their lead coordinating role does not appear to be formally 
acknowledged. For example, while Statements of Intent are developed in collaboration 
with MoH and MoRST and are signed off by both responsible Ministers this does not 
necessarily constitute a national health research strategy. Further, there does not appear to 
be any formal coordinating structure in place to specifically manage cross agency 
contributions to health research. 
 
• We recommend that MoRST should establish an interdepartmental health 
research coordinating committee including MoH and Education. HRC should 
have a lead role in the committee. 
 
Further to our recommendation for an enhanced coordinating role for HRC we note a need 
for their more direct engagement, together with MoH and MoRST, with the higher 
education sector, FRST and Marsden. During our interviews with stakeholders there is a 
perception that HRC is to some extent ‘remote’ from implementation agencies. Although 
this may be perception more than reality, effective coordination requires confidence at all 
levels. Some researchers, during the evaluation meetings, offered the view that the location 
of HRC in Auckland inhibited interagency coordination proposing that relocation to 
Wellington would improve the situation. In considering this issue we note that a review of 
the feasibility of relocating HRC in Wellington was carried out in 2000. While that review 
did not recommend a move to Wellington it did draw attention to a potential increased 
capacity to ‘influence change’, ‘pick up information’ and be ‘involved in policy and 
strategy development discussions’ that such location might offer (Calverley 2000). We 
believe that the formation of the health research coordinating committee proposed above 
will assist HRC in further developing this capacity. 
 
Indicators for monitoring and evaluating health research 
 
There is a range of internationally accepted indicators for assessing the quality of research. 
Typically these include publication counts, citations and international awards. The HRC 
has a well developed peer review system for ex ante and to some extent ex post research 
evaluation. There was virtually unanimous confidence expressed by researchers in this part 
of the system. However, in reporting on relevance and contributions to strategic objectives, 
New Zealand, like other countries, is struggling to establish indicators, appropriate for 
application across all agencies, for assessing outcomes and impact against strategic 
objectives. HRC appears to be well advanced, by international standards, in developing 
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portfolio based indicators and is contributing to the WHO global project on evaluation of 
national health research systems. The task ahead is to put in place a system of indicators 
(covering everything from inputs and resources through to outcomes) that can be applied 
systematically by all agencies and institutions contributing to health research, and that can 
be reported regularly. We note that while comparator countries are also struggling with this 
task there has been considerable progress toward this goal, particularly in the US, UK and 
the Netherlands. 
 
The HRC’s Progress and Achievements Report identifies the considerable work in the 
development and application of input and output indicators already under way for 
monitoring and evaluation of HRC’s research investments. Appendix 5, reporting on terms 
of reference 3 and 4, make extensive use of these indicators. Case-studies and additional 
survey work also contribute to the assessment of health research outcomes. This work 
stands up well against similar work carried out in the benchmark countries. The progress 
already made by HRC in monitoring and evaluating health research could be further 
enhanced by providing the Council with a clearer structure and mandate for coordinating 
health research evaluation across the system and the design of reporting systems. 
 
• We recommend that the coordinating committee proposed above should have 
a specific mandate to coordinate and develop a national health research 
reporting strategy and develop performance indicators for monitoring system 
wide outcomes and impact against national strategic objectives. The HRC 
should provide the lead role in this activity. 
 
Some further suggestions for consideration and action are proposed in the concluding 
section of this chapter.   
 
 
Supporting Collaborative Research 
 
New Zealand is experimenting with various models for collaborative research. The current 
purchase agency arrangements, which are organised to provide support for basic-
fundamental research (Marsden) strategic-public good research (HRC) and commercially 
applied research (FRST), or support to a particular sector (CoRE and PBRF) carries the 
potential to create competition and counter-productive boundaries as different approaches 
develop.  
 
The Education Minister established the Centres of Research Excellence (CORE) Fund in 
2001. Funds of $38 million were allocated over 4 years, with an additional $20 million for 
capital asset purchases. The principal objectives of the fund are ‘to promote excellent 
research, undertake research that can contribute to New Zealand’s future development and 
undertake research that incorporates knowledge transfer activities in training’. Seven 
Centres have been funded, with no current expectation of more. Two of the centres support 
health or biomedical research (Table 7.1) 
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Table 7.1: Core Centres of Research Excellence in Health  
Centre Host Institution/Partners Operational Funds 
Centre for Molecular 
Biodiscovery 
University of Auckland $8,900,000 over three years 
Capital Funds: $4,314,043 
National Centre for Growth 
and Development 
University of Auckland; 
University of Otago; Massey 
University 
Operational Funds: to be 
negotiated 
Capital Funds to be approved 
Source: TEC 
 
Internationally, research policy is increasingly emphasising research activities that 
contribute to economic and social outcomes. This is certainly the case in New Zealand, 
where, for example, MoRST’s Output Class approach reflects the requirement for the 
RS&T system to ‘catalyse and accelerate economic, environmental and social 
development’ (Minister of Research Science and Technology 2003). 
 
Hand in hand with this focus on socio-economic outcomes comes an organisational change 
in the way that research is carried out. Put simply, the organisational forms that were 
effective for disciplinary based academic research and for applied research in large 
manufacturing companies’ laboratories no longer work. What has changed? There are 
many factors at play, including the distribution of knowledge production (through mass 
tertiary education), the globalisation of business, the nature of emerging technologies and 
the facilitation of distributed knowledge intensive collaboration through information and 
communication technologies.  
 
International experience shows that research is increasingly being carried out in 
organisational forms built around cross-sectoral (government, academic, private) and 
transdisciplinary teams with well-defined national social, economic or environmental 
objectives in mind. These teams go beyond ‘applied research’ in the accepted sense to span 
fundamental research and the applied knowledge.  
 
Two influential models have been developed to explain the institutional configuration of 
knowledge-based innovation systems that can be observed in many countries today. The 
‘triple helix’ model of university-industry-government relations advanced by Etzkowitz 
and Leydesdorff premises that the university can play an enhanced role in innovation in 
increasingly knowledge-based societies. Gibbons and his co-authors propose a Mode 2 of 
knowledge production which they term ‘science in the context of application’. This 
contrasts with, and appears to be supplanting, traditional Mode 1, that is, internally focused 
scholarship controlled by strong disciplinary peer groups. 
 
Each of these models implies a challenge to the traditional research structures. As a result, 
new and unfamiliar forms of organisational arrangements are emerging in universities and 
elsewhere. These have been variously termed ‘hybrid’ or ‘parasitic’, depending on the 
analyst’s perspective. Both description has an element of truth. Collaborative research 
centres are hybrid in the sense that they embody some of the culture and processes of all 
partners. But they are also ‘parasitic’, in the sense that their existence depends both on the 
maintenance of the ‘host’ institutions while at the same time changing the character of the 
host institution.  
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A trend in support of collaborative research arrangements is clearly evident in New 
Zealand science and research policy. In the universities, several CoRE have been 
established. The HRC has a new and expanding Partnership scheme. The objective behind 
this scheme is similar to many overseas agencies, for example, the Irish partnership 
program. However, the mechanism for driving the focus and funding of partnerships in 
New Zealand is somewhat different. The Irish and Swedish approach to research funding is 
to engage the research providers, as far as possible, in determining the focus of research. 
The HRC project and program grants certainly follow this trend as they are submission 
based. FRST is also developing its model of research consortia. 
 
Increasingly, then, health research support is built around interdisciplinary, cross-sectoral 
research centres with a focus on the application of the research, funded for 5-7 years. New 
Zealand cannot afford to be without such centres in health research. To some extent they 
are emerging, through the CoRE programme, thorough FRST’s consortia, and by the 
initiative of individual research groups and universities. This in itself is evidence of a gap 
in the current investment system. HRC must be involved in the development of such 
centres. Their themes could be ‘investigator driven’ or nominated. In many benchmark 
countries, national centres are being jointly funded by several research councils. 
Networked Centres of Excellence in Canada and Cooperative Research Centres and 
Centres of Excellence in Australia are examples – see Chapter 3).  
 
HRC’s Partnerships and Joint Ventures appear to have been very effective in marshalling 
both funds and research expertise around defined research priorities. This innovative 
arrangement works extremely well where the HRC has an unchallenged mandate to pursue 
these priority areas, for example where they reflect key national priorities for health.  
 
As a general approach to collaborative research, however, we see several potential issues 
with the current HRC Partnership scheme. First, while the choice of researcher is fully 
contestable, the choice of priorities for funding is not necessarily so. Current priorities are 
determined by the degree to which the HRC is able to identify appropriate stakeholders, 
funders and health issues that are amenable to research led solutions to pursue. While we 
have no grounds to question the effectiveness of the existing Partnerships, HRC’s 
Partnerships appear to have been very effective in marshalling both funds and research 
expertise around defined research priorities. This innovative arrangement works extremely 
well where the HRC has an unchallenged mandate to pursue priority areas that reflect key 
national priorities for health. However, HRC could be challenged on why it selected a 
particular topic rather than an alternative one with equal potential As the partnership 
program develops we note a need for on-going planning and targeting of the programme. A 
‘priority setting exercise’ would help ensure the most effective alignment between national 
research capabilities, funding support and the application of research outcomes. 
 
• HRC should instigate a consultative priority setting exercise for future 
Partnership/Joint Venture investments that involves a wide range of 
stakeholders including researchers, policy agencies, other potential funders 
and the health industry. The exercise should consider both the feasibility of 
research and the potential outputs and outcomes of the investment in the 
research.  
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Second, overseas experience suggests that cooperative research has a successful outcome 
when both the researcher and the user of the research are involved in defining the problem 
and the solution. As noted above, there is substantial international experience to draw upon 
in the construction and management of collaborative research organisations (see Chapter 
3). It is important to note that schemes such as the Australian CRC Program support both 
industrially oriented and public good research. In the latter category, the CRC for 
Aboriginal Health involves partners including universities, State government health 
departments and Aboriginal organisations such as the Central Australian Aboriginal 
Congress.  
 
We consider that MoRST should explore with HRC, FRST, the Ministry of Education and 
RSNZ the potential benefit of establishing a new cross-cutting arrangement to support long 
term university-industry/user cooperation in health research. This may require a new 
National Collaborative Research Centres Output Class under Vote RS&T. HRC would be 
the primary purchase agency for health related centres and purchase agencies would jointly 
fund Centres where the Centres met the objective of several purchase agencies. Some co-
funding would be required from Centre partners.  
 
We recommend that:  
 
• HRC should develop proposals for a National Health Research Centre grant 
scheme, complementary to those funded by CoRE and FRST, for 
consideration by MoRST. The adoption of this recommendation should be on 
the basis of HRC receiving additional funding and should not draw on existing 
funds. 
 
Without prescribing the form of such a scheme, it would be ‘bottom up’, ‘proposal driven’ 
collaborative research support scheme where researchers and potential users develop 
proposals for assessment and support by HRC. We expect that the Research Centres 
(which could be physical or virtual) would be (i) application oriented, (ii) involve 
interdisciplinary and/or inter-institutional collaboration, and (iii) include cross sector 
partners (academic, business – where appropriate – and CRI). Centres should be awarded 
stable long term funding (5-7 years) subject of course to periodic review of performance. 
Some element of co-funding by the partners in the centres should be required. 
 
We do not intend by this recommendation to imply that HRC should have its own version 
of the Technology for Business Growth scheme that supports business investment in 
technological development run by FRST. Rather, we suggest complementarity that will 
assist businesses to buy into some medical research partnerships to boost resources and the 
spread and speed of innovation. 
 
 
Health Research Infrastructure in the Universities 
 
Almost all health researchers are in the university system. As a consequence university 
research policy has an implication for health research activities. This situation parallels 
experiences in countries such as Sweden, the Netherlands and Ireland. 
Science for Life 106
  
 
HRC project and programme funds are fully contestable, i.e. any qualified researchers can 
bid for them. In practice, few Crown Research Institutes are involved in health and medical 
research. Researchers in New Zealand’s universities thus carry out the great majority of 
publicly funded health research. A strong relationship exists between HRC and the main 
universities with capabilities in health research: the University of Auckland and the 
University of Otago. For example, the HRC allocated about 80 per cent of its project and 
programme funding to these two universities in 2003-04 and is the single largest external 
research funder for the University of Otago (Richards 2000). The independent Malaghan 
Institute of Medical Research is located in the Wellington School of Medicine and has 
close links with the University of Otago.  
 
As a result, any changes to HRC funding have substantial implications for university health 
researchers, and changes to the structure of research support within the higher education 
system may have a significant impact on the management of HRC’s funds.  
 
Three notable changes have occurred in recent years in the arrangements for funding 
university research. The first is the application of full cost funding, the second is the 
establishment of a Performance-based Research Fund (PBRF) for academic research, and 
the third is the establishment of Centres of Research Excellence (CoRE). A further issue is 
that of provision of capital infrastructure (equipment, buildings, major facilities etc) for 
health research.  
 
Full cost funding 
 
Government policy requires the purchase agencies to move towards full funding of the 
research they support by providing for investigators’ salaries, salary on-costs, project direct 
costs and an appropriate level of institutional central overhead costs. The policy applies to 
new contracts only. Universities have set the level of institutional overheads, at differing 
rates. For example, at the University of Auckland, the rate is now 121 per cent of salary 
costs, while at the University of Otago the rate stands at 114 per cent. These rates are based 
on actual costing exercises, subject to audit by Audit New Zealand and reviewed every 
three years. HRC has agreed, following negotiations with institutions, to increase the level 
of overheads included in project and programme grants from zero in 1996-97 to 85 per 
cent in 1997-98 and 103 per cent in 2003-04. These increases have contributed 
significantly to the growth in the average cost of a project funded by HRC, which has risen 
from $127,000 in 1996-97 to $847,000 in 2002-03 (although the average is skewed by 
several very large projects). 
 
HRC’s budget growth has not increased at a rate sufficient to cover these costs. The 
accumulated shortfall is estimated at around $5.5 million and without supplementary 
funding will increase by $5.5 annually. While full cost funding has now been implemented 
by HRC and adjustments made to transfer funds to cover the new requirements, this has 
not provided for any growth in project and program funding. As a consequence, the HRC 
is funding a smaller proportion of ‘fundable projects’. Thus while there is now more 
accountability for the overall cost of health research, it was pointed out to the evaluation 
team this has been in parallel with a reduced opportunity to adequately fund the top end of 
New Zealand’s health researchers.  
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HRC is ultimately responsible for the effective application of funds from HROC provided 
to the universities, and is required to report on outputs gained from these funds. In order to 
enable the HRC to fulfil this obligation there will need to be supporting obligations placed 
on the universities. In order to ensure these changes adequately support the infrastructure 
underpinning health research in universities it will be necessary for the internal allocation 




International practice varies very widely as it is contingent on the funding model adopted 
for research activities within the higher education sector. This ranges from funding 
research almost entirely from block funding to the universities through the education 
ministry  (a model that is less common than in the past) to full funding of all project costs 
via separately budgeted grants from special research granting agencies. In practice, most 
countries operate a variant of the ‘dual funding’ model where both streams of research 
funding contribute. The practices of HRC’s sister research councils overseas are 
summarised in Appendix 2. While there are moves in traditionally ‘marginal funding’ 
agencies such as the UK MRC and Australia’s ARC and NHMRC to fund a proportion of 
full costs, the level of overhead costs being mooted is around the 40-45 per cent level, not 
the 100 per cent plus in place in New Zealand. We also observe that agencies that fund 
overheads (not necessarily the research council itself) usually require that application of 
the funds be assessed through a range of performance indicators, which the universities 
agree to report upon.  
 
Our recommendations for enhancing health research infrastructure at universities are as 
follows.  
 
• The government should accept the principle that the HRC should receive full 
budget supplementation for any increase in costs arising from the ‘full cost 
funding’ policy. We understand that the Ministry is aware of the position that 
HRC is facing in respect of full cost funding and is considering the issue 
favourably.  
 
• The HRC should maintain discussions with the universities to ensure that full 
grant costs are effectively applied to the infrastructure and facilities required 
by health researchers. The universities should be obliged to report on their use 
of these funds, against agreed performance indicators.*  
 
* Further to our proposals for coordinating research evaluation through an 
interdepartmental health research coordinating committee we suggest that an overview of 
university infrastructure funding be available to this group. 
 
We were advised that the full cost funding policy allows for arrangements of fully costed 
projects to be co-funded by the HRC and the host institution (or other partner). This should 
be encouraged where appropriate.  
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Performance-based research funding 
 
The government’s 2002 Budget announced an Integrated Funding Framework for higher 
education, an integral component of which is a Performance-based Research Fund (PBRF) 
to be introduced progressively from 2004. This arrangement allows the newly established 
Tertiary Education Commission (set up in 2002) to separate research funding from the 
student-centred funding of the universities and to reward the better performing institutions. 
The fund is aimed at:  
 
rewarding researcher excellence and excellent research, defined in terms of: producing 
and creating leading-edge knowledge; applying that knowledge; disseminating that 
knowledge to students and the wider community; and supporting current and potential 
colleagues to create, apply and disseminate knowledge. (Ministry of Education 2002)  
 
Education Ministry funds for research and research training will be transferred to the 
PBRF by 2007. The PBRF pool is made up from a ‘clawback’ from enrolment-based 
funding of around $114 million with about $20 million of new money (Ministry of 
Education 2002: 3).  The fund is expected to have a strong effect on the research income of 
the universities and according to the Ministry of Education ‘should provide significantly 
more funding to academics assessed as being at the highest levels of excellence’ (Ministry 
of Education 2002:1). A funding model with three elements is being used: quality of 
academic researchers, (60 per cent of the total PBRF); research degree completions (25 per 
cent); and external research income (15 per cent). 
 
Given the high level of excellence shown by health researchers, the PBRF may have a 
positive effect on funding for health research in New Zealand’s universities. However, 
while the funds may serve to enhance the strategic research capacity of universities 
generally, they will not automatically translate to benefits in health research. There are 
several possible reasons for this. First, health faculties have contributed proportionally less 
than other disciplines to the ‘top up’ fund; and second, it is quite likely that universities 
will chose to invest the PBRF funding to develop research capabilities rather than to 
support strong researchers with the ability to win external grant funds. We therefore 




The PBRF is similar to arrangements for general university research funding in several 
countries and the design drew upon analysis of policies in the United Kingdom, Hong 
Kong and Sweden (Boston 2002). The assessment model appears based on the United 
Kingdom’s periodic research Assessment Exercise (RAE), while the funding model is 
similar to that adopted by the federal Department of Education, Science and Training in 
Australia. The Australian model uses only publication counts as a measure of excellence. 
These arrangements have promoted concentration of research strengths within the 
university system and the performance indicators used have almost certainly influenced the 
research and publication behaviours of academics.  
 
It is desirable that the reporting system and performance measures required of university 
grantees through PBRF should as far as appropriate, be consonant with those applying to 
those in receipt of HRC funds.  
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• We recommend that HRC should be provided with information to enable the 
Council to monitor the effect of the PBRF on health research funding and 
research groups.  
 
 
Appropriate performance indicators 
 
This section considers the further development of performance indicators for the New 
Zealand health research system. It discusses the international experience with the use of 
health research indicators, briefly reviews current activities being undertaken by the HRC 
and presents proposals for further development.  
 
The international experience 
 
While the terminology of research performance measurement is by no means standardised, 
most authors agree that there is a spectrum of indicators and qualitative measures that can 
be used to assess the level of research resources (inputs), and quantity and effectiveness of 
research ‘results’ (outputs, outcomes and impacts). These may be defined as follows 
(Garrett-Jones 2000):  
 
• Inputs are the resources made available to the research community and the costs 
associated with providing those resources. 
• Outputs are the routine products of research activity, (e.g. publications, conference 
papers, data sets, training courses and research degrees etc.). 
• Outcomes are the achievements of the research activity, whether conceptual (a new 
theory), practical (a new analytical technique) or physical (a new device or product 
– although some authors regard this as an output). Research outcomes are 
potentially available for use. 
• Impact is a measure of the influence or benefit (economic, social or environmental 
benefit, and either realised or expected) of the research outcomes, either within the 
research community itself, or in the wider society. Impact measures the scale, 
effects or implications of use. 
 
As one moves from outputs to impacts, the results of research activity are generally 
broader in their effect, take longer to manifest themselves, are harder to quantify and are 
less readily traceable to particular research projects, funding programs or agencies. This is 
the so-called ‘attribution factor’: while desired impacts may be seen, they clearly have a 
plurality of causes, the individual contribution of which is not readily measurable. For 
example, while it may be possible to demonstrate statistically a decline in mortality or 
morbidity from a particular disease, it is in most circumstances impossible to attribute this 
with any confidence to a single cause, such as a major research council research program 
on the topic.  
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Input, output and outcome indicators are all vital for signalling to policy makers and 
managers the health of particular systems – revealing whether they are improving or 
providing early warning signs that they are in trouble. As Godin (2001:6) points out 
science and technology indicators can generally demonstrate a system’s ‘strengths and 
weaknesses and follows its changing character notably with the aim of providing early 
warning of events and trends which might impair its capability to meet the country’s 
needs’. 
 
To perform this function indicator must meet a number of criteria to be useful, Godin 
(2001:5) nominates the following: 
• Indicators measure dimensions of a phenomenon in order to warn about changes; 
• Statistics that must be recurrent – to measure change rather than to present a 
‘snapshot’; and 
• Indicators usually appear as a collection of statistics: a lone statistic can rarely be a 
reliable indicator – usually the analyst is seeking ‘converging indicators’. 
 
While the performance of many science and engineering disciplines resourced both by 
government and business has been scrutinised closely over the last twenty years, relatively 
few national health research organisations have established comprehensive public 
reporting of measures of the performance of health research.  
 
This bias against reporting health research indicators is obvious by their lack of 
development in international data. Each two years the OECD publishes its science and 
technology scoreboard publication (OECD 2003) that has a heavy emphasis on 
comparisons across countries of expenditure with relevance to industrial technologies - 
business R&D, patenting and high technology trade. Only government budget expenditure 
towards health research is reported, whilst another OECD report (OECD 2001b) reveals 
that there are systematic difficulties in even reporting simply the total health research 
expenditures across the OECD.  
 
Turpin et al (2003) surveyed the performance reports of health research councils in several 
countries to assess the range of indicators used. Most councils used data on publications  
(or were planning to), several reported on local patent activity, whilst a few were reporting 
international patenting comparisons. At the time of the review one county reported on 
commercialisation income, while several councils agencies reported on the number of 
licenses and assignments. Surprisingly few councils reported their funding against 
international disease classifications.  
 
However, the range of health research performance indicators available internationally is 
expanding. Australia recently released a Performance Measurement Report covering a 
range of topics (National Health and Medical Research Council 2003b) as well as a 
bibliometric study of NHMRC supported research (Butler 2003). In Canada the CIHR’s 
predecessor research council had developed an indicators system and the CIHR is currently 
going through the process of establishing organisational wide indicators. Importantly, the 
trend towards more detailed reporting of indicators is likely to gather strength. The prime 
reason for this is that many health research agencies in OECD countries have received 
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substantial increases in funding over the last half-decade or so, partly on the expectation of 
economic returns. Governments are demanding increased accountability for those funds. 
The decision by the WHO to focus its 2004 World Health Report on research, and its work 
on the Health Research System Analysis Initiative, are significant moves. 
 
The HRC’s current performance indicator reporting and activities  
 
In New Zealand, the HRC has already taken significant steps towards improved indicator 
reporting and collaboration with other purchase agents on data availability. Some of these 
achievements are: 
 
• The health research outputs reporting database HEARD has been implemented, and 
will be developed further into a national health research database; 
• Plans to present HRC relevant bibliometrics in future (similar to Butler’s work for 
the NHMRC). The evaluation team did not see a copy of the draft national 
bibliometrics study; 
• ‘Vision 2008’ nominates a range of performance indicators against its goals and 
strategies (see Appendix 3);  
• The recent national consortium that fund a national bibliometrics analysis; and  
• A workshop to discuss evaluation being undertaken by purchase agencies and 
MoRST, and the potential for coordination of researcher surveys being conducted 
by the purchase agents (HRC 2003d:94). 
 
The evaluation team also acknowledges HRC’s efforts to monitor the balance of its 
research funding across the spectrum of portfolios, level of science (basic to applied) and 
on a time basis to ensure it maximises its expenditure.77 We commend these developments 
and encourage future activity in these areas in line with international practice and 
developments. HRC’s performance assessment work is of high quality and deserves a 
wider audience.  
 
Comments on specific indicators currently used, and suggestions for their improvement, 
may be found in Appendix 3.  
 
 
Future development of health research performance indicators 
 
This report recommends substantially increased investment in health research in New 
Zealand. It also recommends that HRC take on a greater role in facilitating the 
coordination of strategy development for New Zealand’s health research system. A 
consequence of both recommendations is the need for best practice reporting upon the 
performance and achievements of the health research system. We would emphasise here 
                                                 
77‘The HRC’s Research Policy Framework’ – presentation to the evaluation team by Dr Patricia Anderson. 
 
Science for Life 112
  
that it is those on the inside of the research system who are is best place to design specific 
indicators, as is apparent from ongoing discussions within CIHR.78
 
In this section we propose the third ‘leg’ of such a system enhancement. We propose that 
HRC in collaboration with other agencies be mandated to produce a ‘scorecard report’ 
for the New Zealand health research system every three years. The first edition of the 
report could be produced in time for the next review of the Health Research Output Class. 
The current performance reporting activities of the HRC will of course contribute strongly 
to the proposed report, but the scorecard would include material from the three main 
purchase agents as it relates to health and perhaps contextual material on the health status 
of New Zealanders. In turn, the scorecard  would form a resource  for the New Zealand 
Health Strategy , the proposed a New Zealand health research strategy and other priority 
setting exercises. 
We offer Table 7.2 as a starting point for discussions about the scope of the scorecard 
report. The proposed scorecard is only partially an evaluation tool for monitoring the 
HROC. It should be wider in scope to allow the government to monitor the health of the 
health research system in toto, and to inform the New Zealand community.  
 
Table 7.2  Possible scope of performance indicators in the proposed New Zealand Health 
Research Scorecard 
 
Theme Area Concept and rationale Indicator and comparison 
Inputs    
 Funding the 
system 
Health research funding 
over time – various 
measures to report on 
international comparisons 
and local trends. 
• OECD GBAORD Stats 
(hopefully including updated for 
NZ) 
• HRC funds as a percentage of NZ 
GDP. (time series) compared 
against OECD GBAORD 
estimates [the latter will probably 
be published every 2 yrs in the 
OECD STI scorecard] 
• HRC share of MoRST funds to 
purchase agents – which are 
available as competitive research 
grants. 
• All medical & health (HRC, 
FRST and Marsden as % GDP). 
• Stats NZ reporting of total health 




 • Percentage of HRC funds devoted 
to administration compared to 
                                                 
78 http://www.cihr-irsc.gc.ca/e/publications/20394.shtml
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Theme Area Concept and rationale Indicator and comparison 
other organisations overseas. 
 Active research 
workforce 
Active researchers by field 
of research • Australia uses a measure of active research as 
 A certain number of 
publications 
 Some external income 




The ability of projects to get 
outside money (public or 
private is an indicator of the 
external environment’s 
assessment of the value of 
the research. 
• Leveraged funds as percentage of 




Business activity is an 
importance indicator of the 
health of the local 
environment for the 
commercialisation of health 
research. It is not a measure 
of the HRC but a measure of 
the health research system. 
• Business expenditure on R&D in 
NZ on pharmaceuticals and 
clinical trials. 
Outputs    
 Post graduate 
& fellowship 
completions 
HRC categories according 
to its funding and strategies. • Suggested design of the indicators would be along the 
lines of: 
 category completions as 
percentage of postgraduate 
fellowships.  
 category completions as share 
of the workforce in various 
research portfolios. 
 Bibliometrics   
  We support the planned 
developments. • Publications by field 
• Citation rate  




  Patents • Trend in NZ patenting in NZ 
• Data on international patenting 
(NSF data, USPTO etc)  
  FRST grants to health 
researchers. As FRST has a 
primary responsibility for 
funding commercialisation 
• Health researchers as percentage 
of all university academics 
applying for FRST funds in 
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Theme Area Concept and rationale Indicator and comparison 
activities in New Zealand 
then FRST should be 
included in the scorecard. 
HRC should see itself as 
successful if a health 
researcher gets a FRST 
grant. Such a perspective 
might help develop the 
greater collaboration 
between HRC and FRST.  
commercialisation categories. 
• $ value of FRST grants to health 
researchers as percentage of 
FRST grants. 
 Other outputs   
   • Electronic products – software & 
multimedia. 
• Training courses 




  Business start-ups • Mapping new business activity 
from Marsden, FRST and HRC 
support – in the health research 
field. 
Impact    
  We acknowledge that 
researchers have been 
surveyed on whether they 
think they have made an 
impact. 
• We support this move but also 
suggest that HRC look for 
additional measures for more 
objective changes through actual 
policy changes, new government 
programmes or health outcomes 
surveys. 
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8. Conclusions and summary of recommendations  
 
This report provides an evaluation of the New Zealand Health Research Output Class and 
the health research investment framework in the context of international experiences across 
a range of other OECD countries. It was observed through earlier chapters that in terms of 
strategy and delivery of programs the New Zealand health research system stands up well 
against international experiences.  
 
However, the evaluation identified growing tensions within the system. At one level these 
tensions were associated with a contradiction between the ability to develop, assess and 
carry out high quality health research and the ability to deliver adequate funding to support 
such research. These tensions appear to be exacerbated by some structural features 
associated with organisational arrangements, coordination and shared responsibilities for 
some elements of the health research system. New Zealand’s health research investment 
system seems more strongly compartmental than in the benchmark countries, to the point 
where it risks failing to act as a cohesive system, as it lacks the structural linkages 
between purchase agents that are evident in countries like Australia and Canada. 
 
We recognise the finite nature of funding resources. But New Zealand appears to be 
marking time in terms of health research funding while other countries are developing 
quite bold plans for expanding investments. We also recognise that New Zealand has taken 
some bold steps in terms of redesigning the funding framework. This includes 
implementing a clear and transparent mechanism for assessing the full cost of health 
research, shifting from a disciplinary based funding system to a program and strategic 
objective system, and identifying and sustaining long term strategies for building Māori 
research capacity. 
 
In order to consolidate and reap advantage from this development we believe it is 
important to take some immediate steps to introduce some additional funding to sustain the 
top band of high quality health research capability in the country and to provide more 
coherent support for collaborative health research. 
 
However, at the same time we believe making some readjustments to organisational 
arrangements can enhance the outcomes and impact of health research investments. We 
believe that New Zealand is at the stage where an increased funding commitment, together 
with increased capacity for coordination, monitoring and evaluation will enhance return on 
investment. The options and recommendations for achieving this have been discussed in 
the preceding chapters. They are summarised below under three general headings that 
reflect the main terms of reference for the study: 
 
1. An appropriate policy and investment framework 
2. The future vision for health research (including appropriate performance 
indicators); and 
3. The level of investment required.  
 
The final section considers the costs and appropriate timeframe for implementation the 
recommendations of the report.  
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An appropriate policy and investment framework 
 
Structural arrangement of purchase agents 
 
The health research system in New Zealand, as in other OECD countries, needs to be 
understood not as a single system but as the product of the intersection of various systems. 
The multi agency approach to the health research investment in New Zealand is similar to 
other comparable countries. New Zealand, however, is a small country and this, as 
elsewhere, presents a challenge for determining appropriate concentration of investment in 
the various agencies and how the boundaries between agencies and programs should best 
be managed. We do not consider that a substantially increased concentration of research 
funding through HRC would automatically produce benefits in terms of the coherence and 
coordination of health research. Rather the challenge is to make the various funding 
agencies work more effectively together within a plural system, as is the case in many of 
the benchmark countries. 
 
1. We consider that the establishment of a single research agency, responsible for 
funding all health research, broadly defined, would not be in the best interests of 
the New Zealand research system overall. We recommend the maintenance of 
diversity in the funding base provided through different agencies. However, we 
also propose an enhanced role for HRC in steering research policy, coordination, 
and evaluation toward strategic national goals. 
 
Coordination (between purchase agents and output classes) 
 
The evaluation draws attention to the need to enhance coordination between purchase 
agents, both in terms of developing health research strategy and in implementation. The 
HRC is in a good position to contribute to the overall strategic planning, coordination and 
evaluation of New Zealand health research in line with its statutory responsibilities. This 
role should be strengthened where possible. 
 
Coordination could be strengthened between purchase agencies and at strategic program 
levels by supporting HRC as the lead agency for developing and coordinating a high 
profile national health research strategy (see Recommendation 11). This would require 
deepening the structural relationship between HRC, MoRST and MoH.  
 
2. We recommend that MoRST establish an interdepartmental health research 
coordinating committee including the Ministries of Health and Education. The 
HRC should have a lead role in the committee. 
 
 
The future vision for health research  
 
Building partnerships for collaborative research  
 
HRC’s Partnerships and Joint Ventures have been very effective in marshalling both funds 
and research expertise around defined research priorities. This innovative arrangement 
works extremely well where the HRC has an unchallenged mandate to pursue these 
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priority areas, for example where they reflect key national priorities for health. As the 
partnership program develops we note a need for on-going planning and targeting of the 
programme. A ‘priority setting exercise’ would help ensure the most effective alignment 
between national research capabilities, funding support and the application of research 
outcomes. 
 
3. We recommend that HRC should instigate a consultative priority setting exercise 
for future Partnership/Joint Venture investments that involves a wide range of 
stakeholders including researchers, policy agencies, other potential funders and the 
health industry. The exercise should consider both the feasibility of research and 
the potential outputs and outcomes of the investment in the research.  
 
Overseas experience suggests that cooperative research has a successful outcome when 
both the researcher and the user of the research are involved in defining the problem and 
the solution. We consider that MoRST should explore with HRC, FRST, the Ministry of 
Education and RSNZ the potential benefit of establishing a new cross-cutting arrangement 
to support long term university-industry/user cooperation in health research. This may 
require a new National Collaborative Research Centres Output Class under Vote RS&T. 
HRC would be the primary purchase agency for health related centres and purchase 
agencies would jointly fund Centres where the Centres met the objective of several 
purchase agencies. Some co-funding would be required from Centre partners.  
 
4. We recommend that HRC should develop proposals for a National Health 
Research Centre grant scheme, complementary to those funded by CoRE and 
FRST, for consideration by MoRST. The adoption of this recommendation should 
be on the basis of HRC receiving additional funding and should not draw on 
existing funds. 
 
Without prescribing the form of such a scheme, it would be ‘bottom up’, ‘proposal driven’ 
collaborative research support scheme where researchers and potential users develop 
proposals for assessment and support by HRC.  
 
Health Research infrastructure in the university system 
 
Almost all health researchers are in the university system. As a consequence university 
research policy has an implication for health research activities. Government policy 
requires the purchase agencies to move towards full funding of the research they support 
by providing for investigators’ salaries, salary on-costs, project direct costs and an 
appropriate level of institutional central overhead costs. But HRC’s budget growth has not 
increased at a rate sufficient to cover these costs.  
 
5. We recommend that the government should accept the principle that the HRC 
should receive full budget supplementation for any increase in costs arising from 
the ‘full cost funding’ policy.  
 
HRC is ultimately responsible for the effective application of funds from HROC provided 
to the universities, and is required to report on outputs gained from these funds. In order to 
enable the HRC to fulfil this obligation there will need to be supporting obligations placed 
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on the universities. To ensure these changes adequately support the infrastructure 
underpinning health research in universities it will be necessary for the internal allocation 
of research funds and facilities within universities to be closely monitored.  
 
6. We recommend that the HRC should maintain discussions with the universities to 
ensure that full grant costs are effectively applied to the infrastructure and facilities 
required by health researchers. The universities should be obliged to report on their 
use of these funds, against agreed performance indicators.  
 
Further to our proposals for coordinating research evaluation through an interdepartmental 
health research coordinating committee (Recommendation 2) we suggest that an overview 
of university infrastructure funding be available to this group. 
 
The full cost funding policy allows for arrangements of fully costed projects to be co-
funded by the HRC and the host institution (or other partner). This should be encouraged 
where appropriate.  
 
Given the high level of excellence shown by health researchers, the Performance-based 
Research Fund (PBRF) to be introduced progressively from 2004, may have a positive 
effect on funding for health research in New Zealand’s universities. However, while the 
funds may serve to enhance the strategic research capacity of universities generally, they 
will not automatically translate to benefits in health research. It is desirable that the 
reporting system and performance measures required of university grantees through PBRF 
should as far as appropriate, be consonant with those applying to those in receipt of HRC 
funds.  
 
7. We recommend that HRC should be provided with information to enable the 
Council to monitor the effect of the PBRF on health research funding and research 
groups.  
 
Consolidating and sustaining the Māori health research strategy 
 
As noted in previous chapters the overall level of funding for health research in New 
Zealand has not grown in real terms. Already a considerable proportion of fundable 
projects assessed by the HRC remain unfunded. Unless there is growth in the system 
overall, the capacity to consolidate the gains already made in Māori health research can 
only be achieved at the expense of other areas.  
 
We note that in comparison with other national experiences, the development and 
implementation of the Māori health research strategy has met with considerable success. 
However, urgent funding increases for the system overall are now required to consolidate 
the gains already made and reduce unproductive tension within the system (see 
Recommendations 5 and 17). The HRC has already nominated a priority setting process 
within its plan for Māori health research. We endorse the approach marked out for these 
next steps, however, we consider that it will be difficult to establish achievable goals for 
this unless there is growth in the overall system. 
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At present HRC is devoting considerable effort in developing a research capability for 
Māori and Pacific populations. However, HRC nominates a number of population groups, 
some of which (such as the disability) sub-group do not appear to have such well-
developed strategic frameworks. While these population groups remain a defined target 
for HRC’s funding framework similar development strategies should be set in place with 
similar emphasis on building research capacity and evaluation measures. We suggest that 
the HRC consider developing a process that identifies the strategic research that needs to 
be conducted in New Zealand for all priority populations.  
 
8. We recommend that the HRC, in consultation with the proposed health research 
coordinating committee, establish a set of performance indicators for priority 
population groups that, as far as possible, allow for international comparison.  
 
Supporting the HRC research investment strategy 
 
The HRC’s comprehensive peer review system for assessing the scientific excellence of 
research proposals is central to maintaining the quality of research funded and is of a clear 
and continuing national benefit and receives strong endorsement from the research 
community. The operation of best practice assessment and evaluation processes within 
HRC is also vital in leveraging funding from other sources, such as international partners.  
 
9. There is clear benefit to New Zealand in the high standard of assessment and 
evaluation for health research set by HRC and we recommend that these processes 
should be maintained. 
 
HRC’s move towards investment portfolios focused on health outcomes is in line with 
trends in the benchmark countries and should receive continued support. 
 
The view was put to us by researchers was that HRC’s support for biomedical research is 
‘teetering on the sub-critical’ and cannot provide the prospect of a reasonable chance of 
continuing funding for the best researchers. The most compelling argument therefore is 
that such increase is required to retain existing research capability in the country and to 
build up the research teams and facilities that would attract expatriate and overseas 
researchers. The HRC in its Strategic Plan argues for an increase of the order of $10.5 mill. 
in 2004-05 to achieve sustainable outcomes. The HRC has the assessment processes in 
place to handle some increase in grant applications that might flow from such an increase. 
 
We consider that an increase in resources for HRC’s current research project grant, 
research programme grant, and scholarship and fellowships schemes is necessary to ensure 
the sustainability of New Zealand’s capability in world class health research. HRC requires 
additional funding to invigorate its fellowship and scholarship programmes. Overall, the 
target for the proportion of HRC expenditure on ‘people’ needs to be set at 20-30 per cent 
of budget if it is to reach norms common in some of the overseas research councils studied. 
 
HRC’s research programme funding provides longer stability of funding for research 
groups, and provides opportunities for synergy between interrelated, often 
multidisciplinary projects. They also provide greater opportunity for research training 
activities.  However, we believe there would be a stronger case for increased programme 
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funding if the research programmes had a character that was clearly differentiated from 
project grants. We suggest a review of the scope and objectives of the various schemes. 
 
10. We recommend that HRC should give further consideration to the relationship 
between its project and programme funding, and between programme grants and 
the proposed National Health Research Centres scheme.  
 
The HRC has the statutory responsibility to advise the Minister of Health on national 
health research policy. Section 34a of the Health Research Council Act 1990 further 
requires that ‘the Council shall set up formal mechanisms of liaison to develop a national 
health research strategy for New Zealand’. We consider that there should there be more 
explicit articulation between the New Zealand Health Strategy (NZHS) and health research 
priorities. We also consider that, towards this end, there is a strong case for a published 
national health research strategy (or strategies) to complement and extend HRC’s 
existing Strategy documents, which refer to the Council’s own activities. 
 
11. ·We recommend that HRC should coordinate the publication of a National Health 
Research Strategy (or Strategies) to complement the New Zealand Health Strategy 
and that the Council be adequately resourced for this task. 
 
The benefits deriving from a competitive advantage in health research supported by HRC 
may be or scientific reputation, social application, or commercial exploitation. We note 
that HRC has a crucial role in supporting research with commercial potential and 
supervising clinical trials. These activities require close cooperation with other purchase 
agents, notably FRST.   
 
12. We recommend that HRC should collaborate with FRST to provide advance 
warning of those health researchers working on technologies or research outcomes 
with potential for commercial exploitation.  
 
New Zealand’s small size and geographic location mean that international collaboration is 
especially important 
 
13. We recommend that HRC should instigate an international collaboration grant 
scheme for individual health researchers and teams to complement the support and 
grants offered by MoRST and the FRST. These could be targeted for HRC project 
and program grant holders or more widely. Funds from the new ‘Developing 
International Linkages’ output class should be made available for this purpose. 
 
Indicators for monitoring research investments and outcomes 
 
Noting the lack of currency of the New Zealand health research data published by the 
OECD and the implication of full cost funding on international comparability; 
 
14. We recommend that MoRST review the procedures for reporting current health 
research expenditure data to the OECD and for ensuring that these data are 
presented in a manner that provides for international comparison of research effort. 
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Performance indicators of various types are already widely used in the evaluation of 
purchase agents within the New Zealand system. The HRC has made excellent advances in 
establishing appropriate qualitative and statistical measures of health research performance 
and outputs. International practice in health research performance assessment is developing 
rapidly and should be monitored closely by New Zealand. 
 
15. We recommend that the coordinating committee proposed in Recommendation 2 
should have a specific mandate to coordinate and develop a national health research 
reporting strategy and develop performance indicators for monitoring system wide 
outcomes and impact against national strategic objectives. The HRC should provide 
the lead in this activity. 
 
The indicators being developed alongside Vision 2008 are moving in the appropriate 
direction as accountability indicators. Such indicators will be useful for measuring HRC’s 
performance for the annual agreements between it and MoRST and with the Ministry of 
Health. However, they could be extended in terms of monitoring the overall status of the 
health research system. 
 
16. We recommend that HRC be mandated to produce a New Zealand health research 
system scorecard report every three years. 
 
This reporting framework for the scorecard would differ from that already being 
developed for the strategic plan. The scorecard, unlike the micro indicators proposed 
against the Strategy’s goals would have three dimensions: inputs, outputs, and outcomes. 
 
 
The level of investment required 
 
Three main observations can be made on level of health research funding in New Zealand 
by comparison with the benchmark countries.  
 
• Taking all the results into account. New Zealand’s current level of public 
investment in health research is substantially lower than almost all the benchmark 
countries. Of these countries, only Ireland spends less, proportionally, on health 
research and development. 
 
• Most of the benchmark countries are increasing their investment in health 
research – some by as much as 20 per cent per annum. By contrast, there is no 
evidence of sustained increase in health research investment in real terms in New 
Zealand in recent years. Indeed, national data provide clear evidence of a decline in 
New Zealand’s expenditure on health research, as a proportion of GDP. 
 
• The cost structures of many of the comparator health research funding agencies 
are lower than those of the HRC. Given that the overall envelope of health research 
funding available to the HRC in New Zealand is already comparatively smaller 
than in most of these countries, the cost structure in New Zealand means that the 
HRC’s capacity to purchase high quality health research is all the more limited. 
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We note that the HRC will need funding increases for the next three year to implement full 
cost funding. By the end of the period HRC will require about $16.5m more than the 
current budget for this policy. Such funding budget increases will only maintain the 
system at its current level. 
 
We consider that on the basis of international comparisons and the recent history of static 
to declining funding in real terms in New Zealand that the system requires a substantial 
increase in expenditure above full cost supplementation.  
 
17. We recommend that MoRST adopt a target budget for the HRC’s Output Classes 
(the HROC + Māori OC [health] + SPI OC [health]) of a real increase of 0.01% of 
GDP over the next four years. 
 
Over the next four years (i.e. by 2007-08) this would require a real increase in HRC’s 
annual budget of at least $17.8 million over the current year (2003-04). This costing is 
based on New Zealand’s GDP of $127 billion in 2003 and includes an adjustment of 40 per 
cent to take into account the higher research cost structures faced by HRC. This 
recommendation is for dollars in addition to any supplementation of the HRC’s budget to 
cover the full cost funding of grants (Recommendation 5). 
 
 
Financial implications and priority timeframe 
 
A timeline and cost estimate for implementing the report’s recommendations are shown in 
Tables 8.1 and 8.2. The cost estimates provided are a first approximation, offered as the 
basis for further discussion.  
 
Table 8.1: Estimated costs of recommendations and timing of implementation 
 




1. Maintain diversity in the 
funding base 
nil Existing OCs continuing 
2. Establish interagency 
coordinating committee on 
health research 
$100k Vote RS&T 2004-05 
3. Priority setting exercise 
for future Partnerships 
$25k HRC 2004-06 
4. Develop National 
Health Centre Research 
Grant Scheme 
$200k (proposal)  
$2-3 mill. annually 
(Centres) 
HROC (new 




5. Budget supplementation 
for full cost funding 
$5-6 mill. annual 
increase. Note that these 
costs are included in the 
estimates at 
Recommendation 17) 
Vote RS&T From 2004-05 
6. Liaison with universities 
on full costs 
minimal HROC 2004-05 
7. Information sharing on minimal MoRST/Ministry 2004-05 
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PBRF of Education 
8. Performance indicators 
for target populations 
$120k HROC; HRC 
Partnerships 
2004-05 – 2006-07 
9. HRC research 
assessment and evaluation 
existing funds HROC continuing 
10. Programme, project, 
centres scoping 
$100k HROC Prior to any proposal 
under Rec. 4 
11.National Health 
Research Strategy 
$450k HRC Partnership For discussion 








13. HRC international 
grant scheme 
$0.5-0.75 mill. DIL OC 2004-05 











HROC, MoRST 2004-05 
16. NZ Health Research 
Scorecard report 
$250k HROC, HRC 
Partnership 
First report by 2006-
07 
17. Growth in health 
research system capacity – 
budget increases for HRC 
project grants, programme 
grants, scholarships and 
fellowships 
Funding target: achieve 
0.01% GDP real 
increase above full cost 
supplementation = $17-
20 mill. + $16.5mill. for 
FCF supplementation 
over 2003-04 by 2007-
06. 
Estimated annual cost: 
2005-06 = $20.1 mill. 
2006-07 = 26.3 mill. 
2007-08 = 34.4 mill. 
(see Table 8.2 for 
derivation) 
To HROC, Māori 
OC and SPI OC  
Phased in over 4 
years – (see 
indicative annual 
budget in Table 8.2) 
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Table 8.2 Indicative annual budget for HROC, based on implementation of the 
recommendations 
 
  Incr. over base year (2003-04)   
  (a) FCF 
supplement-
ation (Rec. 5) 
* 






















2003-04^           42.2
2004-05^ 5.5 5.5 47.7
2005-06 11.0 6.5 2.6 9.1 20.1 62.3
2006-07 16.5 7.0 2.8 9.8 26.3 68.5
2007-08 16.5 12.7 5.1 17.8 34.3 76.5
* FCF = Full cost funding. FCF figures from HRC for 2004-05 to 2006-07. Figure for 2007-08 is 
assumed similar to previous year, but will be subject to review. 
# Total as per table 8.1  
^ Indicative only – not part of our recommendations.  
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Table A1.1: Canadian research funding schemes providing research grant 
opportunities 
 
CFI Canadian Foundation for Innovation 
CIHR Canadian Institutes of Heath Research 
CSA Canadian Space Agency 
MRC Medical Research Council – renamed Canadian Institutes of Heath Research 
NRC National Research Council 
NSERC Natural Sciences and Engineering Research Council 
SSHRC Social Science and Humanities Research Council 
  
Source: Data from Statistics Canada 2003, choices of research grants by evaluation team. 
 
Other sources of funding, although, providing valuable sources of funds for some 
researchers has not been included. 
 
Table A1.2: Canada - R&D funding sources not included in the grants list 
 
EMR Energy, Mines and Resources (Ministry) renamed Natural Resources Canada) 
F&O Fisheries and Oceans (Ministry) 
IND3 Industry Canada (Ministry) 
NRCan Natural Resources Canada 
Original source data: Statistics Canada 2003 Federal government expenditures and personnel in 
the natural and social sciences, 1993-1994 to 2002-2003 Table 8 Cat. No. 88F0006XIE2003009 
Statistics Canada May 2003 www.statcan.ca  
 
The CIHR has a set of virtual institutes that capture its priority fields. 
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Table A1.3: Canada - Affiliation of Grants and Awards to Institutes (Year 2001–2002) 
 
INSTITUTE No. of Grants 
& Awards 
Total Funded 




Aboriginal Peoples’ Health 39 4,577 1.0 
Aging 82 7,730 1.7 
Cancer 461 33,558 7.5 
Circulatory & Respiratory Health 667 51,667 11.5 
Gender & Health 57 3,790 0.8 
Genetics 429 40,256 9.0 
Health Services & Policy Research 191 12,040 2.7 
Human Development, Child & Youth 
Health 
282 23,412 5.2 
Infection & Immunity 538 42,662 9.5 
Musculoskeletal Health & Arthritis 248 16,605 3.7 
Neurosciences, Mental Health & Addiction 909 66,121 14.7 
Nutrition, Metabolism & Diabetes 404 31,265 7.0 
Population & Public Health 206 14,481 3.2 
Unable to allocate 166 8,015 1.8 
Unallocated 2,015 92,352 20.6 
 6,694 448,531 100.0 
Note: These figures exclude the Networks of Centres of Excellence Program and the Canada 
Research Chairs Program. 




The Irish Council for Science, Technology and Innovation (2003) notes: 
The implementation of the science for health elements of the Strategy for Health 
Research would require annual revenue expenditure of €33 million in 2001 prices by 
2006, compared with just under €15m in 2003. The establishment of an R&D function 
in the health services would mean an increase in annual revenue expenditure from €3 
million in 2003 to €44 million by 2006. 
 
Estimated expenditure on health research in Ireland in 1998 was equivalent to 0.3% of 





There are two broad ways of calculating this Government expenditure on science and 
innovation. The first relies upon the identification of stand alone government programs to 
fund any of; research, science, development, technology and innovation. This seems to 
most closely align to the Vote RST expenditure. The second way is to survey government 
to collect data on all science and innovation related funding and expenses. MoRST (2003: 
13) estimates this total NZ government science and innovation envelope to be $767.4m. 
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The international comparisons presented in this report are typically reflective of approach 
1. 
 
Table A1.4: New Zealand R&D grants 
 





RS&T Policy Advice  $7.28m
RS&T Contract Management $0.57m
Growth and Innovation Advisory Board $1.33m
4th APEC Science Ministers’ Meeting $1.68m
Research Contract Management $17.38m
Venture Investment Fund - Governance and Operation $1.22m
Marsden Fund  $32.79m
Non-Specific Output Funding $28.53m
Supporting Promising Individuals $14.55m
Promoting an Innovation Culture $2.72m
New Economy Research Fund $63.88m
Maori Knowledge and Development Research $5.48m
Developing International Linkages $3.00m
Research for Industry $185.04m
Technology New Zealand $44.03m
Pre-Seed Accelerator Fund $4.80m





Sources for data presented are:  
 
• Science and innovation budget data from Office of Science and Technology. 
• http://www.ost.gov.uk/setstats/index.htm  
• GDP data: National accounts: GDP: expenditure at current market prices 1946 – 
2003 from http://www.statistics.gov.uk/STATBASE/tsdataset.asp?vlnk=208  
 


































































































































A1.1: Real $ expenditure on health research - National agencies and NIH institutes 
 
 
NIH Research Studies 
 
Sample Programs – Research. The research programs listed below are a representative 
example of the variety of ongoing and new research studies that NIH supports as part of its 
strategic plan for understanding and reducing health disparities among ethnic and racial 
minorities and other populations (NIH 2002). 
 
Selected Examples of Measuring Program Performance 
 
• Track the number of articles published in scientific journals  
• Percentage increase mechanisms for healthcare providers to better diagnose, 
prevent, and treat minority health and health disparities  
• Percent of studies which are “targeted studies”  
• Percent of studies that are “Inclusion studies”  
• Percent of total research budget spent on addressing minority health and health 
disparities  
• Percentage research that influence policy  
• Track rates of health disparity indicators and project a percent reduction of the 
those rates over a set period of time 
 
Sample Programs – Infrastructure. Ongoing research infrastructure programs provide 
selected examples of the variety of ongoing and new research infrastructure activities that 
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the NIH will support as part of its strategic plan for understanding and reducing health 
disparities among ethnic and racial minorities. 
 
Selected Examples of Measuring Program Performance 
• Monitor number and progress of minorities entering training programs (% increase 
in minorities entering training programs over previous years and number 
completing training programs)  
• Increase and track the number of minority scientists engaged in research (establish 
targets)  
• Increase and track minority subjects enrolled in research and clinical trails  
• Percentage increase in partnerships with minority institutions  
• Increase number of research projects addressing minority health and health 
disparities  
• Track the number of articles published in scientific journals by minority 
investigators  
• Number of minority faculty, post doctoral fellows, and graduate students trained 
while conducting research 
• Number of competitive grants issued to minority researchers 
 
Sample Programs – Outreach. NIH is continuing its efforts to translate highly technical 
research advances into clear, culturally relevant explanations of the steps individuals can 
take to improve their health. 
 
Selected Examples of Measuring Program Performance 
• The number of materials developed or adapted for minority and underserved 
populations  
• Linkages with minority organizations 
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Appendix 2: Survey of Cost Structures and Success Rates for 
Health Research Councils in Benchmark Countries 
 




Australia79  The overheads rate is pre-built into the application. The NHMRC 
specifies the total cost of researchers at different levels. Applicants must 
specify project requirements using the table provided by NHMRC. 
NHMRC payments are marginally costed. 
http://www.nhmrc.gov.au/research/project/budget4.htm 
Canada80 0% Universities do not "impose" any indirect or overhead costs. Last year, 
the government of Canada agreed to provide effectively a 20% overhead 
for indirect costs. 
Ireland81 10% Up to this year the HRB, similar to most other Irish funding agencies, did 
not pay any overheads. However in 2003 Forfás and the Higher 
Education Authority produced a report with recommendations for 
payment of overheads by Irish funding agencies. The HRB was involved 
in the steering group and have agreed to implement the recommendations 
in the report. The report recommends that overheads should be paid at 
30% on modified total direct costs (i.e. direct costs less equipment) for 
laboratory based research and at 25% for desk based research. The report 
also proposed an implementation timetable with introduction of the new 
system on a phased basis up to 2006. To that end the HRB has committed 
to paying 10% overheads on 2004 awards. 
Netherlands
82
0+% Generally, the money from the department of science doesn't include 
overhead of any kind (except for social insurances such as health 
insurances). The universities have to pay for all bench fees, usage of 
equipment and buildings. Which means that in those schemes the 
universities pay more or less half of the real costs. In most of the schemes 
paid by the ministry of health (mostly strictly subject-directed), 
applicants more or less can apply for all overhead costs they want, but 
next to quality, these applicants (which could even be commercial 
parties) are evaluated for 'value for money' which means that the best and 
best fitting in the chosen subject AND cheapest party will be awarded. 
The way to remain cheap is not to apply for too many overhead costs, 
something most commercial parties of course cannot do. 
New 
Zealand 
114%+ Full cost. (contract FTE) 
Sweden83 30% The University overhead cost is approximately 30%. 
United 
Kingdom 
46% As part of the UK dual support system all Research Councils pay all 
Universities a flat rate on the salary component of all grants. This rate is 
determined by the government .For some time there has been concern 
that this is insufficient to sustain investment by Universities in the 
research they undertake and a recognition that this would have to 
                                                 
79 Comments provided by Roland Wise. 
80 Correspondence with Dr Alan Bernstein, President of the CIHR. 
81 Comments provided by Dr Norma O'Donovan Evaluation Officer, Ireland’s HRB. 
82 Communications with Stefan Ellenbroek of ZonMw. 
83 Comments provided by Maria Starborg, Scientific secretary, Swedish Research Council. 
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increase. The Universities pressed for an increase to at least 100%.This 
was not adopted as it was considered that a % based on salaries provided 
an incentive to maximise staff on grant applications and universities took 
on research without knowledge of the full cost. It was therefore decided 
that all Universities be required to move to a system of full project 
costing known as TRAC and to submit grant applications based on full 
economic costs from Sept 2005.The Research Councils will then pay a 
percentage (yet to be determined but probably about 65%) which means 
that Universities must know that they can find the remainder from their 
own resources before applying for grants. As part of this process it has 
been agreed that the proportion of PI time on the grants can be included. 
MRC understands this is going to be based on some form of broad brush 
arrangement in Universities to avoid the need for timesheets in 
universities but this will need to be monitored and audited! 
USA84 30-100% Overhead costs (AKA indirect costs or F&A costs - Facilities and > 
Administration) vary from institution to institution, and are sometimes 
capped for certain grant mechanisms (e.g., 8% for training and career > 
development awards). The rates are negotiated periodically and can be as 
low as 30%, and sometimes be 100% or more. The average these days is 
> probably around 50%. 
   
Comments Av approx 
0-30%  
A number of countries do not have on-costs charged to the research 
council. Where the system is used they are usually 30% or below (with 
the exception of the USA). 
The lower overhead charge rates in the countries studied allows the 
medical research funding bodies to purchase significantly more research 
per $ spent. 
 
Table A2.2: Payments to Chief investigators 
Country Chief Investigator payments 
Australia There is provision within the Project Grants scheme for a Chief Investigator to seek 
to have his/her salary covered by the budget of a grant although justification for 
that request is required and approval is subject to the Grant Review Panel's 
consideration of that request.  Salary is paid as a package which covers all on-costs 
and is based on the relative experience of the Chief Investigator. 
Canada CIHR does not pay a protected time allowance. We do have a completely separate 
awards competition to fund partially the salary of some of Canada's top 
investigators85. 
http://www.cihr-irsc.gc.ca/e/services/3736.shtml# Principal Applicants may not 
receive a salary, stipend, or honorarium from any CIHR grant. They may hold a 
CIHR salary award (e.g., an investigator award) or an award from a CIHR program, 
that explicitly allows for salary support of investigators (e.g., within a New 
Emerging Team.) co-applicants may not receive a salary, stipend, or honorarium 
from CIHR grants on which they are co-applicant. 
Ireland We have a number of different grant schemes which can be divided into 3 
categories: research project grants, programme grants and fellowships. On research 
project grants and programme grants the chief investigators cannot apply for 
funding for their own salary. For the fellowship schemes the investigators full 
salary is paid.  
                                                 
84 Comments provided by Minerva Rojo Director, Division of International Relations (NIH). 
85 Correspondence with Dr Alan Bernstein, President of the CIHR. 
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Also it is hoped that a new clinician scientist scheme will be introduced which 
would cover part of the clinician's salary in order to free up some of their time for 
research. 
Netherlands The applicants themselves can apply for the support they need. As long as they 
remain between the boundaries of the granted funds, they themselves are free to 
request for the personnel they need86. 
New Zealand Provides payments to Chief Investigators for the time on projects. 
Sweden87 Research Council project grants do not cover payments for the principal 
investigator’s (applicants) salary. 
United Kingdom  
USA Yes, for the per cent effort expended.  The rate at which they are paid, however, 
cannot exceed the salary for employees in Executive Level I, 
Comments Canada, Ireland and Sweden do not provide payments to Chief Investigators on 
project grants. 
Australia, the Netherlands, New Zealand and the USA do provide payments to CIs 
on project grants. 
 
Table A2.3: Grant application successes 
Country History Current 
Australia88 Projects funded in 2000 = 30% 
Projects assessed as fundable but not 
funded 37% 
Projects funded in 2002 = 23% 
Projects assessed as fundable but not 
funded 34%.  
57 % of projects applications are 
rated as fundable. 
Australia is funding 40% of fundable 
research. 
Canada Results of the September 1995 Operating 
Grants Competition 04/19/96 
Council is pleased to announce that 203 of 
the 946 applications in the September 
1995 Operating Grants competition have 
been approved for funding (see full list 
below). Funding of this number was made 
possible by a decision of Council to cut 
budgets to 77%, on average, of the 
amounts recommended by peer review 
committees. Council deeply regrets that, 
due to budget limitations, it has not been 
possible to fund a considerable number of 




Currently89, CIHR's overall success 
rate for project applications is 29%. 
This number is largely based on the 
results of our open competition –
success rates for RFAs, Awards , 
equipment, etc will vary from this 
number. But the29% figure is a good 
measure of what the community looks 
at and certainly represents our largest 
investment. 
 
Ireland In 2000 Ireland was funding 25% of 
project grants. 
In 2003 Ireland HRB funded 13% of 
project grant applications. 
Netherlands  One of our biggest Schemes, our so 
                                                 
86 Communications with Stefan Ellenbroek of ZonMw. 
87 Comments provided by Maria Starborg, Scientific secretary, Swedish Research Council. 
88 Data from NHMRC 2003 Performance measurement Report p34. 
89 Correspondence with Dr Alan Bernstein, President of the CIHR. 
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called Open Competition (dep. of 
Science) has i.e. a score of ~15% in 
initial (short) applications; these 
applications are pre scanned, after 
which the most of the people who get 
the advise not to write a full 
application, don't write a full 
proposal. This means that ~40% of 
the full applications can be awarded. 
For other schemes, the success ratio 
differs greatly, but I think that the 
highest success ratio is somewhere 
between 50-60%, but this is in 
schemes in which only a selected 
number of institutes is requested to 
apply (mainly in dep. of health 
schemes). 
New Zealand90 A high rate of 40% in 1996-97. 
A low rate of 20% in 2000-01. 
The project application success rate 
currently stands at 23%91 2002-2003.  
 
61.7 % of projects applications are 
rated as fundable. 17% are getting 
funded. 28% of fundable research is 
getting funded92. 
Sweden   
United Kingdom  Overall total eg in 2002/3 strategic 
grants were 30% Cooperative 
components were 18% and the overall 
was 24%. 
USA  A ballpark average is about 30%. 
   
                                                 
90 HRC December 2003. 
91 Data from the HRC table HRC Investment in Project Contracts through the Annual Contestable Funding 
Round 1993/94 – 2002/03. 
92 Calculations based on data in the presentation to the Evaluation team by HRC staff “Annual Contestable 
Funding Round Overview: by Dr Andre George. 
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Appendix 3: The Health Research Council’s goals, strategies 
and performance measures  
(from ‘Vision 2008’, Oct 2003 draft, slightly abridged) 
 
IMPORTANT NOTE: The details of HRC’s Strategic Plan documents are 
CONFIDENTIAL to the Council until release of the final Plan 
 


























50% of total 
expenditure to 
enhance quality and 
quantity of research 
outcomes  
c) ensure all areas in 
which New Zealand 
has a competitive 
advantage are 
developed  
d) work with MoRST 
and other RS&T 
purchase agencies 
to ensure that 
investment in 








discipline and type 
of research 
 
• number of research 
Programmes and 
funding as % of 
total expenditure 
• number and 




• number of 
research groups 




• investment in 
health research 
through HRC as 









Goal to increase 








researchers, could be 
linked to the PBRF 
assessment process. 
 
Some measure of 
cooperation would be 
a more effective goal 
and indicator. 
 







e) re-establishment of 
training 
fellowships in 
clinical research  
 





























No. of PDFs and PhD 
scholarships in each 
area. 
 
Some measure of the 
retention rate in 
health research, career 
paths etc 
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Pacific peoples  
i) linkage of research 
funding for fellows 

















for scholars and 
fellows 
3. Bridging 








scientist(s) to New 
Zealand  






l) identification of 





build the needed 
capacity  















research teams to 
expand their 
workforce 




recruited to or 
repatriated to 
New Zealand 






• evidence for 
implementation of 






• number of 
partnerships with 
research 
providers to attract 
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o) investment in 
research to develop 
Matauranga Māori 
(Māori generated 




p) investment in 
health research 
which addresses the 
needs and diversity 
of Pacific peoples 
in New Zealand and 
in the region  
q) investment in 
health research 
which addresses the 




refugees) in New 
Zealand 93 
r) exploitation of 
expertise and 
knowledge held in 
New Zealand (e.g. 
sheep models for 
foetal development) 
s) taking full 
advantage of the 
significant 
international links 
which exist for 
New Zealand health 
research scientists 





for Māori  
 
 





















to New Zealand 


























































v) enhancement of 






• number of joint 
initiatives 
established by 










                                                 
93 HRC Priority population groups are: Maori; Pacific peoples; Children & youth; Older adults; People 
with disability 
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x) investment in 
research to 
enhance the 
delivery of key 
health sector 
strategies  





solutions for key 
evidence needs  
z) investment in 
translational 
research to 
enhance transfer of 
research findings to 
clinical outcomes  
aa) recognition and 
capture of the 
sector convergence 
opportunities from 
discoveries in the 
life sciences sector 
• number of 
contracts linked to 











• number of 
contracts and funds 









































bb) inclusion of the 
health research 








facilitate access to 
new technology 
platforms 
• evidence that 
infrastructure 
needs for a 
globally 
competitive health 
research sector are 
in place 
• number of national 
collaborations 




• number of 
international 
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dd) investment in 
translational 
research which 
“adds value” to 
HRC funded 
research outputs  
ee) working with 
research providers 







ff) HRC to actively 
participate in the 
implementation of 
the New Zealand 
Biotechnology 
Strategy  
gg) HRC to contribute 
to the development 





relevant to health  
• number of 
contracts in which 
research outputs 


















• evidence of HRC’s 
role in 







General Comments on improved performance indicators 
 
Indicator development and reporting is a resource intensive and requires specific expertise. 
Generally, indicator collections need to maximise the use of: 
• Time series 
• System comparisons for meaningfulness. 
• International comparisons 
For each of these, examples of HRC current and proposed reporting practices are taken as 
examples, with suggestions then made on how they could be improved with a minimum of effort. 
The following discussion is not intended as a criticism of current practices but to show how with 




The example for time series presentation comes from the HRC PAR 2002 and PAR 2003 
documents. Both documents present a range of data but typically for only the last year. It is noted 
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that the [confidential] evaluation of the research portfolio system does present some time series 
data. However, in PAR 2002 and PAR 2003 the number of journal papers is reported for only one 
year. Any reader of both documents would notice that for the period June 2001 – June 2002, ‘768 
journal articles were cited in annual reports received for the period’ (HRC 2002b: 96), whilst for 
the period September 2002 – September 2003 ‘670 journal articles were cited by researchers as 
outputs of HRC funded research’ (HRC 2003d: 79). These two data points may be incomparable 
for any number of legitimate reasons. However, there is no discussion of previous journal output 
performance in the latter report. If the numbers are developed on a different basis then the reader 
should be alerted; otherwise there should be some presentation of the time series. In fact, given the 
funding constraints there might be an expectation of falling journal output – but without presenting 




Currently, the ‘measures’ that HRC has nominated in its Vision 2008 document are couched as 
simple numbers for various objectives. Being able to find out what the actual number of people 
involved or dollars spent (rather than indicators) is more important in a small system than for a 
large one, but they are also more prone to fluctuations. We would suggest that as they stand these 
measures could be supplemented to give greater insight and potential for evaluating performance. 
Some examples chosen from Vision 2008 with our commentary follows. 
 
Vision 2008 Goal: investment in people – current proposed measures include: 
• number of clinical fellows successfully completing training programmes 
• number of Māori scholars and fellows successfully completing training programmes 
• number of Pacific scholars and fellows successfully completing training programmes 
 
Comments: Geisler (2000:75) points out ‘a measure is simply a given quantity … conversely an 
indicator is a measure earmarked for the description or representation of a given event or 
phenomenon’. Therefore in this situation the number per se is not helpful. Budget constraints, 
difficulties recruiting potential applicants or any other factor may force a decline in the number of 
people completing their training. What might be a better indicator over time is: 
• the number of completions over the number of positions funded.  
This provides a benchmark indicator that informs HRC and other interested parties whether an 
improvement is necessary or whether the system is finetuned.  
 
Vision 2008 Goal: Investment in research which contributes to health sector policy and practice – 
measures include: 
• number of contracts linked to priorities of New Zealand Health Strategy 
• number of contracts arising from research originally conducted in biological / life science 
sector(s) 
Contract numbers alone says nothing about their value. The number could be increasing and the 
value decreasing. A possible change would be: 
• percentage of overall expenditure that is linked to priorities in NZHS (or arising from life 
sciences sector. etc.  
Such indicators build a capacity for monitoring the profile of the funding system over time. 
 
International comparisons 
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The initiation of the national bibliometrics consortium is an excellent initiative. However, other 
international data are also available to compare systems. Organisations such as the US National 
Science Foundation and other health research councils have some useful performance measures. 
We note that HRC has in the past produced reports with international comparisons – e.g. New 
Zealand Health Research: Putting excellence into practice (HRC 2002a) – and encourage further 
international collaboration on health research performance measures.  
Science for Life 141
  
Appendix 4: Consultations 
 
The following tables list those people that the evaluation team contacted for data or held 
discussions with during the course of the project. 
 
Health Research Council of New Zealand 
HRC team Title of presentation 
Dr Bruce A Scoggins 
CEO HRC 
HRC’s Strategic Plan 2004-2008 “VISION 2008” 
Dr Patricia Anderson 
Group Manager, Research 
Policy 
The HRC’s Research Policy Framework 
Louisa Wall  A Strategic Framework for Māori Health Research 
Karlo (‘Ulu’ave) Mila-
Schaaf 
Manager, Pacific Health 
Research 




Catalysing Collaboration between Agencies: The HRC’s 
Partnership Programme 
Dr Andre George Annual Contestable Funding Round Overview 
 
New Zealand National Contacts 
Interviewee Position 
Dr Anthony Rodgers Co-Director 
Clinical Trials Research Unit 
University of Auckland 
Professor Richard Faull Head of Department  
Division of Anatomy with Radiology 
Faculty of Medical & Health Sciences 
University of Auckland 
David Schaaf Division of Community Health, FMHS 
University of Auckland 
Private Bag 92019 
Dr Nigel Murray General Manager, Building Programme 
Auckland District Health Board 
Professor Norman Sharpe Medical Director 
National Heart Foundation 
Professor John Fraser Head of School of Medical Sciences 
Faculty of Medical & Health Sciences 
University of Auckland 
Professor Rod Jackson Head of Department 
Department of Social and Community Health 
School of Population Health 
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Interviewee Position 
University of Auckland 
Professor Peter Smith Dean 
Faculty of Medicine and Health Sciences 
University of Auckland 
 MOH 
Dr Don Smith (tel.) Manager, Marsden Fund 
 
Professor Graeme Fraser Chair of the HRC 
Dr John Smart Foundation for Research, Science and Technology 
Professor Linda Holloway Assistant Vice Chancellor 
University of Otago Division of Health Sciences 
Professor Chris Cunningham  Māori HRC Board 
Professor David Green University of Otago School of Medical Sciences 
Professor Warren Tate Department of Biochemistry 
University of Otago 
Professor John Tagg Department of Microbiology 
Founder of Blis 
Dr Richie Poulton Director 
Dunedin Multidisciplinary Health and Development 
Research Unit 
Dunedin School of Medicine 
University of Otago 
Professor Mark Richards Christchurch School of Medicine,  
University of Otago 
Professor Christine 
Winterbourne  
Christchurch School of Medicine,  
University of Otago  
Michael Peters NZVCC, Wellington 
Professor Vernon Squire PVC Research , Otago University 
 
Ministry of Health  
Elizabeth Knopf  Sector Policy  
Paola Serle Māori Health Directorate 
Stephen Rungley Sector Policy 
Pam Fletcher Sector Policy 
Francis Dickson Public Health Div. 
Damien  Zelas DHB F&P 
Francis Graham Public Health 
Cynthia Maling Public Health 
Carmel Peteru Public Health 
John Hobbs Sector Policy 
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International Contacts 
Roland Wise National Health and Medical Research Council 
AUSTRALIA 
Professor Kerin O'Dea Director, Menzies School of Health Research 
AUSTRALIA 
Dr John Condon Research Fellow, Menzies School of Health Research 
AUSTRALIA 
Dr Danielle Smith Menzies School of Health Research 
AUSTRALIA 
Dr Alan Bernstein 
 
President 
Canadian Institutes of Health Research 
CANADA 
Dr Norma O’Donovan Evaluation Officer 
Research Funding and Policy Division 
Health Research Board 
IRELAND 
Dr. Edvard P. Beem Co-director 
ZonMw 
The Netherlands Organisation for Health Research and 
Development 
THE NETHERLANDS 
Dr Stefan Ellenbroek Staff member Strategic Policy and Board Affairs of the 




Dr Maria Starborg Scientific Council for Medicine 
The Swedish Research Council 
SWEDEN 
Dr Peter Dukes 
 
Strategy Manager for DH Partnerships and Foresight 
Medical Research Council 
UK 
Dr Robert Eiss 
 
Senior Advisor for Strategic Initiatives 
Fogarty International Centre (NIH)  
(currently on secondment to WHO) 
USA 
Dr Minerva Rojo 
 
Director, Division of International Relations 
Fogarty International Center 
U.S. National Institutes of Health 
USA 
Alison Young Consultant to the OECD and the Global Forum for Health 
Research 
Science for Life 144
  
Appendix 5: OECD ‘Frascati Manual’ guidelines on identifying 
health-related R&D in GBAORD 
 
 
8. Those seeking data on government funding of health-related R&D are 
often drawn to GBAORD because there is a specific category of socio-economic 
objective for this topic. However, they may not realise that this category only 
covers R&D whose primary purpose is the protection and improvement of 
human health (NABS 4) and that funds for relevant activities may be included 
in other categories. 
9. The most important additional category is “General university funds 
and non-oriented research”. The core coverage recommended for health in 
GBAORD is therefore: 
– Health. 
– General university funds and non-oriented research: medical sciences. 
10. Health-related research funded for other objectives, for example 
military medical research, health and safety research at nuclear 
establishments or support for relevant enterprise R&D as part of industrial 
policy should also be included when available. 
11. Countries that collect and report two-digit NABS data to Eurostat may 
include two sub-categories of aid to industry (Table 1): 
– Manufacture of pharmaceutical products (NABS 0742). 
– Manufacture of medical and surgical equipment and orthopaedic 




12. Perhaps the most important gap is the health-related R&D included in 
general university funds or non-oriented research elsewhere than in the 
medical sciences, especially in the biological sciences. Where any R&D funded 
by health research councils or similar research programmes is included in 
non-oriented research, it may be possible to identify the health-related 
element of biology to be included. 
13. Health-related R&D data derived from GBAORD give an incomplete 
picture of total public funding of such R&D, as GBAORD only covers the central 
government budget. Some health R&D may be funded by extra-budgetary 
public sources such as social security funds. Provincial and local governments 
may fund health R&D, particularly when they are responsible for higher 
education or for general hospitals. Where these sums are significant, an effort 
should be made to add them to the data derived from GBAORD in order to 
obtain a figure for total government funding of health-related R&D. 
 
OECD (2002: 182-3) 
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Appendix 6: An evaluation of HRC-funded research 
 
Terms of Reference 
1. Determine the extent to which research outputs are accessible and assess levels of 
uptake. 
 
2. Determine the current capabilities, capacity and areas where internationally 
recognised research excellence exists within the system. 
 
An evaluation of HRC-funded research.  
 
A key aspect of the Health Research Evaluation is to provide evidence and information on 
the benefits of investing in health research. The following section presents a number of the 
evaluative studies that the HRC has conducted to determine the outcomes of HRC-funded 
research.  
 
The extent to which research outputs are accessible, and the level of research uptake 
To identify the accessibility of research outputs and the uptake of research the HRC has 
adopted a set of performance indicators that provide quantifiable information on the 
outputs of its current research investment, case studies of research funded within the 
portfolio framework are also conducted, as are retrospective evaluations of research 
outcomes. The performance indicators employed by the HRC are collected each year 
through researchers’ annual and final reports. All reports are peer-reviewed, while the 
information that is gathered on performance indicators is used collectively to identify the 
intermediary outputs of research. These outputs fall within the following themes: policy 
impact of research; research dissemination; commercialization of research; and research 
recognition94.  
 
The accessibility of research is identified through the dissemination of research findings to 
appropriate audiences, such as policy makers, stakeholders, other researchers, practitioners, 
and participants. Researchers are required to disseminate the findings of their research to 
appropriate audiences, and this is reported annually. The HRC’s surveys on biomedical, 
clinical and public health research funded through Output Class 2 also provide evidence of 
the dissemination of research and accessibility of research outputs, including the ways in 
which research has been taken up into policy and practice. Included in this section are 
examples from these surveys that highlight the uptake of research into practice, and the 
impact that HRC-funded research has had on policy. This uptake is seen in the application 
of research into clinical practice, and its incorporation in clinical guidelines, as well as the 
engagement of researchers in groups developing policy and the implementation of research 
in health services.  
Current research capabilities, capacity and areas where internationally recognised 
research excellence exists within the system 
The HRC has conducted a number of case studies that highlight internationally recognised 
research, with the case studies included in this Annex identifying just some of the research 
                                                 
94 An explanation of the indicators that are used within these themes is provided under the heading of  
‘Quantifying the Impact of HRC-funded research’. 
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capabilities present in the national health research sector. The health research sectors’ 
capacity and the growth of this capacity through HRC-funded research is also identified 
through the surveys of Output Class 2, while the HRC’s annual workforce analysis95 
provides an overview of the current HRC workforce, identifying both the capacity and 
capability of this workforce.   
 
The international standing of health research is also evidenced in the numerous 
collaborative relationships HRC-funded researchers have formed with international 
research groups, as well as the contribution researchers make to multinational 
organisations (such as the World Health Organisation), and input into policies and 
guidelines at a local, national and international level. These international collaborations 
provide the RS&T sector in New Zealand with access to new technologies and resources, 
as well as providing opportunities for researchers that, in turn, strengthens RS&T capacity 
in New Zealand.  
 
In 2002 the HRC, with the Foundation of Research, Science and Technology (FRST), the 
Royal Society of New Zealand (RSNZ) and MoRST undertook a bibliometric analysis of 
the Research, Science and Technology Sector. This analysis identified the performance of 
health research in terms of peer-reviewed publications, and areas of research strength were 
identified based on this quantitative measure. The following presents an overview of the 
findings of this study. 
 
National Bibliometric Study  
 
In total, 23,757 New Zealand-authored research publications were indexed in the ISI 1997-
2001 National Citation Report database. The highest publication output for a subject was 
nearly 9000 papers for ‘Medical Science’ in the 5-year period from 1997 to 2001 – 
accounting for over a third of the total publications. The second largest subject field was 
‘Biological Sciences’ (approximately 4800 papers), in which a number of publications 
relate to health research. 
                                                 
95 The HRC”s annual Progress & Achievements Report presents the current HRC workforce. These 
documents are available from the HRC website: www.hrc.govt.nz. 
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For the purposes of this analysis, health research publications were defined as all 
publications with a hospital and/or medical school address, plus those papers that were 
included within the ASRC ‘medical/health science’ category. In terms of citations by 
sector, the highest citation rate per paper was in the health sector (7.5), followed by the 
private sector (6.4), the tertiary sector (6.1), then CRIs (5.9).  
 
Under a subject-based definition of health research (the ASRC medical science category), 
1675 ISI-indexed health research papers were published in 2001, which represents 
35 percent of New Zealand publications for that year. 
 
In terms of collaboration, as identified by co-authorship, the largest degree of collaboration 
with overseas co-authors (48 percent) occurred in the health sector (New Zealand hospitals 
and medical schools). There was also a high degree of intra-sector collaboration, with 44 
percent of collaborations occurring between two institutions within the health sector.  
 
Health Research Council’s Performance Indicators 
The following information presents the indicators for research outputs that are collected 
annually for HRC-funded research. These outputs give some indication of the ways in 
which research is being disseminated, the engagement of research in policy, as well as the 
commercial application of research and the formation of research networks and 
collaborations.  
 





Bibliometric Outputs from HRC-funded Research Between September 2002 and 
September 2003.  
 
Journal articles 
A total of 670 journal articles were cited by researchers as outputs of their HRC-funded 
research. Articles were only included in this analysis if they were published or ‘in press’ 
and were classified according to whether they were indexed (580 articles) or not (90 
articles) by ISI, or Medline. An analysis of impact factors was undertaken on the 580 
articles in peer-reviewed, indexed journals. The increase in this number over last year’s 
analysis may be due to the HRC’s new reporting database, which has improved the system 
for recording outputs from research contracts i.e. all outputs are submitted electronically by 
researchers into specific output fields.  
 
The analysis captures all journal articles published during the contract, rather than the total 
number of publications that occur as a result of this research. As is evidenced in the 
research outcomes surveys for biomedical, clinical and public health, the publication of 
research findings is likely to continue for a number of years following the completion of a 
research contract. Consequently, analysis of outputs generated whilst the research is 
ongoing captures only a fraction of the outputs overall.  
 
Articles were published in 276 different journals, with impact factors ranging between 
0.147 for the New Zealand Journal of Psychology and 28.66 for the New England Journal 
of Medicine. The average impact factor across all publications was 3.64, with the greatest 
number of publications recorded in the New Zealand Medical Journal (58 in total). 
Australasian journals, as well as non-indexed journals, play an important part in 
disseminating research to stakeholders and end-users, and the majority of articles published 
in these journals are likely to impact on health sector management and services in New 
Zealand.  
 
A large proportion of non-indexed journal articles were published in Australasian journals, 
but less than a quarter of indexed, peer-reviewed articles were published in these journals. 
Almost three quarters of the indexed articles were published in journals from the USA and 
the UK, with the remainder attributed to journals published in Australasia and Europe (see 
Figure 2 for a breakdown of journal by country). 
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Figure 2. A breakdown of articles according to the country of origin in which the 














The international recognition of New Zealand research is evidenced in the number of 
articles that researchers publish in prestigious, peer-reviewed journals such as Nature 
Medicine and Science. A list of the top 10 high impact publications arising from HRC-
funded research in 2002/2003 is provided below, with the impact factor for the journal of 
publication and the primary Research Portfolio from which the contract was originally 
funded:   
 
Sears MR, Greene JM, et al. A longitudinal, population-based, cohort study of childhood 
asthma followed to adulthood. N Engl J Med 2003; 349(15):1414-22. 
Research Portfolio: Determinants of Health  [Impact Factor: 28.66] 
 
Reid IR, Burckhardt P, Brown JP, et al. Bisphosphonates and osteoporosis. N Engl J Med 
2002; 346:2088-2089. 
Research Portfolio: Non-Communicable Diseases [Impact Factor: 28.66] 
 
During MJ, Cao L, Zuzga DS, et al. Glucagon-like peptide-1 receptor is involved in 
learning and neuroprotection. Nat Med 2003; 9(9):1173-9.  
Research Portfolio: Non-Communicable Diseases [Impact Factor: 27.93] 
 
Caspi A, Sugden K, Moffitt TE, Taylor A, et al. Influence of life stress on depression: 
moderation by a polymorphism in the 5-HTT gene. Science 2003; 301(5631):386-9. 
Research Portfolio: Determinants of Health [Impact Factor: 24.38] 
 
Roos D, Winterbourn CC. Immunology. Lethal weapons. Science 2002; 296(5568): 669-
71. 
Portfolio: Biological Systems and Technologies [Impact Factor: 24.38] 
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Bloomfield FH, Oliver MH, Hawkins P et al. A periconceptional nutritional origin for 
[Impact Factor: 24.38] 
oh J, Fraser J. Metal-derivatized major histocompatibility complex: zeroing in on contact 
[Impact Factor: 15.88] 
hii H, Zanesi N, Vecchione A, Trapasso F et al. Regression of upper gastric cancer in 
pact Factor: 13.86] 
zzati M, Lopez AD, Rodgers A, Vander Hoorn S et al. Selected major risk factors and 
9] 
oulton R, Caspi A, Milne BJ. Association between children's experience of 
2; 
nts of Health  [Impact Factor: 11.79] 
ooks 
of 46 books and book chapters were published, 39 book chapters and 7 books. 
lth, 
 the 
he list of publishers includes many well-known publishing houses, such as Cambridge 
 
noninfectious preterm birth. Science 2003; 300(5619):606. 
Portfolio: Health & Independence of Population Groups 
 
L
hypersensitivity. J Exp Med 2003; 197(5):549-52. 
Portfolio: Communicable Diseases 
 
Is
mice by FHIT gene delivery. FASEB J 2003; 17(12):1768-70. 
Portfolio: Non-Communicable Diseases [Im
 
E
global and regional burden of disease. Lancet 2002 Nov 2; 360(9343):1347-60. 
Portfolio: Non-Communicable Diseases [Impact Factor: 11.7
 
P






These books cover a range of topics, from fetal nutrition, through to air quality and hea
and biological agents. The majority of these books were published internationally (87 
percent), with only six published in New Zealand. Figure 6 shows a breakdown of the 
countries in which these books were published, with almost three-quarters published in
UK and the USA (72 percent).  
 
T
University Press, Oxford University Press, and J Wiley & Son, and is an indication of the
recognition that is given to New Zealand research internationally.   
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Figure 3. A breakdown of the country of publication of books published over the past 12 














Researchers were involved in a number of media events, with 117 individual outputs 
identified through this medium of dissemination. This figure is not representative of all 
outputs generated in this area, as for many researchers it is difficult to quantify these types 
of outputs, which occur relatively regularly. This information does, however, provide us 
with an overview of the types of dissemination HRC-funded researchers are undertaking, 
and how they actively engage a wider audience through the public dissemination of their 
research findings. 
 
While the majority of these outputs occurred at a national level, HRC researchers also 
disseminated their findings internationally. This included articles published in The 
Economist, the New Scientist and the New York Times, as well as radio interviews in the 
USA and Singapore, and television appearances on Australia’s ABC Science Online. One 
researcher also had their research chosen by organisers of the European Society of 
Cardiology for European press release.  
 
Newspaper articles (29 percent) and radio broadcasts (31 percent) were the most common 
medium through which researchers disseminated their research to the public, followed by 
magazine articles (18 percent). Researchers had their work profiled in magazines such as 
the National Business Review, Metro, and North & South. A breakdown of the media 
dissemination is provided in Figure 4.  
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There were 46 outputs indicating the potential and successful commercial application of 
HRC-funded research in the 2002/2003 period. Almost a third of these outputs are patents 
at the Patent Corporation Treaty (PCT) stage, followed by patents pending, and 
international contracts. The outputs recorded are primarily in the area of fundamental 
biomedical research, and include research groups led by Associate Professor Christopher 
Williams, Professors Bill Wilson and William Denny, and Dr Alistair Gunn. 
Examples of these outputs include:  
 
• the development of software for clinical analysis of cardiac magnetic resonance 
images;  
• a contract with Pfizer Global Research for the structure-based design of anti-cancer 
drugs;  
• a contract with Exelixis, Inc USA to generate transgenic zebrafish for biodiscovery 
research; 
• patents awarded for the preparation of prodrugs, and  
• a patent to cover research that is developing methods of enhanced delivery of candidate 
antigens using modified superantigens.  
 
A breakdown of the types of commercial applications from HRC-funded research is provided in 
Figure 5.  
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Recognition of Research Accomplishments 
Recognition of a researcher’s accomplishments in their field of research comes in a variety 
of forms, one of which is the receipt of an award. Of HRC-funded researchers, 29 recorded 
the recognition of their research through the receipt of an award. These awards were both 
national and international (see Figure 6), including awards for best poster or presentation at 
a conference, the Health Innovation Award, appearing in the Queen’s Birthday Honours 
List, the receipt of the Royal Society of New Zealand Award, as well as a number of study 
and travel awards through universities, the medical foundations, and charitable 
organisations such as the National Heart Foundation of New Zealand, and the Maurice & 
Phyllis Paykel Trust.  
 
 


























The impact of HRC
mpact of HRC-funded Research 
-funded research on policy occurs through a number of mediums, including: 
submissions to parliamentary bills; membership on advisory committees; participation in policy 
workshops; guidelines; and commissioned reports, to name but a few. The HRC collects these 
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inputs and aggregates them on a local, national and international level, as well as the medium 
through which this policy impact is occurring. Although journal articles and books undoubtedly 
feed into policy, for the purposes of this analysis, policy impact is measured as information that is 
directly targeted at developing policy through governmental departments, and multinational 
organisations, such as the WHO. 
 
In total, 78 outputs were attributed to policy development, with two thirds of these outputs 
he majority of the input to national policy was provided through the involvement of researchers in 




impacting on national policy. While this number is higher than reported in previous years, it is still 
well below what we believe is the actual involvement of researchers in policy development. 
However, the outputs reported illustrate the diverse range of activities that researchers are involved 
in, in terms of influencing and informing policy development. 
 
T
the drafting of ministerial reports (23), and on advisory committees (10). Researchers made the 
greatest contribution to international policy development through reports. A breakdown of all 
policy outputs is provided in Figure 7, with a breakdown of national and international policy 
outputs given in Figure 8.  
 
T
including DHBs, the Ministry of Health, the Ministry of Youth Affairs, the Treasury, th
Ministry for the Environment, and the Ministry of Social Development. The topics covere
were similarly varied, and included the following reports: ‘Nga Ahuatanga Noho o te 
Hunga Pakeke Maori: Living Standards of Older Maori’ (Ministry of Social 
Development); ‘Nutrition and the Burden of Disease: New Zealand 1997-201
of Health); and ‘Health Effects Due to Motor Vehicle Air Pollution in New Zealand’ 
(Ministry of Transport).  
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Figure 8. Breakdown of the type of outputs that have impacted on policy at a national 












































Internationally, researchers have also contributed to the development of policy through 
eight WHO reports, government reports and membership of expert working groups. A 
breakdown of the agencies and stakeholders that HRC-funded researchers have contributed 




Figure 9. Breakdown of the type of outputs that have impacted on national and 
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Meetings, Hui and Fono 
In 2002/2003 researchers presented their research at 212 national (64 percent) and 
international (44 percent) hui, fono and meetings (including scientific meetings). Research 
findings reached a broad audience that included stakeholders (e.g. the Ministry of Youth 
Affairs and the Ministry of Health); and interest groups (e.g. the Lions Club and the Rotary 
Club); as well as end-users (e.g. primary community services and Plunket nurses); and 
research participants.  
 
The majority of international meetings were scientific meetings. Figure 10 provides a breakdown of 
meetings held to disseminate research findings in New Zealand, and provides comparable 
information to the analysis of meetings, hui and fono provided in the Progress and Achievements 
Report in 2002. In total, researchers have recorded 116 national meetings. Research was most 
widely disseminated to interest groups (39 percent), closely followed by Maori and Pacific Peoples 
(33 percent).  
 
 
Figure 10. A breakdown of meetings to disseminate research findings in New Zealand, 


























During the 2002/2003 reporting period, HRC-funded researchers recorded 596 contributions in 
relation to national and international conferences. These contributions included the delivery of 
keynote or plenary lectures (69), oral presentations (456) and poster presentations (71). From these 
presentations 282 conference proceedings were published. Figure 11 provides a summary of these 
contributions (excluding conference proceedings, which are included in the total for oral and 
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Figure 11. A breakdown of the types of contribution to national and international 

























A significant number of these presentations were keynote or plenary addresses, which 
serve as an indication of the quality of HRC-funded research in the international context. 
These keynote addresses were presented at a number of conferences, including the Xth 
Annual International Conference in Advances in Pediatric Neonatology, the Food for Life 
International Conference, and the Shaping the Future, Contemporary THEMHS in Mental 
Health Services Conference. 
 
International conferences accounted for over half of all conference outputs (63 percent). It 
is pleasing to note the wide dissemination of HRC-funded research, and the opportunity 
that affords for the development of research networks and the establishment of research 
collaborations. Evidence of the importance of conferences in terms of building research 
networks is peppered throughout the research profiles. Figure 12 presents a breakdown of 
the regions in which these international conferences were held. 
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Note: This includes oral presentations, keynote or plenary lectures, and poster presentations (these figures do not include 






In total, researchers reported 217 collaborative ventures (on average, 50 percent of 
contracts involve an international collaboration). More than half of these collaborations 
involved international researchers, and the remainder were split equally between local and 
national collaborations (see Figure 13 for a breakdown of these collaborations). Of the 
collaborations formed with international groups, the greatest numbers were with groups in 
the United States (38 in total), followed by Australia (23 in total) and Europe (23 in total). 
A breakdown of collaborations by country is given in Figure 17. Examples of these 
collaborations include: researchers based at the University of the South Pacific, Samoa’s 
Ministry of Health, researchers at Stanford University, researchers based at the National 
Institutes of Health in the United States, and the World Health Organisation. 
 
Local and national collaborations were predominantly with university-based researchers 
(77 percent in total), with the remainder of research collaborations formed with community 
groups and iwi, District Health Boards, the Ministry of Health, Crown Research Institutes, 
NGOs, and one collaborative venture with industry (Healtheries of New Zealand Ltd).  
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The Outcomes of Biomedical, Clinical and Public Health Research 
In 2002 and 2003 the HRC undertook a survey of biomedical, clinical, and public health 
research with an expiry date between 1994 and 1999. These surveys used both quantitative 
and qualitative methods to collect information on the outputs and outcomes of HRC-
funded research during this period. The following section outlines just some of the 
examples in the survey results of the application of HRC-funded research, and the 
capabilities in the health research sector.  
 
NB. The following section consists of extracts from all three surveys that address aspects 
of the Terms of Reference 3 and 4. This section does not present the surveys in their 
entirety.  
 
Public Health Research Outcomes Survey 
Main Findings of the Self-administered Questionnaire:  
Almost all first named investigators that responded to the questionnaire had reported the 
findings of their research (97%), with the most common output for both contract types 
(public health limited budget projects and project contracts) being peer-reviewed 
publications (87%). More than three quarters of the respondents (80%) believed that their 
research had influenced policy to improve public health, and 67% thought that their 
research had influenced practice. Three quarters of the respondents (76%) stated that their 
contracts had led to further research. 
 
Building Capacity and Capability 
Half of all research projects contributed to the building of research capacity through postgraduate 
training, with a total of 40 postgraduate qualifications attained. Projects accounted for 65% of these 
qualifications, the majority of which were PhDs (55%), while limited budget projects accounted for 
the remaining 35%. In terms of building the capacity of the Maori and Pacific research workforce, 
18% of research contracts included Maori within their research team, while 7% included Pacific 
peoples.  
 
Public Health Research Outcomes Survey - Interviews 
The interviews were aimed at gathering more in-depth information on a number of the themes that 
were covered in the questionnaire, and were not intended to provide comparative information on 
limited budget projects and project contracts. In total eight semi-structured interviews were 
conducted. An analysis of the interviews divided these themes into eight categories: research and 
its application in policy and practice; the dissemination of research and strategies for its 
enhancement; the forming of collaborations and networks during research; career development and 
the building of group capabilities as a result of research; access to policy makers; further research 




All researchers interviewed considered their research to have had an impact on policy or to 
have been taken up into practice. The utilisation of the research would often become 
apparent at a later date, with one researcher who did not initially feel their research had any 
impact, subsequently finding that people were referring to their research, and that it had 
been used for a similar study in Denmark. Likewise, an epidemiological study that was 
conducted in 1998, and was of relevance to Maori and Pacific peoples, was still generating 
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interest from people in Canada and Alaska in terms of its applicability to the Inuit 
populations of these countries. 
 
The utilisation of research is often dependent on the nature of the research, with applied 
research, such as that which aims to improve health service delivery more likely to impact 
on policy or practice. For one interviewee working in this area, they considered their 
research to have failed if it was not utilised. The applicability of research into practice was 
a consideration for researchers during the conduct of their research, and for one researcher 
stakeholder involvement improved the chances of this happening: 
 
… “we’re always looking for research opportunities which will offer both an opportunity 
to enhance basic science and an opportunity to provide some practical input to the people 
that we’re studying. Because this is workplace research it’s obvious that there’s going to be 
implications always for the workforce involved, and that’s why we work wherever possible 
in collaboration with the workforces – the workforce representatives and management 
representatives involved in the studies – so that we can all be looking with an eye to how 
change can be made on the basis of results.” 
 
Researchers noted the impact of their research on policy and practice both nationally and 
internationally. In a two-year project that expired in 1995, a publication resulting from this 
research had been referred to in a number of background papers in relation to UK policy, 
as well as being published by UNICEF, while nationally the research findings had been 
included in a number of the Ministry of Health’s strategic documents.  
 
Those interviewed attributed their research to the development of interventions, and as 
resource tools for the training of medical students, as well as the improvement of health 
service delivery. 
 
The majority of researchers interviewed considered it relatively easy to disseminate 
information to policy makers, with access resulting from the involvement of researchers on 
advisory committees, as well as personal networks and approaching the “right people with 
the right information”. One researcher felt that it was often the case that you needed to be 
involved in advisory groups to have your research noticed by policy makers. A researcher 
who had previously worked for an NGO did not consider it to be easy to access policy 
makers within government departments, and found NGO’s were more likely to take notice 
of their research results.  
 
The importance of disseminating research in peer-reviewed journals was noted by 
researchers, as was the need to disseminate results on a national and local level to end 
users and stakeholders, as well as the participants and communities involved in or affected 
by the research.  
 
“From my perspective there are two target audiences, the first are participants, to whom I 
think we have an obligation to get information back in an understandable and useful form, 
and the second is to scientific peers, so that the work will have more impact and become 
part of the body of knowledge.” 
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As with the applicability of research in policy development or its uptake into practice, the 
means of dissemination is integrally related to the type of research conducted. For 
researchers involved in studies that had an impact on communities, it was important to 
them that their findings reached these groups. Community feedback involved fact sheets 
and newsletters, as well as community meetings, and media work to inform the community 
involved of the findings. For another researcher the involvement of stakeholders in the 
research, which included a Pacific cohort, ensured that the research was disseminated to 
the Pacific community and end-users. 
 
The importance of disseminating results in national journals was raised by two researchers, 
as was a dilemma in relation to disseminating in national as opposed to high impact 
international journals. For both researchers it was important to publish in national journals 
so that there was the opportunity for the research to have an impact at this level. The 
dilemma was raised in relation to publishing in prestigious international journals that 
reflected well on a researcher’s CV, but did not carry the same weight in terms of 
influencing factors as national journals. 
 
A number of themes emerged in terms of enhancing the dissemination of research results, 
including media training of researchers, time allocated to the writing up of results, as well 
as an increase in funding for international conferences. Three researchers felt that funding 
for international conferences should be made available and/or increased, as conferences 
provided researchers with opportunities to develop networks with other researchers 
working in their field. In terms of the importance of conferences, one researcher 
considered it to be: 
 
… ”the networking – you find out whose doing what; what work is going on that hasn’t 
been published that you don’t know about; where you might link in with that; whether 
there are comparisons to be made; whether or not you could work together, and that in turn 
can be a catalyst to further research.” 
 
Two researchers commented that the HRC’s allocation for conferences was insufficient for 
the cost of attending an international conference, and that this was a deterrent in attracting 
postdoctoral fellows, for whom conferences acted as an incentive in terms of career 
development mechanisms. Time and/or budget restrictions were also cited as issues in 
relation to writing up research results.  
 
Half of the researchers noted the important role the media played in the dissemination of 
research findings, and felt that researchers should be given training in terms of media 
liaison. The HRC’s media guidelines document (HRC, 2000) was cited as a useful 
resource, while suggestions to enhance dissemination via the media included the 
introduction of researchers to ‘responsible’ journalists, and support for researchers in 
disseminating their findings through this medium. Other suggestions for dissemination 
included a summary of HRC-funded research on the HRC’s website. 
 
All researchers interviewed had formed networks with other researchers, and these 
included informal networks based on a shared research interest, as well as both national 
and international collaborations involving the actual design and methodology of the 
research and its implementation.  
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Four research projects had involved collaborations with stakeholders and end-users and 
another had involved researchers based overseas. Research looking at health service 
delivery included collaboration with a number of the agencies under review, with advisory 
committees made up of individuals from each agency, as well as Maori, Pacific and 
consumer representatives. These collaborations were considered to have influenced the 
dissemination of the research findings and their application: 
… “they had a major influence on the research design itself, in that the questionnaires, the 
topics that were covered and the interviews and so forth were shaped by them… We 
wanted to ensure that the questions we were asking would be of relevance to the people in 
those agencies.” 
 
In terms of career development, the majority of the research projects contributed to the 
training of researchers and their attainment of qualifications. Two of the limited budget 
projects had contributed to the named investigators’ PhDs, while one limited budget 
project had contributed to a PhD, an Honours dissertation, and three Masters theses. Two 
of the named investigators interviewed did not consider their research projects to have 
contributed to career development, although one of these projects did in fact support and 
train a young Pacific researcher who has continued their involvement in research. Two of 
the researchers considered their projects pivotal in their career development, with one 
researcher crediting their HRC contract with a change in career, and the other for 
establishing their research career.  
 
In terms of developing the capabilities of research groups, HRC funding was cited as being 
fundamental in the establishment and growth of one research group. The leader of this 
research group originally came back to New Zealand on an HRC Repatriation Fellowship 
and set up their group, which to date has included two HRC Training Fellows, both of 
whom completed PhDs, and a PhD candidate with an HRC Maori Health Postgraduate 
Scholarship.  
All researchers reported that their research had led onto further research in the area, if not 
the actual topic itself.  
 
… “the limited budget grant seeded a bigger study and this following piece of research 
contributed to PhD theses. One of these theses was completed last year and the data has 
been disseminated through a number of avenues… this second study has again generated 
data that has led to another study. So from that original limited budget grant a whole series 
of studies has evolved.” 
 
For one researcher working with Pacific communities, although the research that was 
conducted did not lead onto further research in the area, it was invaluable in terms of 
forming relationships with the communities involved, with research in other areas 
developing from these connections. 
 
Five of the researchers interviewed felt that HRC funding had provided them with further 
opportunities for funding from other agencies. Two researchers did not feel that their 
research funding had opened any doors with regards to funding from other organisations, 
while one researcher had not required further funding. Of those researchers who 
considered that their HRC funding had played a part in allowing them access to further 
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funds, the reasons given were based on the success associated by other organisations in 
acquiring HRC funding, and the credibility of the HRC’s peer review process: 
 
… “my perception is that the HRC funding, because of its rigorous peer review process is 
highly regarded, and if you pass that hurdle than that’s a tick in your credibility box so to 
speak, in terms of the quality of what you do.” 
 
Biomedical Research Outcomes Survey 
Results of the Self-administered Questionnaire:  
The following section presents the results of the biomedical self-administered 
questionnaire and extracts from the case studies that address objectives 3 and 4 of the 
Health Evaluation.  
 
NB. The following are extracts only, and are not presented in their entirety. 
 
Application and commercialisation of research 
Seventeen percent of research had led to the development of software, intellectual property or 
diagnostic tools. Of this research, 64 percent of projects had led to the development of intellectual 
property (e.g. patents, licenses), 27 percent to diagnostic tools, and 9 percent to both intellectual 




Figure 15. A breakdown of the commercial applications reported by respondents as arising from their HRC-






















Examples of the commercialisation and application of research included diagnostic tools for 
automated (CAG) repeat length determination relevant to Huntington’s disease, the development of 
software for use in clinical testing, and the licensing to a company in the United States of a 
monoclonal antibody to lens Connexin 50. 
 
Significant Advances in Research 
Researchers were asked to report on any significant advances that they considered their research 
had made to their field of study, as well as unexpected findings that had resulted from the research 
and were likely to advance knowledge in this area. Respondents who did not specify these 
advances or findings were not included in the analysis below.  
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Eighty-five percent of researchers felt that their findings had contributed to significant advances in 
their research field, while 64 percent of researchers said that their research had resulted in 
unexpected findings.  
 
The following are just some of the responses that respondents gave when asked to provide details 
of key findings from their HRC-funded research: 
 
 The research demonstrated an entirely new mode of action through which superantigens attack 
the human immune system. The research also revealed the basis by which the toxin SpeB 
triggers off the "flesh-eating" disease necrotising fasciitis. 
 
 The research demonstrated that the natriuretic peptides, hormones recognised primarily for 
their role in control of blood pressure and volume, are expressed in the brain in regions not 
traditionally thought of as cardiovascular control centres. Furthermore, physiological 
challenges to salt and water balance resulted in changes in natriuretic peptide expression in the 
hippocampus (memory), cerebellum (motor control) and sensory facial nerves. 
 
 The research contributed to knowledge of the bacteriocins of Streptococci and their potential 
role in control of infections in humans. 
 
 The research resulted in the establishment of a clinical MRI facility for research and clinical 
use in Auckland; with two new methods for analysing magnetic resonance images developed. 
The development of analysis software resulted in 10 times improvement in speed.  
 
 The research provided a detailed understanding of the chemical, cellular, and molecular 
pathology in the human brain in Huntington's disease and Alzheimer’s disease, showing that 
brain cells die by apoptosis in these diseases. It also demonstrated that transplanted fetal 
neurons grow, survive and form replacement brain cells in an animal model of Huntington’s 
disease. In addition, the research showed the localisation of marijuana (cannabinoid) receptors 
in the human brain. 
 
 The research developed the concept of purinergic regulation of hearing sensitivity. A new 
discovery in how the cochlea regulates the electrochemical driving force for sound transduction 
and how ATP provides a co-transmission/neuromodulatory role in auditory neurotransmission. 
 
 The research provided the first detailed sequence (109,000 base pairs) of a large human intron 
that appeared to be involved in the aetiology of Duchenne Muscular Dystrophy. It showed that 
this intron (in contrast to neighbouring introns) has increased steadily in size over a period of 
100,000 years and first suggested the hypothesis (expanded in later research) that the instability 
of this portion of the genome might be a consequence of distortion in chromatin structure. 
 
Building research capacity 
In total, 75 percent of research contracts had contributed to the training of postgraduates. 
Respondents reported the successful completion of 123 academic qualifications by students 
working on their HRC-funded research. Figure 16 presents a breakdown of the academic 
qualifications gained as a result of this research funding. In addition, thirty-two postdoctoral 
fellows were supported through the respondents’ contracts. 




Figure 16. Academic qualifications gained by students working on HRC-funded 













Establishment of Networks 
Sixty-two percent of respondents said that their research was part of wider national or 
international research collaborations. Of these collaborations, 59 percent were 
international, 30 percent were national, and 11 percent were both national and 
international. Nearly a third involved university-based researchers (62 percent), with 30 
percent involving more than two collaborators (see Figure 17).  
 
























Three percent of collaborations involved Crown Research Institutes (CRIs), while 5 
percent did not fit within the categories defined in the survey96. Figure 18 illustrates the 
types of research collaborations that involved two or more collaborators. 
 
                                                 
96 Collaboration categories included university-based researchers, clinical researchers, industry, and CRIs.  
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Dissemination of Research 
Nearly all respondents (98 percent) had reported the results of their research, with half of these 
researchers anticipating that further publications would arise. Almost all had published their 
research findings in peer-reviewed articles (97 percent), with 475 peer-reviewed journal 
publications listed by researchers - an average of 8 publications per research contract. The 
maximum number of publications to result from a research contract was 36.  
 
Out of the 475 peer-reviewed journal articles reported, researchers provided information and copies 
for 396 articles that were indexed by the National Library of Medicine and the ISI citation indexes. 
These 396 articles were spread across 166 journals in total, with the majority published in North 
American or European journals (only 5 percent were published in Australasian journals in 
comparison to 32 percent for the public health research outcomes survey), see Figure 19. The 
journal that published the greatest number of articles was Biochemistry (14 articles in total) 
followed by the Journal of Molecular Biology (11 articles in total), see Table 1. 
 
A quarter of researchers reported publications in other journals and professional magazines, with 
almost a third (27 percent) reporting outputs in the form of books and book chapters. Three 
quarters of researchers had reported the results of their research at conferences, both with published 
proceedings (62 percent) and without published proceedings (65 percent). 




Figure 19. A breakdown of the country/region of publication for journals in which 













Media coverage was a dissemination medium used by just under a quarter of researchers, with 
the majority of coverage attributable to printed media material (20 percent), followed by radio 
coverage (17 percent) and television coverage (10 percent). Less than 10 percent of research 
contracts led communications in the form of manuals and resource materials (7 percent), and 
the Internet (5 percent), with 2 percent attributed to technical reports. See Figure 20 for a 
breakdown of the different types of dissemination output. 
 
Table 1. Journals publishing HRC-funded biomedical research. 
 
 
Journal Number of articles 
Biochemistry 14 
Journal of Molecular Biology 11 
Neuroscience 10 
Hearing Research 10 
American Journal of Physiology 10 
Clinical and Experimental Pharmacology and 
Physiology 9 
Acta Crystallographica Section  9 
Others (7 or less publications each) 323 
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Clinical Research Outcomes Survey 
Results of the Self-administered Questionnaire:  
The following section presents the results of the clinical research self-administered 
questionnaire and extracts from the case studies that address objectives 3 and 4 of the 
Health Evaluation.  
 
NB. The following are extracts only, and are not presented in their entirety. 
 
Establishment of Networks 
A third of those interviewed said that their research had been part of a wider national or 
international collaboration. Of these collaborations, 53 percent were national 
collaborations, while 47 percent involved international collaborators. The majority of these 
collaborations involved more than two collaborators, with 16 percent involving 
collaboration with university–based researchers, and 5 percent each attributable to health 
practitioners, industry or ‘other’. Figure 21 provides a breakdown of these collaborations, 
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Clinical application of research 
Almost a quarter of respondents (21 percent) reported that their research had resulted in the 
development of therapeutic interventions, such as diagnostic tools and/or software, with the 
majority of these developments being therapeutic interventions. None of the research had 
contributed to changes in systems management. Figure 23 provides a breakdown of the outputs 
within this category. 
 
Examples of these developments include: 
 
• interventions that impacted on shearing industry training; 
• the identification of a genetic variant that may influence the risk of side effects with tricyclic 
antidepressants; 
• the clinical use of BNP and NEP inhibitors in the treatment of cardiovascular disease; 
• the identification of low selenium levels in babies on formula feeding resulting in at least one 
manufacturer supplementing their formula;  
• the development of a polymerase-chain-reaction assay for diagnosing B. pertussis infection, 
and  
• the use of low-dose aspirin for prevention of deep vein thrombosis. 
 
 
Figure 23. A breakdown of the commercial applications reported by respondents as 











Uptake of Research into Practice 
Respondents were asked a number of questions in relation to the broader dissemination of 
their research and its potential impact on clinical practice. It was pleasing to note that half 
of all researchers considered their research to have resulted in changes to clinical practice 
(49 percent), and that almost a third of this research had contributed to clinical guidelines 
(27 percent). In the analysis of these results, only respondents who had specified these 
contributions were considered to have contributed to clinical guidelines or changes in 
clinical practice (see Figure 24).  
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A small number of respondents had participated in official review groups, such as the 
Cochrane Collaboration Group (7 percent), with 10 percent of respondents being aware of 
the inclusion of their research in the Cochrane Library. It was apparent from comments 
made on the survey forms that researchers were not always aware of the impact of their 
research, in terms of the questions that were posed.  
 
 

































In future analyses, it would be worthwhile to establish the number of publications resulting 
from research included in reviews and guideline documents. This was beyond the scope of 
the present survey. 
 
Dissemination of research 
Nearly all researchers (93 percent) had reported the results of their research, with half of these 
researchers (51 percent) anticipating that there would be future publications from it. The majority 
of respondents had published their research findings in peer-reviewed articles (84 percent), and in 
total 264 peer-reviewed publications resulted from 57 contracts - an average of five publications 
per research contract. The maximum number of publications to result from a research contract was 
47, arising from a Training Fellowship. The maximum number of peer-reviewed publications to 
arise from a project contract and a Limited Budget contract was 33 and 18, respectively. 
 
Out of the 264 peer-reviewed journal articles reported, researchers provided information on and 
copies of 236 articles that were indexed by the National Library of Medicine or the ISI citation 
indexes. These 236 articles were published in a total of 111 different journals, almost half of which 
were European journals (44 percent). Figure 25 provides a breakdown of the country of publication 
for the journals printing articles arising from clinical research. The journal that published the 
greatest number of articles was the Journal of Hypertension (15 articles in total) followed by the 
Australian and New Zealand Journal of Medicine (12 articles in total), see Table 2.  
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Journal Number of articles 
Journal of Hypertension 15 
Australian and New Zealand Journal of Medicine 12 
Lancet 9 
European Heart Journal 9 
Journal of the American College of Cardiology 8 
Journal of Affective Disorders 8 
New Zealand Medical Journal 8 
Circulation 6 
The Australian and New Zealand Journal of 
Surgery 5 
Others (4 or less publications each) 156 
 
 
Figure25. A breakdown of the country/region of publication of journals printing articles 





















Almost a quarter of researchers (23 percent) reported publications in other journals and 
professional magazines, with 18 percent of researchers reporting outputs in the form of books and 
book chapters.  
 
Published conference proceedings were the second most popular medium for dissemination, with 
three-quarters of researchers reporting their findings through this avenue (70 percent). Conferences 
Science for Life 174
 Quantifying the Impact of Health Research 175
without published proceedings were a mechanism for dissemination for almost half of the 
respondents (46 percent). 
 
Media coverage was a medium used by a quarter of researchers, with the majority of coverage 
attributable to printed media material (32 percent), followed by radio coverage (26 percent) and 
television coverage (16 percent).  
 
Less than 20 percent of this research led to other communications such as manuals and resource 
materials (16 percent), or the Internet (9 percent), with 12 percent producing technical reports. See 
Figure 26 for a breakdown of dissemination outputs.  
 
Building research capacity 
It was pleasing to note that half of the respondents reported that postgraduate students had 
received research training through their research (55 percent), and that 18 postdoctoral 
fellows had been employed on research contracts. In total, 47 academic qualifications 
resulted from this research, with the greatest number of qualifications being PhDs (23 in 
total), followed by Masters degrees (8 in total). A breakdown of the qualifications that 
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Only a small percentage of contracts had contributed to building research capacity for 
Maori or Pacific researchers. In total, nine percent of respondents had employed Maori 
researchers on contracts, partly contributing to one academic qualification. While, 7 
percent of respondents had employed Pacific researchers on contracts, none of these 
individuals had gained an academic qualification through the research. 
 
Biomedical and Clinical Case Study Results 
The following section is an overview of the case studies conducted as components of the 
biomedical and clinical surveys. Case studies were conducted for five biomedical and 
clinical researchers, who addressed among other issues the impact of their HRC-funded 
research in building research capacity and capability, the dissemination of their research 
findings, as well as the uptake of their research into practice. 
 
Research Uptake into Practice 
The five biomedical and five clinical HRC-funded researchers interviewed following their 
completion of the respective surveys, identified and discussed a number of avenues through which 
they felt the outcomes of their research had been taken up. The researchers described both the 
traditional or expected pathways for the transfer of research knowledge, namely contributions to 
policy, clinical practice and the development of guidelines, as well as several less expected and 
tangible sources of informational transfer and influence.  
 
Generally speaking, the biomedical researchers interviewed talked about the ongoing development 
of their research and the potential future implications the knowledge being generated and 
accumulated would have in the future. However, there was evidence that the outcomes of research 
even at the more fundamental end of the spectrum were having an impact on policy and practice. 
One biomedical researcher identified and provided examples of some of the ways the research they 
were undertaking had both influenced and directly sped up the introduction of therapy into clinical 
practice. Examples demonstrating the application of the outcomes of their research being taken up 
into practice included the introduction of flow cytometry as a routine analysis for blood leukocytes 
and cancer diagnosis, as well as the introduction of DNA testing for histocompatibility. Indeed, this 
technology has been transferred to the haematology diagnostic area and has impacted on the 
diagnostic practices employed. 
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The clinical researchers interviewed outlined how the outcomes of their research had both 
influenced and contributed to clinical practice, treatment protocols, and the management of 
patients. One clinical researcher, who collated retrospective data regarding the case history and 
tubal microsurgical outcomes for a group of over 900 women over four years, indicated the results 
of his research have enabled surgeons to better determine who will benefit most from 
microsurgery, or alternatively, who is a more suitable candidate for IVF. In this regard the results 
have become a valuable clinical aid in surgical case management and treatment.  
 
A further two clinical researchers outlined how the results of their research had provided the 
evidence base to either support, or contradict, current clinical treatment and drug administration 
approaches. In the first instance, one researcher indicated that the findings generated by his teams’ 
research into the drug therapy used to treat bronchial asthma provided the evidence base to support 
the way drug therapies were being administered in clinical practice for the treatment and prevention 
of asthma. In the second instance, another researcher described how her research demonstrated that 
the use of low-dose aspirin as a therapy for pregnant women who were carrying small for 
gestational age babies was of no benefit, as the introduction of aspirin once signs of abnormal fetal 
development have been identified, is too late.  
 
Network Building and Collaborations 
All of the biomedical and clinical researchers interviewed provided in-depth information on the 
collaborations that existed or evolved as a result of their respective research projects. Generally 
speaking, the information provided by researchers concerned the means by which the 
collaborations they were involved with developed, the opportunities provided by these research 
collaborations, and the outcomes and ongoing research generated by these respective national and 
international collaborations.  
 
The Opportunities Provided by Collaborations 
Involvement in both national and international collaborations was identified by the clinical and 
biomedical researchers interviewed as providing vital training and knowledge building 
opportunities, as well as important access to new knowledge and techniques. Significantly, the 
development and maintenance of the professional contacts and collaborative relationships of the 
Primary Investigators interviewed also provided several important research training opportunities 
for students working on the research contract concerned. The researchers indicated that through 
these mechanisms, the potential and the capacity for New Zealand to both generate and be involved 
in world-class health research, is greatly enhanced. Several of the researchers interviewed alluded 
to the importance of student’s having these international research training opportunities. The 
majority also expressed the view that making such international training opportunities available did 
not simply amount to exporting our best and brightest for the benefit of others. 
 
“It is absolutely critical for students to go overseas, and it is kudos for this country that our 
students are so sought after, and they actually do come back, and science is all about having open 
boundaries. And you never know when that New Zealander over in a lab in Switzerland, or Lund in 
Sweden, or Cambridge in the UK is going to apply a unique attitude, which New Zealanders have 
for advancing science. You never ever lose graduates, and they do come back … so it’s not a brain 
drain, it’s a brain gain.”   
 
In this instance, two PhD students working with the Primary Investigator on this contract had 
returned from research positions overseas are were looking to continue the next phase of the 
research in New Zealand, using their newly acquired skills in genetic engineering.  
 
“They’ve rejoined the group as senior investigators on the research programme, and bring with 
them expertise that the group did not previously have.” 
 
Another feature of the information generated by the interviews with researchers was the frequent 
necessity of developing collaborative research relationships, given the size, location and access to 
Science for Life 178
 
resources afforded within New Zealand. Several of the researchers described how their research 
projects relied heavily on collaborations with others regarding access to technology, techniques and 
samples, as well as drawing on the experience, knowledge and expertise of others.  
 
Examples of the resources and opportunities made available through the collaborations developed 
by the researchers interviewed include:  
 
• Obtaining the clone for a gene being sequenced and gaining access to a large enough 
sample of DNA to be able to determine the intron structure of the gene that is responsible 
for Duchenne Muscular Dystrophy;  
• Enabling the delivery of prodrugs to the site of tumours through the use of a vector system 
developed by another research team so that the effectiveness of the gene-directed enzyme 
prodrug therapy (GDEPT) could be evaluated;  
• Gaining access to a technique used to analyse tissue from airway inflammation that was 
more advanced than what was currently available and in use in New Zealand, and 
• Having access to a large enough pool of families with a history of premature menopause in 
order to undertake a study on the genetic analysis of premature ovarian failure.  
Issue 7.  
The Outcomes of Collaborations 
As discussed above, one of the most significant outcomes of the development of 
collaborative research relationships was the access generated through the collaborations formed by 
these researchers, to new technologies and techniques, to clinical samples and families, and to the 
diverse skill base required to implement the research. However, some of these collaborations also 
produced valuable resources in their own right. In one project, the national and international 
collaborations developed through the course of the research resulted in the accumulation of one of 
the world’s largest international collections of patient samples for the genetic exploration of 
premature menopause.  
 
In another project, the extensive collaborative relationship and the networks built between the 
researchers and the Huntington’s disease community and people with neurological disorders and 
their families, has been the advent of the Brain Bank. On an international scale, the Brain Bank 
constitutes a highly unique and valuable resource. This research project represents one of the most 
successful models used in the study neurodegenerative diseases of the brain, and the development 
of the Brain Bank is a clear indication of the effort that has been made to engage both the 
community and individual families with the research.  
 
Building Research Capacity and Expertise 
The vast majority of the clinical and biomedical researchers interviewed believed that the research 
project they led had made a significant contribution to building research capacity. A number of 
students working with the Primary Investigators on this contract had gained Masters, MD’s and 
PhD’s, across a variety of disciplines. The number of people employed on the research contracts of 
those interviewed ranged from one to thirty-five, and supported individuals working at honours 
level through to postdoctoral fellows. Importantly, the researcher who constituted the sole 
employee on a contract also felt that the research project had contributed significantly to building 
her own research capability by greatly enhancing her ability to design clinical trials and analyse 
complex statistical data.  
 
The Success of Research Projects in Attracting and Training Students 
The training potential offered by the research projects undertaken was alluded to many of the 
researchers. One of the Primary Investigators interviewed described the research project as 
providing “a tremendous training ground for postgraduate researchers”, adding that the ability to 
obtain research funding “has a real impact on the potential to train researchers coming through”.  
 
In relation to capacity building, several of the researchers also discussed how successful the 
research projects had been in attracting the highest calibre of students, with many having to turn 
highly capable and talented students away. In this vein, several of the Primary Investigators also 
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referred to the invaluable contribution made by the students and fellows involved on their projects. 
So while several of the researchers interviewed drew attention to the exciting skill and knowledge 
development opportunities afforded to students involved in their research, they were also aware of 
the value of the skill and commitment demonstrated by the students in this context.  
 
The Benefits Available to Students Involved on Research Projects 
In the majority of cases, international research collaborations and networks provided a number of 
unique overseas training and mentoring opportunities for a large number of the students and 
postdoctoral fellows who had worked on the research contracts led by the clinical and biomedical 
researchers interviewed.  
 
Postdoctoral fellows working with the Primary Investigator involved in the largest study have gone 
on to work in the laboratories of international research teams that the researcher in question formed 
collaborations with. A close collaboration with a group in Cambridge University has resulted in 
two postdoctoral fellows working with this group, and a third due to go over this year. There are 
also New Zealanders who have been associated with the research group now working in Wales, 
while a PhD student who will finish early next year is going to work in Lund in Sweden. At 
present, 15 PhD students are associated with the programme and at least 10 to 12 PhD students 
have graduated over those last 5 or 6 years.  
 
However, these opportunities were frequently still available through the collaborative networks 
established by researchers who in terms of funding levels, would be regarded as leading smaller 
research projects. As a result of their involvement in one such project, a PhD student is currently 
working with a research team in Australia, while another student on a Summer Scholarship has had 
the opportunity to visit and work in a research lab in the United Kingdom. Meanwhile, other 
students working with these researchers have both attended and presented at international 
conferences, have been accepted into advanced surgical or clinical training, and/or have gone on to 
secure their own research project funding.  
 
Knowledge Transfer and Dissemination 
The clinical and biomedical researchers interviewed described disseminating the results of their 
research through many of the traditional and expected academic channels, including publishing 
peer-reviewed articles in relevant journals, making oral or poster presentations at national and 
international conferences, writing chapters in books, contributing to annual health reports, and 
participating in departmental seminars. The following were described as forms of dissemination 
used by the researchers that were interviewed: 
• The results of the research project exploring the chemistry, anatomy and molecular biology 
of basil ganglia in the human brain have thus far been published in 29 international peer-
reviewed journals, have been presented at 29 conferences, and have resulted in three book 
chapters.  
• The findings from the research project on the design and evaluation of prodrugs for the 
gene-directed enzyme prodrug therapy (GDEPT) for cancer, have continued to be 
published up until the present, resulting in 14 international peer reviewed publications, as 
well as four patents. 
• The results of the research project on the diagnosis, treatment and outcome of infertility 
regarding structural disorders of the fallopian tube, have been disseminated in the form of 
publications in two peer-reviewed journals, namely Assisted Reproductive Reviews and 
Fertility and Sterility. The Primary Investigator also attended two conferences in the 
United States, and after being placed in the top three submitted posters, was asked to make 
an oral presentation at the international Fertility and Sterility Conference.  
• The results of the research project on the interaction between beta-agonists and inhaled 
corticosteroids and their effect on the control of bronchial asthma, were published in the 
third most prestigious international respiratory journal. In addition, the findings, which 
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supported the combined use of beta-agonists and corticosteroids, were incorporated at Step 
3 of international guidelines for the treatment of asthma. 
• The results of the pilot study exploring metabolism and nutrition following liver 
transplantation, which included a full time-series assessment of fifteen patients’ body 
composition and nutritional status, have been published in a peer-reviewed journal, with 
abstracts in three other journals. The results have also been presented orally to the 
American Society of Transplant Physicians Scientific Meeting in Chicago, 1999.  
• The findings from a study on the role of Doppler in small for gestational age fetuses and 
their subsequent postnatal growth and development, have been published in five peer-
reviewed journal articles and presented at an international conference on Maternal Fetal 
Medicine in the United States. Presentations of the results have also been made to the 
Australian and New Zealand Perinatal Society Meetings as well as local Perinatal Society 
meetings. The research has also received media coverage in the mediums of both print and 
radio.  
 
In conjunction with these more traditional outputs and avenues for dissemination, the researchers 
also made reference to their engagement in several alternative means of knowledge transfer. It was 
evident from discussions with the researchers that engaging with the relevant health communities, 
with clinicians, affected families and the wider public, was a very significant part of the research 
teams’ dissemination strategies. An example from one of the research projects was the use of 
educational seminars, which proved to be highly successful in raising awareness among clinicians, 
which in turn affects the quality of clinical care. Researchers who specifically targeted 
dissemination towards clinicians indicated that providing clinicians with latest science and being 
available to answer their questions greatly enhanced the uptake of research findings into clinical 
care.  
 
Several of the researchers interviewed had also taken steps to directly disseminate their research 
findings to the relevant health related community. The measures taken to achieve this included 
involving target communities in monthly seminars and attending the meetings of relevant interest 
groups. Several researchers also specifically sought input and feedback from these communities at 
various junctures throughout the research process. Some of the researchers took a broader 
educational approach to dissemination again and were involved in informing the general public as 
to how basic research impacts on medicine and the uptake of technology into practice. In most 
instances, this contact with the wider public occurred on a regular basis through formalised 
channels implemented by their respective University Departments and Faculties.  
 
It was very apparent that the dissemination of the research findings as well as associated activities 
promoting the transfer of knowledge spanned a number of forums. An example illustrating the 
breadth of this process from an interview with one of the clinical researchers, included writing 
accessible articles for publication in General Practitioners and Women’s Health magazines, 
responding to media enquiries, educating post-graduate doctors in teaching forums about premature 
menopause, providing information and detailed feedback to clinicians as well as women who may 
have the condition, initiating and participating in a support group for women, and engaging in any 
opportunity to raise the level of awareness about premature menopause in the wider community. 
Underlying many of the discussions with researchers regarding strategies for dissemination was an 
awareness of the pivotal role dissemination plays in facilitating and promoting the uptake of 
research.  Generally speaking, these researchers indicated that the broader and more diverse the 
dissemination opportunities available were, the more influence the research findings were likely to 
have on policy and practice.  
 
Impact of Research Project on Career 
There was a clear indication that undertaking these research projects had had an impact on the 
careers of the researchers, and in some instances had influenced both the direction and the 
emphasis of their research careers. Several of the researchers interviewed had gained international 
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recognition on the basis of both the specific project in question, as well as from their cumulative 
body of research work. Recognition and esteem was evident in these researchers invitations to 
present at international conferences; lead international workshops; participate on expert advisory 
panels co-opted by the World Health Organisation; and be included in the Cochrane Library.  
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Case Studies - Biotechnology and biomedical research in New Zealand 
The following case studies present examples of HRC-funded researchers who are leaders 
in their field.  In many cases their research has moved beyond the laboratory into clinical 
application, with a number of the case studies highlighting research that has culminated in 
the launching of innovative companies to commercialise their discoveries.   
 
The case studies highlight: national research teams involved in global consortiums that are using 
the bacterial genome to identify potential new drug targets in the fight against TB; research that 
was the first to identify that the adult human brain is capable of repair; research that has led to the 
development of a monitor with the potential to detect brain injuries at an early stage in preterm and 
newborn babies; that cooling the brain after severe hypoxia-ischemia can dramatically improve 
outcome; that under-nutrition throughout pregnancy results in offspring who are susceptible to 
diabetes, obesity and hypertension; a new treatment for osteoporosis; the benefits of aspirin in 
preventing blood clots after surgery; and research that is uncovering  the complex interplay 
between genes and life experiences in the prediction of outcomes such as violence and depression. 
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Medical molecules – Professor Ted Baker – University of Auckland 
 
Unravelling the molecular mysteries of disease is giving a group of University of Auckland 
researchers a deeper understanding of the causes of disease and helping them in the search 
for new therapeutic targets.  
 
Professor Ted Baker and his colleagues, Drs. Peter Metcalf, Shaun Lott and 
Vickery Arcus, from the School of Biological Sciences, are particularly interested 
in proteins because they are the molecules which carry out all the essential processes in 
living things. 
 
Developing their knowledge of the three-dimensional structures of proteins may open the 
way for controlling biological activities through structure-based drug design or protein 
engineering. 
 
“Structural biology is an extremely fast growing, fast evolving area of research,” Professor 
Baker says. “The advances in genome sequencing have further accelerated this. We now 
use structural biology to help discover the functions of the many genes and proteins whose 
functions are a mystery at present.” 
 
He says that there are basically two strands to this research: “One is to understand disease 
at the molecular level by looking at the structure and function of key proteins, and the 
second is to use the proteins themselves as the target for new drugs.” 
 
The team uses X-ray crystallography to work out a protein’s precise three-dimensional 
structure, then collaborates with other biomedical researchers to further this work. For 
example, their work (with a Massey University team) on the kiwifruit enzyme, actinidin, 
was used in the design of anti-malarial drugs by San Francisco researchers.   
 
Professor Baker’s group is also part of an international group of more than 40 labs world-
wide known as the International TB Structural Genomics Consortium. Researchers in this 
consortium work together in a co-ordinated way, using the bacterial genome to identify 
potential new drug targets against TB, and then analysing their three-dimensional 
structures. 
 
“Our lab has recently solved the precise atomic structures of several enzymes essential for 
the viability of the bacterium. We believe that these are good drug targets because they are 
essential for the bacterium but they are not present in humans.” 
 
Professor Baker’s team has also been working with the laboratory of Professor John Fraser, 
at the School of Medical Sciences, to determine the structures of superantigens and other 
toxins from the common human pathogens Staphylococcus aureus and Streptococcus 
pyogenes. 
 
They are also investigating proteins that cause antibiotic resistance, and 
understanding proteins that act on folic acid and may be useful in designing 
more effective anti-cancer drugs. 
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Neuronal rescue thearapies – Professor Peter Gluckman – University of Auckland 
 
Neuronal rescue therapies developed by University of Auckland researchers offer a whole 
new approach to preventing brain cell death caused by acute neurological injuries. These 
injuries cover a whole range of problems such as stroke, head trauma, perinatal asphyxia, 
or neurodegenerative diseases such as multiple sclerosis, Alzheimer’s and Parkinson’s. 
 
The key discovery, made by a team headed by Professor Peter Gluckman, Liggins Institute, 
University of Auckland, was that brain cell death is not immediate after injury but actually 
takes place over hours or days, providing a window for intervention. 
 
The research team has identified growth factors and small molecules that have important 
therapeutic applications for both acute and chronic neurodegenerative conditions. They 
have also demonstrated that administering growth factors after injury can prevent cell 
death. 
 
Neuronal rescue therapies target both acute brain juries and chronic neurodegenerative 
disease. In the case of acute brain injuries, they intervene in the pathological process that 
leads to cell death and assist recovery by augmenting neuronal function. 
 
In the case of models of neurodegenerative disease, neuronal rescue agents are able to 
prevent the death of neurons that have been exposed to the pathological processes caused 
by the disease. They also enhance functional recovery, underlying their potential for 
treating cognitive dysfunction in ageing, for example, memory, reasoning and attention. 
Because the therapy uses the growth factors and small molecules that are the recovery 
mechanisms intrinsic to the brain, Professor Gluckman’s group believe they may be safer 
than other therapies under development. 
 
The technology developed by the research team includes a Brain Rescue Monitor (under 
development by Tru Test Ltd) that tracks evolving brain injury and the factors that 
influence treatment. Real time information enables physicians to predict outcomes, decide 
on treatment and monitor the effects of neuronal rescue therapy. The monitor has shown 
promising results in clinical trials detecting brain injuries at an early stage in preterm and 
newborn babies. 
 
The research team showed that many brain injured babies appear to rally in the first few 
hours after birth, but later succumb to brain damage as cells commit ‘cell suicide’. 
A biotechnology company, NeuronZ Limited, was established and it has now merged with 
EndocrinZ to become NeurocrinZ Limited. The company has attracted co-investments 
from national and international sources to enable the further development and ultimately 
the clinical trial of neuronal rescue therapies. 
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Using cooling to counteract brain damage in premature infants – Dr Alistair Gunn – 
University of Auckland 
 
Clinically induced hypothermia and the use of endogenous growth factors both offer hope 
as ways of countering brain damage in premature infants.  
 
Infants between 23 and 30 weeks premature often suffer poor neurodevelopment, with 
about five per cent developing severe handicaps such as cerebral palsy. 
 
Dr Alistair Gunn, director of a programme of research in preterm brain injury at the 
University of Auckland, points out that there is also a lot of concern about less noticeable 
effects that may not become obvious until the child gets older. 
 
“We are now tending to see less severe disabilities, but we are seeing more subtle problems 
such as learning difficulties and attention deficit disorder hyperactivity which surface later 
in life. That's not five per cent, that's half or more." 
 
The Auckland group has already discovered that active, ongoing damage means that 
premature infants with white matter brain damage in the first week or two after birth have 
smaller or less complex brains when they reach full term. This makes finding ways to 
disrupt or even reverse this damage even more vital. 
 
Dr Gunn’s focus is on hypothermia, which has already been shown to interrupt cell death 
after asphyxia, leading to a major clinical trial whose results are expected soon. He is now 
investigating whether early cooling can interrupt the early phase of cell death in premature 
infants and improve long-term development. 
 
Co-researcher Dr Laura Bennet is, meanwhile, looking at the possibility of using 
endogenous growth factors in the brain to halt ongoing damage and help the brain repair 
itself. 
 
“The immature brain is very plastic, it is still producing new cells which help build the 
brain. We can use that plasticity to kick-start the process of helping regrow damaged 
brains," she says. 
 
"Whether we will ever be able to do that is another matter but our preliminary data show 
very excitingly that we can in fact stop the evolving process of damage and improve brain 
activity, suggesting that not only are we saving cells but they are doing something useful." 
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Impaired fetal growth – its costs and consequences – Professor Jane Harding – University 
of Otago 
 
Poor fetal growth is known to cause a range of major problems, including increased risk of 
stillbirth, pre-term delivery, and neonatal illness. 
 
University of Auckland Liggins Institute researcher and Professor of Neonatology, Jane 
Harding, explains that researchers have also become increasingly aware that the 
consequences can reach not only into childhood but also later life in what is now known as 
the fetal origins of adult disease (FOAD). 
 
“There are difficulties with growth and with learning in childhood, and they are at risk of 
diseases in adult life, particularly diabetes and heart disease.”  
 
The Liggins Institute’s current programme includes three projects designed to explore the 
mechanisms involved in slow fetal growth or intra-uterine growth restriction (IUGR) and 
how these can be prevented or treated.  
 
Professor Harding says that the first of their three projects looks at possible approaches to 
reversing impaired growth in the womb. A number of naturally occurring growth 
hormones have already been identified and they are looking at these as possible means of 
treatment. 
 
The group’s second project is expanding on earlier work they have done which showed 
that nutrition around the time of conception alters a range of aspects of fetal development 
in late gestation. 
 
“It alters growth, it alters metabolism, it even alters time of birth,” Professor Harding says. 
“We are interested in what the long-term consequences of those changes are.” 
 
Science Journal recently published an article by Professor Harding in collaboration with 
researchers at the Liggins Institute, University of Toronto, and Monash University, which 
showed that in sheep, just a modest reduction in food intake prior to conception and for 30 
days after led to premature delivery. 
 
If these findings are applicable to human pregnancies then they could have significant 
implications in combating one of the major causes of pre-term birth, especially given that 
an estimated 50 per cent of pre-term deliveries are idiopathic – not attributable to a known 
cause such as infection. 
 
Knowing the best time to treat is all important if there is to be any sort of successful public 
health strategy, Professor Harding explains. “If it turns out that the critical time is actually 
before you become pregnant that has very different implications from if the critical timing 
is in the mid trimester,” she says 
. 
The Liggins Institute’s third project is examining nutrition during pregnancy, because past 
studies have shown that in rats, under-nutrition throughout pregnancy results in offspring 
who exhibit the “couch potato syndrome”.  They are susceptible to diabetes, obesity and 
are hypertensive.  
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Professor Harding points out that all these abnormalities seem to be linked, so the group 
are interested in understanding what underlying mechanisms are disturbed. Eventually 
understanding these mechanisms may point the way to possible interventions. 
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Finding answers to neurodegenerative diseases – Professors Mike Dragunow and Richard 
Faull – University of Auckland 
 
Two University of Auckland researchers are examining opposite sides of the same coin in 
an effort to fight neurodegenerative diseases such as Alzheimer’s, epilepsy, Huntington’s 
and Parkinson’s. 
 
Professor of Pharmacology Mike Dragunow is looking at the mechanisms of brain cell 
death, while Professor of Anatomy Richard Faull is looking at ways the brain generates 
new cells. Both are looking for ways to combat the debilitating effects of these brain 
wasting diseases. 
 
Professor Faull’s work on Huntington’s disease has uncovered evidence that the brain is 
trying to repair itself by using adult stem cells and by forming new neurones. 
 
“It could mean that instead of transplanting embryonic stem cells you could use the adult 
stem cells. So we want to find out what causes them to multiply and form new brain cells.” 
 
This also raises the possibility that similar repair mechanisms could be at work in other 
neurodegenerative conditions. Using existing adult stem cells is also a far more attractive 
proposition than having to harvest embryonic stem cells. 
 
Colleague Professor Mike Dragunow, meanwhile, is looking at the whole question of what 
causes brain cells to die in diseases like Alzheimer’s, Parkinson’s and Huntington’s. 
His team is particularly interested in brain cell apoptosis, where the brain cell appears to be 
programmed to commit suicide. They already know that nerve cell death is not a random 
process in these diseases so are looking at the molecules controlling the genetic cell death 
programme. 
 
“We’ve identified one that seems to be associated with nerve cell death and one which 
seems to be associated with nerve cell life and we are looking to see exactly how they 
control this.” 
 
They are now looking at those same molecules in human brain material to see if they are 
either underactive or overactive in diseased brains.  
 
Professor Dragunow says that they are also looking at what appears like an immune 
reaction in the brains of people with Alzheimer’s and Parkinson’s, which may actually 
worsen the damage, because molecules released by the immune cells go on to kill more 
nerve cells. 
 
His team has successfully developed an experimental cell line that secretes molecules, 
which kill nerve cells. The team is working to identify those molecules. 
 
The New Zealand Neurological Foundation Brain Bank, built up through bequests from 
patients who die with diseases such as Parkinson’s, Huntington’s, Alzheimer’s and 
epilepsy, has proved to be a huge asset in the work of both groups. 




Osteoporosis and Paget’s disease top the list of bone and calcium problems faced by New 
Zealanders.  
 
Osteoporosis causes approximately 15,000 fractures a year while the less well-known 
Paget’s disease affects 5-10% of older New Zealanders, leading to bone deformity, bone 
pain, fractures, premature hip joint wear and other similar conditions. 
 
The University of Auckland’s Bone Research Group, led by Professors Ian Reid and Jill 
Cornish, is a multi-disciplinary group which researches the biology of bone growth, 
examines animal models of bone disease and undertakes clinical studies. 
 
They were the first to demonstrate that calcium supplements could significantly slow bone 
loss in normal older women and also result in fewer fractures. More recently, they have 
shown that calcium supplementation in normal older women significantly improves their 
blood cholesterol pro-files, so much so that long term use could produce a 20–30 percent 
decrease in heart attacks. They are now examining the effects of calcium supplements on 
the cardiovascular and bone health of men. 
 
Intellectual property from this work has been licensed to Mission Pharmacal, the largest 
producer of calcium supplements in the United States. The group is also trialing novel 
drugs to combat osteoporosis. Another avenue of research is the regulation of the cells that 
make bone and the cells that break it down - activity that determines how much bone 
develops, how strong it is and how well it works. 
 
The group discovered two new receptors on bone cells, known to play an important part in 
other cells. They are believed to be key regulators of bone cell growth, and the group is 
examining them as potential therapeutic targets.  They also identified the cause of a rare 
bone weakening condition, which has led to effective treatment of this problem for the first 
time, and provided further understanding of normal regulation of bone cell activity. 
 
Their work on Paget’s disease focuses on identifying what switches on the abnormal bone 
cell activity in this condition, so they can look for a therapy to switch it off again. 
The group is also examining the link between fat mass and bone mass to understand why 
fatter people have stronger bones. 
 
“We identified a number of different hormones that are low in thin people and appear to be 
important in maintaining bone growth. A number of those hormones are now being 
actively investigated as potential treatments for osteoporosis and that intellectual property 
has been licensed to a pharmaceutical company.” They have also been in negotiation with 
a California biotechnology company about licensing further intellectual property for 
other bone growth promoting proteins. 
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Dunedin study readies for age 32 assessments 
 
It is widely recognised as one of the world’s foremost longitudinal cohort studies – 
following the lives of close to 1,000 people born in Dunedin nearly 32 years ago. 
 
Over the years the Dunedin Multidisciplinary Health and Development Study has 
generated more than 400 international and 81 New Zealand scientific journal articles. 
 
Plans are well underway for the next assessment as part of the HRC funded programme. 
 
Study Director Associate Professor Richie Poulton says that participants will return to their 
birthplace from all over New Zealand and the world to complete the comprehensive eight-
hour assessment.  
 
Information will be gathered on cardiovascular health, respiratory and pulmonary function, 
mental health, anti-social behaviour, oral health, living arrangements, relationships, 
religious beliefs, disability, sexual and reproductive health, and self-harm behaviour. Blood 
samples will also be taken for several biomedical studies. 
 
Associate Professor Poulton says that the focus is now on understanding the development 
of risk for the major diseases that impact upon the health of a population, which will 
require studies that range from the genetic right through to the sociological. 
 
“We want to obtain a holistic picture of influences on a person's health using a life course 
approach, so we use all the information about our group of a thousand people gathered 
over the first 25 years to understand why people end up where they do in their early 30s.” 
 
Associate Professor Poulton says that it is also a point along the way to understanding why 
people end up the way they do at 40 and 50 and seeing how far back the first signs become 
noticeable. 
 
“The earlier you know, in theory at least, the easier it is to intervene to mitigate the long-
term negative consequences and maybe even prevent them altogether." 
 
Another development is the appointment of a senior Maori health researcher, Dr Joanne 
Baxter, and a junior research fellow who will examine the potential of the study’s data for 
informing policy relevant to Maori. 
 
Researchers in the US and the UK are conducting studies drawing on information from the 
families of the multidisciplinary study’s participants. 
 
They now have a next generation study going, where they visit the firstborn three year-olds 
of their study members at home to understand why parents parent the way they do. 
Essentially, three generations are now involved. 
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Worldwide CV for clinical trials research unit 
 
The University of Auckland’s Clinical Trials Research Unit has carved out a niche for 
itself co-ordinating trials involving tens of thousands of patients around the world.  
 
The unit, co-directed by Dr Anthony Rodgers and Professor Craig Anderson, has been 
involved in a range of large-scale research projects in the area of cardiovascular disease. 
 
Its glowing CV includes the Perindopril Protection Against Recurrent Stroke Study 
(PROGRESS), involving more than 6,000 patients worldwide, which showed major new 
benefits for blood pressure lowering treatments in stroke patients. A 17,000 patient trial 
showed the benefits of aspirin in preventing blood clots after major surgery. The CTRU 
has recruited 6,500 participants from throughout the Asia Pacific region for ONTARGET, 
a major trial of new treatments in high-risk patients. 
 
The Asia Pacific Cohort Studies Collaboration has brought together data from 50 studies 
involving 600,000 participants allowing them to gather information on cardiovascaulr 
determinants such as blood pressure, cholesterol and body weight for the Asia Pacific 
region. This is one of several collaborations with the Institute for International Health in 
Sydney.  
 
They are also collaborating on the China Salt Substitute Study, looking at a low-sodium, 
high potassium salt substitute and its effect on blood pressure and stroke risk, and a study 
looking at the effects of different classes of blood pressure lowering drugs on 
cardiovascular outcomes. 
 
There is also a diverse range of New Zealand-based trials such as ECHO, testing the 
effectiveness of the Chitosan over-the-counter weight loss supplement, and FITNESS, the 
Frailty Interventions Trial in Elderly Subjects Study. 
 
Ongoing studies include ARCOS, the Auckland Regional Community Stroke Study, 
FOILS, the fish oils in stroke study, and HALT, the Honey as Adjuvant Leg Ulcer Therapy 
Trial, which will evaluate manuka honey as a treatment for leg ulcers. 
 
The unit is also conducting a follow-up of babies involved in the 1969-74 Auckland 
antenatal steroid study, designed to determine the long-term outcomes for babies exposed 
to the corticosteroid betamethasone in utero.  
 
The Stop Smoking with Mobile Phones Trial (STOMP), evaluated mobile phone text 
messages as a way to motivate and educate people trying to quit smoking. This world-first 
trial involved 1700 New Zealanders. Results will be reported in the New Year. 
 
CTRU research has impacted on both policy and practice. Dr Rodgers was principal author 
on the WHO’s main annual publication, the World Health Report in 2002. This research 
assessed burden of disease from major causes globally. The methods were adapted for the 
'Nutrition and the Burden of Disease: New Zealand 1997-2011' report released last year, 
which has fed in to the Ministry of Health’s ‘Healthy Eating - Healthy Action Oranga Kai - 
Oranga Pumau: A strategic framework’. 
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